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Abstract
Age-related macular degeneration (AMD) is of increasing concern given the ageing 
population, and the associated economic and social burdens. Vision-related quality-
of-life (QoL) is arguably one of the most important factors in the management of those 
with AMD. Consequently, there is a clear need for an understanding of the clinical 
outcomes that influence vision-related QoL in order to inform management strategies. 
The principle aim of the studies described herein was to determine the factors that 
predict vision-related QoL in those with AMD, over 1 year. 
Experimental procedures were undertaken at baseline (n=52 individuals with AMD) 
and repeated after 1 year (n=32 individuals with AMD). These included: visual acuity, 
contrast sensitivity, reading speed, microperimetry, optical coherence tomography 
and fundus photography. A questionnaire interview included assessment of vision-
related QoL (Impact of Visual Impairment questionnaire), health status (EQ-5D), level 
of depressive symptoms (PHQ-9) and well-being (Warwick-Edinburgh Well-Being 
Scale).  
At baseline, the optimum multiple regression model accounted for 41% of the variance 
in vision-related QoL and included Mean Total Deviation or Mean Sensitivity with level 
of depressive symptoms. After 1 year, the optimum model to predict change in vision-
related QoL accounted for 43% of the variance and included baseline contrast 
sensitivity and change in health status and reading speed. 
The most clinically useful measures of visual function, in identifying those with a 
reduced QoL or those at risk of a reduced QoL were contrast sensitivity, 
microperimetry, and reading speed. These outcomes may allow a better 
understanding of vision-related QoL if they were adopted in a clinical setting. In 
conclusion, the studies provide sufficient evidence to encourage a review of the 
clinical outcome measures most relevant to vision-related QoL. 
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Chapter 1: Introduction 
An overview of age-related macular degeneration (AMD) including classification 
methods, pathogenesis and clinical presentation is presented in this chapter. Clinical 
measures are reviewed including functional measures and imaging techniques 
relevant to AMD. Quality-of-life (QoL) is also addressed and discussed in the context 
of AMD.  
Age-related macular degeneration is the leading cause of visual impairment in the 
developed world and is the primary cause of registered sight impairment in the UK 
(Evans, Fletcher and Wormald 2004; Bunce, Xing and Wormald 2010; Klein et al. 
2013). It is a degenerative disease, which causes a varied reduction in central visual 
function leading to severe deficits in late stage disease.
Early AMD involves gradual, moderate reductions in visual function. Late stage AMD 
can be divided into two types; geographic atrophy (GA) or neovascular AMD (nAMD). 
GA and nAMD have similar prevalence of 6.7% and 6.3% respectively, in those over 
80 years old in the UK population (Owen et al. 2012). However, GA accounts for a 
larger amount of registered sight impairment (42%) in the UK compared to nAMD 
(29.7%) (Rees et al. 2014). Despite this, the sudden vision loss associated with nAMD 
has more profound initial effects than the gradual progression of GA.  
1.2.1 Clinical presentations 
1.2.1.1 Stages of AMD 
Early to intermediate stages of AMD are characterised by the presence of differing 
sizes of drusen, with or without the addition of hyper- or hypopigmentary abnormalities 
(Ferris et al. 2013). 
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1.2.1.2 Drusen 
Drusen are the first sign of AMD that can be recognised clinically. They are 
extracellular deposits that accumulate between the retinal pigment epithelium (RPE) 
and inner collagenous zone of Bruch’s membrane (Abdelsalam, Del Priore and Zarbin 
1999). They are composed of undigested metabolic debris and lipofuscin, which 
would normally be removed in younger eyes, but in ageing eyes, in which transport 
between RPE and Bruch’s membrane is dysfunctional, the debris accumulates 
(Moore, Hussain and Marshall 1995).  
Figure 1.1. Clinical presentation of the different types of drusen. A: Colour fundus photography 
(CFP) of pigmentary abnormalities and hard drusen, B: Fundus fluorescein angiography of 
cuticular drusen presenting as a "starry sky" appearance, C: CFP with soft drusen and some 
calcified drusen present, D: Infra-red image showing reticular pseudodrusen. Adapted from: 
(Kolb et al. 2011; Sivaprasad et al. 2016) © from Elsevier. 
Drusen can be defined clinically by size and area, and into several types; hard drusen, 
soft drusen, cuticular drusen and reticular pseudodrusen (RPD)(Figure 1.1) (Sarks, 
Sarks and Killingsworth 1994; Smith et al. 2009; Khan et al. 2016). A clinical 
3 
description of the different types of drusen can be found in Table 1.1. Calcified drusen 
are not a specific type of drusen, all drusen are calcified to some extent and it is 
suggested that the level of calcification is associated with age of druse (Khan et al. 
2016). A small number of hard drusen, also referred to as drupelets (<63µm), at the 
macula are suggested to be a normal ageing change of the retina (Sarks et al. 1999). 
However, when they increase in number and become confluent they become a risk 
factor for the development of AMD (Ferris et al. 2013). This risk factor is well 
established and has led to confluent drusen at the macula being classified as early 
stage AMD (Abdelsalam, Del Priore and Zarbin 1999; Midena et al. 1997; Ferris et al. 
2013).  The presence and severity of drusen is also a risk factor for the progression 
to advanced AMD (Chew et al. 2014; Klein et al. 1997), as is the presence of RPD 
(Klein et al. 2008; Zhou et al. 2016). 
1.2.1.3 Pigmentary abnormalities 
Pigmentary abnormalities are characterised as areas of increased 
(hyperpigmentation) or decreased pigment (hypopigmentation) due to RPE 
dysfunction (Bhutto and Lutty 2012). The presence of pigmentary abnormalities leads 
to the classification of intermediate AMD with the well-established AREDS (AREDS 
2001) and Beckman classification systems (Ferris et al. 2013), as these changes with 
the additional presence of drusen are predictive of AMD progression (Chiu et al. 2014; 
Finger et al. 2016). Hyperpigmentation is suggested to precede nAMD, whereas 
hypopigmentation is proposed to be predict the development of GA (Bhutto and Lutty 
2012). 
4 
Type of druse Clinical description
Hard CFP: Located in central and peripheral retina. Small (<63µm) defined 
yellow-white punctate deposits. Associated with normal ageing as well 
as AMD.
SD-OCT: small hyperreflective sub-RPE deposits
FFA and ICGA: hyperfluorescent
SW A-F: areas of reduced AF
Cuticular CFP: Located in central and peripheral retina (more numerous in the 
periphery). Multiple (>50) small (25-75µm) dot like deposits.
SD-OCT: triangular (”saw-tooth”) hyperreflective sub-RPE deposits 
FFA: Numerous hyperfluorescent dots (“starry sky” appearance)
ICGA: early hyperfluorescent
SW A-F: areas of reduced AF
Soft CFP: Located at the posterior pole, most frequently in the central macula 
and in the superior and temporal quadrants. Large (≥125μm) less well 
defined mound-like elevations. Non uniform Yellow appearance.
SD-OCT: Large sub-RPE hyperreflective deposits.
FFA: Some late hyperfluorescence
ICGA: Hyperfluorescent
SW A-F: Moderate hyperAF
Reticular 
pseudodrusen
CFP: Located in perifoveal area (more predominant superiorly). Ranging 
from 100 to 250μm in size. Yellow-white ill-defined interlacing pattern 
(whiter than other drusen).
Enhanced visibility under red-free light but best images on infrared 
reflectance (IR) imaging 
SD-OCT: Deposits between RPE and inner segment ellipsoid lines later 
breaking though the ellipsoid line and subsequently fading.
FFA: Hypofluorescence or no change
ICGA: Hypofluorescence in late stage
SW A-F: Reticular pattern, hypoAF
Table 1.1 Clinical description of drusen type, assessed by colour fundus photography (CFP), 
spectral domain optical coherence tomography (SD-OCT), fundus fluorescein angiography 
(FFA), indocyanine green angiography (ICGA) and short wavelength auto-fluorescence (SW 
A-F). Adapted from: (Abdelsalam, Del Priore and Zarbin 1999; Saade and Smith 2014; Smith 
et al. 2009; Khan et al. 2016; Sivaprasad et al. 2016). 
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1.2.1.4 Geographic atrophy 
Geographic atrophy is characterised by a sharply defined area of RPE atrophy, in 
which choroidal vessels are visible (Figure 1.2) (Chaikitmongkol, Tadarati and 
Bressler 2016).  GA occurs due to RPE loss and photoreceptor thinning at the macula. 
It initially affects the parafovea, gradually increasing in size and sparing the fovea until 
later stages (Brader et al. 2013; Chaikitmongkol, Tadarati and Bressler 2016).  
Figure 1.2 Colour fundus photograph of an eye with late stage AMD, with a central area GA 
involving the fovea. Image from: (Kolb et al. 2011) 
1.2.1.5 Neovascular AMD 
Neovascular AMD refers to the presence of choroidal neovascularisation (CNV), 
either between the RPE and Bruch’s membrane (sub-RPE) or between the neural 
retina and RPE (subretinal) (Ambati et al. 2003). nAMD can be characterised by any 
of the following features; RPE detachments, subretinal or sub-RPE neovascular 
membranes, haemorrhages, hard exudates within the macular area, or glial tissue or 
fibrin deposits (Bird et al. 1995). The new abnormal blood vessels leak blood into the 
retina (sub-RPE, subretinal, intraretinal or pre-retinal); subretinal or sub-RPE 
haemorrhages are generally the first clinical sign of nAMD (Bhutto and Lutty 2012). 
These haemorrhages can cause distortion and reduced vision, and if left untreated 
lead to disciform scarring (Figure 1.3) (Ambati et al. 2003). Additionally, the presence 
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of nAMD in one eye significantly increases the risk of progression to nAMD in the 
second eye (Mitchell et al. 2002; Wang et al. 2007). 
Figure 1.3 Colour fundus photograph colour of an eye with late stage AMD with a disciform 
scar at the macula due to CNV. Image from (Kolb et al. 2011).
1.2.1.6 Retinal Pigment Epithelial Detachment 
Retinal pigment epithelial detachment (PED) is the detachment of the inner layers of 
Bruch’s membrane away from the RPE (Schmidt-Erfurth et al. 2017). AMD associated 
PEDs can be defined as serous, drusenoid, or fibrovascular (haemorrhagic). Serous 
PEDs appear as a smooth well-defined dome-shaped RPE elevation on spectral 
domain optical coherence tomography (SD-OCT) and are commonly associated with 
nAMD (Schmidt-Erfurth et al. 2017). Drusenoid PEDs are formed by the coalescence 
of soft drusen and exhibit uneven RPE elevation with irregular borders when 
visualised with SD-OCT (Ambati et al. 2003; Zayit-Soudry, Moroz and Loewenstein 
2007). Fibrovascular PEDs are caused by new vessel growth through Bruch’s
membrane resulting in an elevation of the RPE. On SD-OCT this appears as well 
defined areas of uneven RPE elevation with additional back scattering due to fibrous 
proliferation and often with adjacent areas of sub retinal fluid (Zayit-Soudry, Moroz 
and Loewenstein 2007) (Figure 1.4). PEDs can resolve to normal or can result in GA, 
nAMD, or retinal tears, leading to functional loss in individuals with AMD (Ambati et 
al. 2003; Ogino et al. 2014).  
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Figure 1.4 SD-OCT images of serous pigment epithelial detachment (PED) (top), fibrovascular 
PED (middle) and drusenoid PED (bottom). Images from: (Zayit-Soudry, Moroz and 
Loewenstein 2007) © from Elsevier. 
1.2.2 Treatment 
Currently nAMD is the only form of AMD that can be treated in clinical practice. 
Supplementation (Gorusupudi, Nelson and Bernstein 2017), alterations in diet 
(Carneiro and Andrade 2017) and lifestyle recommendations (Sin, Liu and Lam 2013) 
are currently suggested to reduce progression in early or intermediate AMD. 
However, recent technological developments provide an optimistic prospect for future 
treatments such as prosthetic retinal implants (Riazi-Esfahani et al. 2014; Mills, Jalil 
and Stanga 2017) and stem cell research (Kuriyan et al. 2017). 
Anti-vascular endothelial growth factor (anti-VEGF) agents block the growth of 
abnormal vessels and are a proven method of nAMD treatment, preventing vision loss 
and even improving vision in some cases (Avery et al. 2006; Jiang, Park and Barner 
2014). Bevacizumab (Avastin, Genentech), Ranibizumab (Lucentis, Genentech), 
Pegaptanib sodium (Macuggen, Pfizer Inc) and Aflibercept (Eyelea, Bayer Pharma) 
have all been demonstrated as effective when used to treat nAMD (Costagliola et al. 
2009; Avery et al. 2006; Studnička et al. 2013; Schmidt-Erfurth et al. 2014). However, 
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currently only Ranibizumab and Aflibercept are National Institute for Health and Care 
Excellence (NICE) approved to treat nAMD (NICE 2014). Prior to the NICE 
recommendation of anti-VEGF treatments, photodynamic therapy (PDT) was used to 
treat subfoveal nAMD. The method involves an intravenous injection of verteporfin 
that accumulates in abnormal vessels, and when subjected to a low-energy laser 
leads to thrombosis and subsequent occlusion of these vessels (Cruess et al. 2009). 
Although less frequently used PDT is currently indicated when subfoveal nAMD is 
unresponsive to anti-VEGF treatment (Amoaku et al. 2015).  
Before the development of anti-VEGF agents, the treatment of nAMD required 
surgical intervention, such as submacular surgery, which initially gave poor results. 
Subsequent surgical intervention for both nAMD and GA included macular 
translocation (van Romunde et al. 2015), and RPE and choroid transplants 
(Alexander et al. 2015; van Zeeburg et al. 2012). However, the introduction of anti-
VEGF treatments revolutionised the treatment of nAMD and led to infrequent use of 
these surgical interventions. 
1.2.3 Grading 
There are a number of classification systems used to define the clinical signs of AMD. 
The most widely used and well established methods are the Wisconsin Age-related 
Maculopathy Grading system (Klein et al. 1991), the International Classification and 
Grading system (Bird et al. 1995) and the Age-related Eye Disease Study (AREDS) 
grading system (AREDS 2001). The most recently developed grading method is the 
Beckman grading scale (Ferris et al. 2013).  
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The original grading scale was the Wisconsin Age-related Maculopathy Grading 
system and this was used for several large scale AMD studies including the Blue 
mountains and Beaver dam studies (Mitchell et al. 1995; Klein, Klein and Linton 1992). 
It has also been utilised in the development of other grading scales. The International 
Classification and Grading system has similar principles to the Wisconsin Age-related 
Maculopathy Grading System, using a standard grid to define lesions, and was used 
in the large scale Rotterdam study (Klaver et al. 2001). The AREDS grading system 
was also developed based upon the Wisconsin Age-related Maculopathy Grading 
System, again using a standardised grid to grade stereoscopic colour fundus 
photographs (CFPs) (AREDS 2001). The AREDS classification uses a standard Early 
Treatment Diabetic Study (ETDRS) grid and standardised circles to grade AMD 
related features on CFPs (Figure 1.5). 
Figure 1.5. Grid and standard circles used to grade AMD with the AREDS system. C=central, 
I = inner and O = outer subfields. Diameter of circles: C-0=0.042 disk diameter (DD), C-1 = 
0.084 DD, C-2=0.167 DD, I-1 = 0.120 DD, I-2 = 0.241 DD, )-1 = 0.219 and O-2 = 0.439 DD. 
(Davis et al. 2005; AREDS 2001) © from Elsevier. 
 Size and presence of pigment abnormalities, GA and drusen are all graded by 
comparison with the standardised circles and the overall grades are based upon the 
size and presence of different features (Table 1.2). 
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AREDS 
classification Criteria
1
Drusen maximum size <C-0 (63µm diameter) and total area <C-1 
(125µm diameter)
2 Presence of one or more of the following:
•Drusen max size ≥C-0 but <C-1 
•Drusen total area ≥C-1 
•Pigment abnormalities consistent with AMD, defined as one 
or more of the following in the central or inner subfields:
a) Depigmentation
b) Increased pigment >C-1 
c) Increased pigment present and depigmentation at least 
questionable
3 Presence of one or more of the following:
•Drusen maximum size ≥C-1 
•Drusen maximum size ≥C-0 and total area >I-2 and type is 
soft indistinct
•Drusen maximum size >C-0 and total area >O-2 and type is 
soft distinct
•GA within grid but none in centre of macula
4 (Late) Presence of one or more of the following:
•GA in central subfield with at least questionable involvement 
of centre of macula
•Evidence of nAMD:
a) Fibrovascular/serous PED
b) Serous (or haemorrhagic) sensory retinal detachment
c) Subretinal pigment epithelial haemorrhage
d) Subretinal fibrous tissue
e) Photocoagulation for AMD
Table 1.2 AREDS classification system 
 The Beckman classification was developed to include the main clinical phenotypes 
of AMD, whilst limiting the grading to only direct or indirect ophthalmoscopy. The 
proposed classification includes 5 stages: ‘no apparent ageing changes’, ‘normal 
ageing changes’, ‘early AMD’, ‘intermediate AMD’ and ‘late AMD’ (Table 1.3) (Ferris 
et al. 2013). 
Classification Definition 
No apparent ageing changes No drusen and no pigmentary abnormalities
Normal ageing changes Only druplets (small drusen ≤63µm) and no 
pigmentary abnormalities
Early AMD Medium drusen (˃ 63µm and ≤125µm) and no 
pigmentary abnormalities
Intermediate AMD Large drusen (˃125μm) and/or any pigmentary 
abnormalities
Late AMD Neovascular AMD and/or any geographic atrophy
Table 1.3 Beckman AMD classification. 
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A disadvantage to all the current grading scales is the lack of SD-OCT images in the 
grading process. This is a limitation as SD-OCT can identify AMD lesions that may 
not be visible by CFPs or clinical examination alone, for example PEDs and subretinal 
fluid (Mokwa et al. 2013). Subsequently, a combination of SD-OCT in addition to one 
of the existing grading methods would be a preferential method to grade AMD 
severity.  
1.2.4 Pathogenesis 
The pathogenesis of AMD is a multifactorial process that is still not fully understood. 
A number of processes have been suggested to contribute including oxidative stress, 
choroidal vascular changes, Bruch’s membrane changes, metabolic insufficiency and 
inflammatory processes (Zarbin 2004; Ambati et al. 2003; Ambati and Fowler 2012; 
Gelfand and Ambati 2016; Tan, Bowes Rickman and Katsanis 2016). These 
processes are not mutually exclusive and a flow diagram to visualise the 
multidimensionality is presented in Figure 1.6. 
To explore the pathogenesis of AMD normal ageing should firstly be addressed. AMD 
is proposed to be an extreme version of the normal retinal ageing process. Normal 
ageing occurs due to the production of damaging toxins (such as reactive oxygen 
intermediates, ROI’s) from metabolic interactions between biological chemicals. 
Accumulation of these damaging toxins over time lead to age-related diseases 
(Ardeljan and Chan 2013). The normal ageing process of the retina involves Bruch’s 
membrane thickening, drusen formation, lipofuscin accumulation leading to RPE 
degeneration, oxidative stress, increased mitochondrial damage and macrophage 
imbalance. Normal ageing also involves a decreased choroidal blood flow due to a 
reduction in density and diameter of choriocapillaris (Ardeljan and Chan 2013). It is 
apparent that there is overlap between the mechanisms of AMD pathogenesis and 
normal ageing processes. These mechanisms will be examined in more detail. 
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Figure 1.6 Flow diagram depicting the multifactorial processes of the pathogenesis of age-
related macular degeneration (AMD) including both neovascular AMD (nAMD) and geographic 
atrophy (GA). ROIs: reactive oxygen intermediates. 
1.2.4.1 Bruch’s membrane
Bruch’s membrane functions as a physical and biochemical barrier between the RPE 
and choriocapillaris. The thickening of Bruch’s membrane with age, ultimately 
impedes photoreceptor function and, consequently, the metabolic exchange between 
the choroid and retina (Ambati et al. 2003). The diffusion capabilities of Bruch’s 
membrane are inhibited by an increase in lipids, increased membrane thickness and 
an accumulation of abnormal deposits in Bruch’s membrane, which result from the 
incomplete phagocytosis of the photoreceptor outer segments by the RPE (Booij et 
al. 2010).  
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1.2.4.2 Oxidative stress 
Oxidative stress occurs due to the production of ROIs at enzyme active sites after 
oxidation. ROIs remove electrons from other molecules to achieve a stable state, 
resulting in those molecules becoming unstable (cytotoxic chain reaction). An 
accumulation of the unstable molecules results in oxidative stress (Beatty et al. 2000). 
The retina is vulnerable to oxidative stress, firstly, due to having the highest oxygen 
demand of any tissue in the body (Vanderkooi, Erecińska and Silver 1991). Secondly, 
the high light exposure that the retina receives produces ROIs (Beatty et al. 2000) as 
does phagocytosis of photoreceptor outer segments, but to a lesser extent (Ambati et 
al. 2003). Finally polyunsaturated fatty acids, which are found in photoreceptor outer 
segment membranes, are readily oxidised and, therefore, can initiate a cytotoxic chain 
reaction (Beatty et al. 2000). ROIs increase the production of VEGF and decrease 
pigment epithelial derived factor (PEDF), promoting vessel growth and resulting in 
nAMD (Ambati et al. 2003; Ambati and Fowler 2012). 
1.2.4.3 Metabolic insufficiency 
The macula is the most metabolically active area of the retina. Yet, the supply of 
oxygen is limited as it is solely supplied by the choriocapillaris, which is not 
autoregulated, resulting in an increased risk of ischaemia when oxygen demand is 
greatest. It has been suggested that AMD is linked to reduced choroidal blood flow 
caused by decreased density and diameter of the choriocapillaris (Grunwald et al. 
1998). This abnormal choroidal flow and perfusion leads to ischaemia and hypoxia, 
which contribute to the activation of VEGF and the subsequent growth of new 
abnormal vessels in nAMD (Boltz et al. 2010). In individuals with GA, a 50% reduction 
in the choriocapillaris area was found in regions with RPE atrophy, and the remaining 
choriocapillaris was significantly constricted (McLeod et al. 2009). Additionally, 
choriocapillaris atrophy extends further than RPE atrophy in GA, suggesting that 
choriocapillaris atrophy precedes GA (Biesemeier et al. 2014).  
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1.2.4.4 Chronic inflammation 
It has also been proposed that chronic inflammation is associated with the 
pathogenesis of AMD (Donoso et al. 2006; Kauppinen et al. 2016). The complement 
cascade is the primary immune mechanism to foreign microorganisms, it regulates 
the immune responses of removal of foreign particles and the recruitment of 
inflammatory cells (Anderson et al. 2002; Anderson et al. 2010). In AMD, the 
complement system lacks the correct regulation required to avoid damage to healthy 
ocular tissue. It is suggested that a combination of oxidative stress, abnormal deposits 
and oxidised proteins lead to a prolonged dysregulated inflammation, which result in 
changes within the choroid and breakdown of the blood retinal barrier (Bhutto and 
Lutty 2012; Chen and Xu 2015).  
1.2.4.5 Risk factors 
Having described the pathogenic processes, some risk factors for AMD will be briefly 
summarised. There are many suggested risk factors for AMD including genetic risk 
factors, environmental risk factors such as sunlight, obesity, smoking and 
socioeconomic status, and additional factors including age, gender and race for a 
comprehensive review see Lambert et al. (2016). 
There have been numerous studies investigating AMD associated genes. There is a 
strong familial link, which accounts for up to 71% of those with AMD, with the age-
related maculopathy susceptibility protein 2 (ARMS2) gene being significantly 
associated with an increased risk of AMD (Priya, Chew and Swaroop 2012; Seddon 
2005; Sobrin and Seddon 2014). The individual differences in AMD severity and 
progression is also proposed to be 50% due to genetic factors (Mousavi and 
Armstrong 2013).  Mutations in complement factor H, complement factor B, 
complement factor C3 and serpin peptidase are genetically linked with AMD, but are 
also associated with the immune response mechanism, in particular the complement 
pathway (Grassmann, Fauser and Weber 2015; Kauppinen et al. 2016).
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The largest controllable environmental risk factor for AMD is smoking, where smokers 
are 2-3 times more likely to develop AMD than non-smokers (Ambati and Fowler 
2012; Chakravarthy et al. 2010). Diet and obesity have also been associated with an 
increased risk of AMD (Zhang et al. 2016), leading to recommendations of a healthy 
diet and regular exercise in those with AMD or a family history of AMD (Sobrin and 
Seddon 2014; Lambert et al. 2016). Other environmental risk factors include exposure 
to sunlight, and wearing UV protective glasses is recommended due to the protective 
effect (Schick et al. 2016). 
Additional to these environmental factors, other factors that increase the susceptibility 
for AMD include age, gender and race. Whereby, AMD risk increases with age; 
females are more susceptible to AMD than males; and those of Caucasian decent are 
significantly more likely to develop more severe AMD (AREDS 2000; Lambert et al. 
2016). 
1.2.4.6 Summary 
In summary, the pathogenesis of AMD is complex, but it is believed to be closely 
related to the normal ageing process. Whilst the reason that AMD develops in some 
individuals and not in others is equivocal, it is suggested that several aspects, 
including genetic and environmental factors, may be involved. Bruch’s membrane 
changes occur at an early stage and lead to metabolic insufficiency and hypoxia. 
Several other processes cause inflammation, oxidative stress, lipofuscin deposition 
and reduced choroidal blood flow. These processes ultimately lead to GA and/or 
nAMD. 
Imaging techniques enable visualisation of the retina, such that AMD associated 
retinal features may be viewed. These include CFP, fluorescein angiography (FA), 
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optical coherence tomography (OCT), fundus autofluorescence (FAF) and infrared 
(IR) imaging.  
1.3.1 Colour fundus photography 
Colour fundus photography is the traditional method for grading AMD (Section 1.2.3). 
It allows en-face visualisation of drusen and pigmentary changes that are associated 
with early AMD, and can be used to monitor other morphological changes indicative 
of development of late stage disease (Klein et al. 2007; Ferris et al. 2013; AREDS 
2001). However, fundus photography cannot identify certain pathological changes 
associated with AMD, and is unable to localise these to a specific retinal layer 
(Kanagasingam et al. 2014). CFP and OCT provide complimentary information and 
both have a role in the detection and monitoring of AMD (Gregori et al. 2011; Holz et 
al. 2017).  
1.3.2 Optical coherence tomography 
Optical Coherence Tomography is a non-invasive imaging technique that enables a 
cross-sectional view of the retinal structures. It was first reported in 1991 and has 
since become a well-established commercial technique (Huang et al. 1991; Fujimoto 
and Swanson 2016). Early studies established OCT as a useful measure in macular 
disease detection, allowing identification of sub- and intra-retinal fluid, which enabled 
detection and monitoring of nAMD and the assessment of treatment efficacy (Hee et 
al. 1996). Subsequently, OCT is the recommended technique in the management of 
nAMD (Amoaku et al. 2015).  
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Comparable to B-scan ultrasonography, OCT uses optical reflections (rather than 
sound) from biological structures to provide spatial information, providing a reflectivity 
profile of the tissue being investigated (Huang et al. 1991). OCT utilises the principle 
of low-coherence light interferometry measuring reflectivity at certain depths in the 
tissue at regular intervals and increasing depth (Fujimoto and Swanson 2016). An 
axial A-scan is a reflectivity depth profile at one specific point in the measured 
structure. Lateral movement of the scanning system produces a series of adjacent A-
scans to form a two-dimensional B-scan, and moving the system in two directions 
forms a three-dimensional C-scan (Figure 1.7) (Van Velthoven et al. 2007). 
Figure 1.7 Cirrus SD-OCT image of a macula with AMD, A-scans, a B-scan and a C-scan are 
illustrated. Modified  from (Regatieri, Branchini and Duker 2011). 
1.3.2.1 Instrumentation 
Currently, SD-OCT is the standard commercially available instrument, with imaging 
speeds ranging from 25,000 to 80,000 A scans per second (Van Velthoven et al. 2007; 
Cense et al. 2004; Fujimoto and Swanson 2016). The fast acquisition time reduces 
the effect of degrading artefacts such as eye movements, and decreases exposure of 
the eye (Yun et al. 2003; Wojtkowski et al. 2004). The capability of SD-OCT to amass 
large three dimensional datasets in a short acquisition time enables high quality data 
to be collected, in individuals with and without AMD (Menke, Dabov and Sturm 2008). 
However, SD-OCT is constrained by a fixed 800nm wavelength, which limits the 
visualisation of structures more posterior to the RPE, such as the choroid. It is also 
unable to image blood flow within the retinal capillaries.  
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The development of enhanced depth imaging OCT, swept-source OCT and of 
instruments with imaging performed at longer wavelengths has enabled visualisation 
of the choroid (Povazay et al. 2009b; Povazay et al. 2009a; Mrejen and Spaide 2013). 
Functional OCT techniques such as doppler OCT or OCT angiography, allow 
measurement of blood flow velocity and visualisation of the retinal vasculature 
(Drexler and Fujimoto 2008; Gao et al. 2016). This technique facilitates detailed 
imaging and quantification of the area of vasculature and of the blood flow, and has a 
potential utility in nAMD (Jia et al. 2014; Al-Sheikh et al. 2017). Additionally, reductions 
in blood flow which are associated with regions of atrophy can be used to identify GA 
(Choi et al. 2015; Schmidt-Erfurth et al. 2017).  
Whilst techniques such as long wavelength OCT are advantageous, SD-OCT is a 
ubiquitous clinical instrument and is a recommended technique in the management 
of nAMD (Mowatt et al. 2014; Amoaku et al. 2015; Fujimoto and Swanson 2016). The 
selection of a specific SD-OCT device for research purposes should consider the 
performance of different devices. The Spectralis HRA-OCT (Heidelberg Engineering, 
Heidelberg, Germany) and Cirrus HD-OCT (Carl Zeiss Meditec, Inc.) demonstrated 
high repeatability and reproducibility when examining nerve fibre thickness (Pierro et 
al. 2012; Bentaleb-Machkour et al. 2012; Tan et al. 2012). The Spectralis HRA-OCT 
is a widely used SD-OCT, enhanced by the addition of a confocal scanning laser 
ophthalmoscope (SLO) to monitor eye movement. It has an acquisition speed of 
40,000 per second with an axial resolution of 3.9μm (Sayegh et al. 2011). A variable 
number of B-scans are collated to produce a mean image of high resolution that is 
corrected for artefacts (Schütze et al. 2011). The Cirrus HD-OCT is a well-established 
SD-OCT. It has an axial resolution of 5μm, a scan speed of 27,000 a-scans per 
second, a scanning depth of 2mm and scans an area 6 x 6 mm at the macula 
(Brautaset et al. 2014). The Cirrus is reported to have good test-retest repeatability 
when used to measure retinal thickness in individuals with AMD. However, increased 
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severity of AMD is likely to have an effect on the variability due to factors such as poor 
fixation (Keane et al. 2009; Parravano et al. 2010a). Three-dimensional OCT (Topcon 
3-D OCT-1000) combines CFP and SD-OCT. It has acquisition speed of 18,000 per 
second with an axial resolution of 6μm. One study comparing these three devices in 
GA reported that the Spectralis and Cirrus instruments acquire the highest quality 
images (Schütze et al. 2011). However, the Spectralis device gave significantly more 
segmentation errors than the Topcon and Cirrus devices (Schütze et al. 2011). 
Furthermore, the Cirrus device acquires a greater number of volume scans and also 
has a higher resolution under a similar acquisition speed than the Spectralis.  
1.3.2.2 OCT quantification 
Originally, hand segmentation of OCT scans allowed for quantification of retinal 
thicknesses. However, this was not clinically viable, due to the time consuming nature 
of marking the intra-retinal layer boundaries manually. Subsequently, automated 
segmentation methods were developed (Garvin et al. 2009). For example, OCT 
Explorer is part of the Iowa Reference Algorithm (Retinal Image Analysis Lab, Iowa 
Institute for Biomedical Imaging, Iowa City, IA), and the automated segmentation 
module is called OCTSeg (Abràmoff, Garvin and Sonka 2010; Quellec et al. 2010; 
Antony et al. 2011; Xinjian Chen et al. 2012). Version 3.6 of the automated 
segmentation software segments 11 retinal boundaries or 10 retinal layers (Figure 
1.8). Using graph theory optimisation, it was initially designed for use with time domain 
OCT, and further developed for use with SD-OCT (Garvin et al. 2009; Kang et al. 
2006).  
Many of the commercially available SD-OCTs also have on-board segmentation 
software, however many of these only segment two boundaries to give total retinal 
thickness. A number of recent instruments such as the Topcon DRI OCT-1 Atlantis 
(Topcon Corp, Tokyo, Japan) and the Spectralis OCT (Heidelberg Engineering, 
Heidelberg, Germany; software version 6.0) have the capability to segment intra-
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retinal layers. However, the Iowa Reference Algorithm can segment images acquired 
from several different devices, and was found to be more repeatable than the 3D-
OCT 1000 (Topcon Corp, Tokyo, Japan) and Cirrus HD-OCT on-board software (Carl 
Zeiss Meditec, Inc., Dublin, CA) (Terry et al. 2016). Furthermore, it has been validated 
in diabetic oedema (Sohn et al. 2013) and nAMD (Xinjian Chen et al. 2012; Quellec 
et al. 2010). 
Figure 1.8 Screenshot from OCT Explorer of 10 retinal layers (11 boundaries) segmentation 
of a Cirrus HD-OCT image. Layers 1-10 as defined by the software: retinal nerve fibre layer 
(RNFL); ganglion cell layer (GCL); inner plexiform layer (IPL); inner nuclear layer (INL); outer 
plexiform layer (OPL); outer plexiform-Henle fibre layer to boundary of myoid and ellipsoid of 
inner segments (OPL-HFL~BMEIS); photoreceptor inner/outer segment layer (IS/OS); inner 
and outer segment junction to inner boundary of photoreceptor outer segment and retinal 
pigment epithelium complex (OPR); and retinal pigment epithelium (RPE). 
Quantification of SD-OCT imaging in AMD also includes the measurements of drusen 
area and volume. The presence of drusen is associated with disease progression in 
AMD (Yehoshua et al. 2011), and therefore, the quantification of drusen is a useful 
biomarker. The level of precision in quantifying drusen size, area and volume from 
SD-OCT images is superior to the measures that may be obtained from fundus 
photography (Jain et al. 2010). The Cirrus HD-OCT has the capability to measure 
drusen volume (Gregori et al. 2011). Drusen volume measurement calculates the 
difference between the RPE segmentation and the virtual ‘normal’ RPE, which gives 
a measure of abnormality and describes drusen area and volume (Gregori et al. 
2011). The segmentation software is reported as a reliable assessment of drusen 
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development over time and has been proposed as a useful strategy to monitor 
disease progression (Yehoshua et al. 2011).  
1.3.3 Other imaging modalities 
Fundus fluorescein angiography is utilised to identify and diagnose CNV; it is an 
invasive technique that involves intravenous injection of a fluorescent dye. This 
technique allows for identification of new vessels associated with CNV, which are not 
always visible on fundus photography (Nivison-Smith et al. 2014; Chalam and 
Sambhav 2016).  
Fundus autofluorescence enables non-invasive visualisation of retinal fluorophores 
accumulating in the RPE  (Wu et al. 2015d; Delori et al. 1995). Hyper or hypo 
autofluorescence are associated with lipofuscin levels in the RPE and can be 
indicative of drusen, GA and CNV (Rossberger et al. 2013; Holz et al. 2007; Peng, 
Dong and Zhao 2013; Paavo et al. 2017).  
Infra-red imaging is a useful imaging modality in monitoring drusen and in the 
identification of RPD (Acton et al. 2011; Elsner et al. 1996; Hogg 2014). IR light is 
absorbed less by the RPE compared to visible light and therefore improves 
visualisation of subretinal structures (Acton et al. 2011; Elsner et al. 1996; Hogg 
2014). Furthermore, it is advantageous in elderly individuals with media opacities, 
whereby IR light is absorbed less by the lens opacities compared to visible light used 
by other imaging techniques (Acton et al. 2011; Hartnett and Elsner 1996; Nivison-
Smith et al. 2014).  
Adaptive optics (AO) was designed to compensate for ocular aberrations that cause 
degradation of images. AO has been implemented in fundus photography, SLO and 
OCT devices, yet mainly within the research environment rather than commercial 
settings (Pircher and Zawadzki 2017). AO-OCT acquires high resolution images of 
the retinal layers allowing for visualisation of cone photoreceptors (Zayit-Soudry et al. 
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2013), retinal nerve fibre bundles (Kocaoglu et al. 2011) and retinal blood vessels 
(Zawadzki et al. 2005). However it has disadvantages, especially in those with AMD, 
as it is affected by motion artefacts which are high in those with poor fixation due to 
macular disease (Pircher and Zawadzki 2017).  
A novel retinal imaging technique is multispectral imaging, which can provide 
information about molecules, structures and cells within the retina due to the different 
reflectance properties they exhibit. One recent study measured retinal oxygen 
saturation and haemoglobin level in normal individuals, in those with systemic hypoxia 
and in individuals with glaucoma (Desjardins et al. 2016). A second study investigated 
oxygen saturation and macular pigment density in a healthy population (Kaluzny et 
al. 2017).  
To conclude, a combination of CFPs and SD-OCT imaging will provide extensive 
visualisation of the structural changes associated with AMD. Standardised 
classification methods of CFPs will enable AMD severity to be defined, whilst 
quantification of retinal thickness and drusen will allow more in depth analysis of AMD-
associated retinal changes. 
Functional measures are vital for the early detection and monitoring of AMD.  These 
measures provide a better understanding of an individual’s everyday visual 
experiences and how these may affect their daily functioning. There are a range of 
measures typically used to assess visual function in AMD. These include visual acuity 
(VA), contrast sensitivity (CS), reading speed and microperimetry, and will be 
discussed in detail. Additional measures relevant to AMD will be summarised. Further 
information can be found in a comprehensive review by Neelam et al. (2009). 
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1.4.1 Visual acuity  
Visual acuity measures the spatial resolving power of the visual system at high 
contrast. It is the most commonly used clinical test of visual function. The ETDRS 
logMAR chart is an accurate and repeatable measure of VA and has subsequently 
become the gold standard for measuring VA in clinical trials (Kaiser 2009; Falkenstein 
et al. 2008). VA is the recommended functional method to judge treatment response 
in nAMD (Huang et al. 2015; Guymer et al. 2013; Amoaku et al. 2015) and is often 
the only visual function outcome in clinical trials in AMD (Ying et al. 2013; Waldstein 
et al. 2016). 
Visual acuity has some limitations. Firstly, it measures the visual function at high 
contrast and, therefore, does not assess the sensitivity of the entire visual system.  
Secondly, VA only examines foveal function and cannot provide localised information 
about visual function across the macula. Additionally, the fovea has a high proportion 
of cones, which perform best under photopic conditions and, consequently, under 
mesopic conditions VA will be reduced. 
The implications of these limitations include, firstly, a lack of sensitivity in the detection 
of early functional deficits in AMD. In early AMD, CS is significantly reduced, however 
due to VA measurement being performed at high contrast, this impairment  in CS 
would not be detected (Midena et al. 1997). Secondly, AMD-related morphology is 
not solely located at the fovea. Some individuals with AMD maintain good VA, despite 
the presence of retinal lesions and functional deficits that are located outside of the 
foveal area. Finally, given that early AMD primarily affects the rod photoreceptors, the 
reduced functional ability under low light levels (Curcio, Medeiros and Millican 1996), 
may not be identified by VA. Alternative functional measures, such as microperimetry, 
CS and dark adaptation, are more sensitive to changes in early AMD, and more useful 
when monitoring longitudinal change or efficacy of treatment (Midena et al. 2004; 
Parravano et al. 2010a; Owsley et al. 2001; Midena et al. 1997). 
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Low luminance VA (LLVA) is a modified measure of VA, which addresses one of the 
limitations of VA with respect to contrast. It involves the measurement of VA with the 
ordinarily lit ETDRS letter chart, and a 2.0 log unit neutral density lens in place 
(reduces luminance by 100 times) (Wu et al. 2014b; Sunness et al. 2008).  The 
difference between the LLVA and best corrected VA (BCVA) gives the low luminance 
deficit (LLD), which has been found to be associated with night vision symptoms in 
intermediate AMD (Wu, Guymer and Finger 2016), and vision loss in GA (Sunness et 
al. 2008). 
The ETDRS logMAR chart is the most appropriate measure of threshold acuity in 
vision research (Johnston 1991). Comprehensive assessment of visual functioning 
requires a combination of VA and additional measures of visual function. 
1.4.2 Contrast sensitivity 
Contrast refers to the difference in luminance between a target and the background 
(Pelli and Bex 2013). CS measures the ability of the visual system to distinguish a 
target from the background at different contrasts, and is expressed in log units. CS is 
a more realistic measure of the visual system and of the ‘real world’ visual functioning 
than VA (Monés and Rubin 2005). CS detects reduced visual function even in 
individuals with no significant drop in VA (Kleiner et al. 1988). In AMD, CS has a high 
test-retest variability; to a greater extent in early than in late stage disease (Patel et 
al. 2009). 
Letter CS charts are now the most ubiquitous method to measure CS in a clinical 
environment. Since 1988, the Pelli-Robson (PR) chart has been one of the most 
common CS charts. It is a letter optotype chart consisting of Sloan letters arranged 
into 16 groups of triplets of the same contrast (Pelli, Robson and Wilkins 1988). It has 
good reliability and repeatability in an extensive range of patients (Bühren et al. 2006; 
Richman, Spaeth and Wirostko 2013; Mäntyjärvi and Laitinen 2001). The Mars Letter 
Contrast Sensitivity test is a more recent design, which also uses Sloan letters, but 
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implements a different scoring procedure based on the number of letters correctly 
identified, rather than triplets of letters (Arditi 2005). The reliability and repeatability of 
the Mars chart were examined in normal individuals and in participants with AMD, it 
was demonstrated to be equal to if not better than the PR chart (Haymes et al. 2006; 
Thayaparan, Crossland and Rubin 2007).  The Mars Letter Contrast Sensitivity test is 
advantageous compared to the PR chart, as it is more convenient and more 
appropriate to the range of contrast sensitivities in those with a visual impairment 
(Haymes et al. 2006; Dougherty, Flom and Bullimore 2005).  
1.4.3 Reading  
Reading performance is a valuable tool in diagnosing reduced visual function in AMD 
(Stifter et al. 2005). In individuals with AMD, reading performance and specifically 
reading speed is significantly reduced and associated with reduced visual satisfaction, 
and a reduced vision-related QoL (Stifter et al. 2005; Riusala, Sarna and Immonen 
2003).  
Reading is a complex task, it requires the ability to resolve the text and the capability 
to cognitively process and understand that which is being read. Different aspects of 
reading can be measured: reading acuity (near VA), critical print size and maximum 
reading speed. Reading speed is a particularly useful measure of reading 
performance. The four visual factors that affect reading speed are acuity reserve, 
contrast reserve, field of view and scotoma size (Whittaker and Lovie-Kitchin 1993). 
In an individual with visual impairment, acuity and contrast reserve typically decrease, 
until a level is reached that prevents fluent reading. An individual’s maximum reading 
speed should be at least 80 wpm for sustained reading. Below this, difficulties with 
reading tasks and reduced satisfaction are reported (Friedman et al. 1999; Whittaker 
and Lovie-Kitchin 1993).  
The International Reading Speed Texts (IRest) were developed as a result of the need 
for a standardised reading speed test across several languages. Paragraphs were 
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chosen over sentences, to enable a more realistic measure of reading speed. The 
IRest was developed in 17 different languages and showed minimal within subject 
variability (Trauzettel-Klosinski and Dietz 2012). The IRest has been used as an 
outcome measure in several studies in glaucoma (Ramulu et al. 2011; Ramulu et al. 
2013) and in a study of depressive symptoms in AMD (Mielke et al. 2013). Compared 
to other widely used measures of reading performance, the Radner Reading Charts 
and MNread Reading Test, the IResT provided the most realistic measure of reading 
performance despite being more time consuming (Brussee, van Nispen and van Rens 
2014). 
1.4.4 Microperimetry 
Microperimetry is comparable to standard automated perimetry (SAP) as it measures 
the differential light sensitivity (DLS), i.e. the minimum luminance of a white spot 
stimulus, superimposed upon a white background of uniform luminance, necessary to 
perceive the stimulus. Microperimetry is novel in that it uses an eye tracking system  
to correct the position of the stimulus to account for fixation losses (Markowitz and 
Reyes 2013). This is particularly beneficial in late AMD, in which unsteady fixation 
and/ or a preferred retinal locus are common (Acton and Greenstein 2013). 
Microperimetry also provides a real-time en-face image of the retina enabling a 
visualisation of the visual field outcome superimposed on to the retinal image. 
In recent years, the clinical use of microperimetry has increased. In 1981, the first 
commercial microperimeter, the SLO 101 (Rodenstock, Ottobrunn, Germany), was 
used to produce scotoma maps of the macula (Timberlake et al. 1982; Mainster et al. 
1982; Webb and Hughes 1981). Currently, the commercially available 
microperimeters include: the Nidek MP-3 (Nidek Technologies, Padova, Italy) and the 
Macular Integrity Assessment microperimeter (MAIA, CentreVue, Padova, Italy) 
(Table 1.4). These instruments have an improved dynamic range of 34dB for the MP-
3 and 36dB for the MAIA, compared to 20dB for the two immediately earlier 
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commercially available instruments: the MP-1 (maximum stimulus luminance 400asb) 
and the Optos OCT SLO (Optos, Dunfermline, Scotland, UK) (400asb). The Optos 
combined both SD-OCT and microperimetry technology to acquire simultaneous 
functional and retinal structure data using a dual-imaging system. The technical 
specifications of the MP-3 and the MAIA can be found in Table 1.4 and a description 
of the MP-1 and the Optos can be found in a review by Markowitz and Reyes (2013).  
MP-3 MAIA
Refractive error correction 
(D)
-25 to +15 -15 to +10
Stimulus correction Gaze-contingent Gaze-contingent
Fixation monitoring method 
and speed
Tracks anatomic 
landmarks: 25Hz
Tracks each pixel of the 
fundal image: 25Hz
Microperimetry field of 
view(˚)
45 36
Background luminance (asb) 4 or 31.4 4
Stimulus attenuation (dB) 0-34 0-36
Differential luminance range 
(asb)
4-10,000 0.25-1000
Table 1.4 Features of two commercially available microperimeters. Modified from Markowitz 
and Reyes (2013) 
A limitation of the current microperimeters is the lack of on-board statistical packages 
enabling the identification of overall and localised loss in the form of Total Deviation 
(TD) and Pattern Deviation (PD) probability analysis. Such analyses are similar to that 
which is implemented in standard perimetry (Heijl et al. 1989). TD is the difference 
between the measured DLS and the age matched normative database value at the 
corresponding location. The Mean Deviation (MD) or mean TD can also be used as a 
summary measure. PD adjusts the DLS values according to the overall height of the 
visual field and thus, shows more localised loss than TD. The majority of 
microperimetry studies use Mean Sensitivity (MS) as the primary outcome of 
microperimetry (Wu, Guymer and Finger 2016; Chandramohan et al. 2016; Hariri et 
al. 2016), which is less robust than pointwise analysis and also lacks probability 
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analysis. The establishment of a normative database allows location specific 
probability analysis, enabling the separation of focal defects from diffuse defects, and 
allowing these defects to be defined (Heijl, Lindgren and Olsson 1987a).  
Whilst probability analysis is considered essential to the interpretation of standard 
perimetry (Flammer et al. 1983; Heijl, Lindgren and Olsson 1987a), to the author’s 
knowledge, there is a paucity of literature in which such analysis has been applied to 
microperimetry. A previous study investigated normative values using the MP-1 
instrument (Acton, Bartlett and Greenstein 2011). A sample of 50 healthy individuals 
were examined and MS in the central 10° reduced by 0.1 dB per decade (Acton, 
Bartlett and Greenstein 2011). Probability analyses similar to that of the Humphrey 
Field Analyser (HFA, Carl Zeiss Meditec, Dublin, CA) were derived from the prediction 
limits around the regression of DLS with age, and TD maps were generated (Acton, 
Bartlett and Greenstein 2011; Acton et al. 2012b; Acton et al. 2012a). In order to 
define abnormality, it is preferable to collect normative values specific to the study 
instrumentation and protocol parameters e.g. stimulus pattern, thresholding algorithm 
and background luminance (Acton, Bartlett and Greenstein 2011; Acton and 
Greenstein 2013). 
A more recent study with the MAIA microperimeter, utilised computational surfaces to 
interpolate normative data between stimulus locations in relation to an individual’s 
fixation (Denniss and Astle 2016). This study enabled location specific TD and PD 
probability analysis to be performed despite a non-foveal fixation location, which has 
benefits in those with unsteady/eccentric fixation associated with macular disease. 
Despite using strong statistical methodology, the study tested 237 stimulus locations 
over either 1 or 2 study visits lasting up to an hour, and these methods do not 
represent the typical clinical perimetric examination. Additionally, a limitation of the 
study is a potential learning effect in those individuals tested over two visits, where 
DLS results improve with experience and are most pronounced from the first to the 
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second visit (Wild et al. 1989; Heijl and Bengtsson 1996). Also, those with an hour 
testing time would be subject to the fatigue effect compared to those with shorter 
testing times (Hudson et al. 1994; Heijl and Asman 1995).  
Further development of microperimetry in recent years has led to the adaptation of 
certain instruments to acquire scotopic measurements (Pfau et al. 2017). Instead of 
measuring largely cone function, as in ordinary ‘mesopic’ microperimetry, such 
instruments measure rod function under dark-adapted conditions (Midena and Pilotto 
2017; Simunovic et al. 2016). It has been suggested that a functional deficit by 
scotopic microperimetry occurs earlier than that by mesopic microperimetry in early 
AMD (Nebbioso, Barbato and Pescosolido 2014) and intermediate AMD (Fraser et al. 
2016), due to the rods being affected before the cones in the disease process (Curcio, 
Owsley and Jackson 2000). 
Additionally, the implementation of AO technology in SLO imaging has led to further 
development of microperimetry measurements. AO-SLO imaging allows visualisation 
of the individual photoreceptors and, therefore, specific photoreceptors can be 
stimulated using this technology (Tuten, Tiruveedhula and Roorda 2012). However, 
research in this area is limited and the combined device is not commercially available, 
therefore, more work is required to establish its utility in AMD. 
A systematic review evaluating the use of microperimetry in assessing visual function 
in AMD is presented in Chapter 2 and is modified from Cassels et al. (2017). 
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1.4.4.1 Macular Integrity Assessment microperimeter 
The MAIA microperimeter became commercially available in 2009 (Figure 1.9). It is a 
near infrared line SLO instrument with an integrated 25Hz eye tracker, which corrects 
for eye movements by monitoring pixels within a fundal image. The MAIA light source 
is an infrared broadband super luminescent diode with a wavelength of 845nm. It has 
a 36˚ field of view and produces 1024 X 1024 pixel images. The MAIA has an 
improved dynamic range compared to that of the MP-1 instrument, however the MP-
3 device has since become available with a similar dynamic range to the MAIA (Table 
1.4) (Markowitz and Reyes 2013; Acton and Greenstein 2013; Acton et al. 2012a). 
Nevertheless, the MP-3 is limited by the lack of SLO technology and by the retinal 
tracking of a landmark rather than each pixel within the image. The MAIA device 
includes pre-defined stimulus configurations, but custom patterns may also be used. 
Figure 1.9 The MAIA microperimeter with customised red filter placed on to the computerised 
screen (right) to avoid excessive light under dark adapted conditions. 
The MAIA has the choice of two red circular fixation targets of a 1° or 12° diameter, 
produced by light-emitting diodes (LEDs) at 633nm. White Goldmann size III stimuli 
are presented onto a background of 1.27cd/m². The stimulus attenuation is 0-36dB 
with a maximum stimulus intensity of 318cd/m². It has three threshold estimating 
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strategies available: a scotoma finder supra-threshold strategy, a 4-levels-fixed supra-
threshold strategy, and a 4-2 strategy.  
The MAIA module software is reported by the manufacturers to contain a normative 
database and analysis software to enable identification of abnormality. However, the 
MAIA does not derive TD or PD analysis and merely displays the measured DLS, in 
dB, at each stimulus location. The DLS value is colour coded, using a continuous 
scale of colour change, to arbitrarily indicate normal, borderline and abnormal 
outcomes (Midena 2013) (Figure 1.10). This colour coding does not take into account 
the variation of DLS in the normal eye either with age, or with eccentricity (Figure 
1.10). Additionally, the raw normative database values for the MAIA are currently not 
freely available, and a detailed methodology for derivation of the normative database 
is not provided in the published literature (Vujosevic et al. 2011).
A useful feature of the software includes the automated measure of fixation stability, 
by calculating the bivariate contour ellipse area (BCEA). The fixation positions 
throughout the examination are plotted on Cartesian axes and the area of the ellipse 
in which 63% or 95% of fixation points occur, is calculated (Figure 1.10). Fixation is 
also categorised as stable, relatively stable or unstable depending on the percentage 
of fixation points within 1° or 2° circular area representing the average centre of all 
fixation points (Fujii 2002). However, this method of quantifying fixation was reported 
to be less appropriate compared to the BCEA measure (Crossland, Dunbar and Rubin 
2009). 
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Figure 1.10 MAIA microperimetry output for a normal 45 year old individual: Infra-red MAIA 
image (top left) and a custom 40 location stimulus pattern (top right). The colour coding 
represents the different decibel values for sensitivity as shown on the frequency bar chart for 
the same individual (middle right). The histogram shown is that used to colour code the 
locations and is the same for all ages and eccentricities. The bivariate contour ellipse is 
overlaid on an IR image and calculated (bottom left). A fixation graph is also included to show 
the deviations in fixation (in degrees) during the examination (bottom right). 
1.4.5 Other functional measures 
A number of functional measures have been identified as potential biomarkers in 
AMD, including: flicker threshold (Dimitrov et al. 2011), colour threshold (Eisner et al. 
1992; O’Neill-Biba et al. 2010) and dark adaptation (Dimitrov et al. 2012; Owsley et 
al. 2001; Owsley et al. 2007; Owsley et al. 2016).
Dark adaptation is the measurement of visual threshold recovery in the dark following 
presentation of a bright light that bleaches the retinal photopigment. The characteristic 
dark adaptation curve indicates that cones mediate the initial recovery after the bleach 
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and rods mediate the second stage of recovery. Rod-mediated dark adaption, cone 
dark adaptation and time to rod cone break are all suggested to be sensitive 
biomarkers for early AMD (Gaffney, Binns and Margrain 2011; Gaffney, Binns and 
Margrain 2013; Owsley et al. 2001; Owsley et al. 2007; Dimitrov et al. 2012).  
Cone function may also be measured by the assessment of colour vision and allows 
for the additional assessment of the cone type affected in AMD. Blue-yellow colour 
vision is primarily affected in early AMD with red-green colour vision becoming 
affected in later stages of AMD (Cheng and Vingrys 1993; O’Neill-Biba et al. 2010).  
Flicker threshold measures the highest detectable flicker rate. A sinusoidal flickering 
stimulus is presented at different frequencies with a fixed luminance and contrast, and 
the threshold is that at which the flickering stimulus appears steady. A flickering 
stimulus increases the retinal metabolic demand and, therefore, in AMD where the 
increase in metabolic demand cannot be met, the measured flicker threshold is 
reduced compared to healthy individuals (Dimitrov et al. 2011). Flicker threshold has 
the capability to detect functional deficits in early AMD compared to healthy individuals 
(Mayer et al. 1994; Dimitrov et al. 2012; Dimitrov et al. 2011). 
To conclude, functional measures are a vital aspect of AMD clinical assessment and 
provide relevant information about the individual’s everyday visual function. VA, CS, 
reading speed and microperimetry have all been shown to be sensitive to changes in 
AMD as a result of both treatment and progression and, therefore, are appropriate 
measures of visual function for individuals at all stages of AMD. 
The World Health Organisation (WHO) states that QoL is the: 
“individual's perception of their position in life in the context of the culture and value 
systems in which they live and in relation to their goals, expectations, standards and 
concerns” (WHOQOL 1995). 
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There are many aspects that affect a person’s QoL including physical and mental 
health, social and economic situation, and education (WHOQOL 1995). This 
multidimensionality of QoL, suggests that change in one of these factors would be 
expected to affect an individual’s QoL. Yet, each factor may affect QoL to a different 
extent depending on the individual. QoL is a highly debated topic and different aspects 
of QoL can be examined (Eurostat 2015). Vision-related and health-related aspects 
are often measured by separate questionnaires, with health-related outcomes 
typically sub-divided by physical and mental health. However, in reality these aspects 
are all intertwined (Figure 1.11).  
Figure 1.11 Venn diagram to illustrate the multidimensionality and overlap of QoL, health-
related QoL, vision-related QoL and visual function. 
1.5.1  Vision-related instruments 
Visual function can be assessed by both objective and subjective methods. Objective 
measurements, such as VA or reading speed, are clinically important in assessing 
functional capabilities; however, this does not necessarily translate as the individuals 
‘real world’ capabilities (Massof and Rubin 2001). For this reason, subjective 
methods, such as questionnaires, are now recommended in the assessment of visual 
function. Different questionnaires aim to assess separate aspects of vision and can 
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be referred to using different terms depending on that which is being measured. These 
terms include, but are not limited to vision-related QoL and visual function. 
There are a large number of questionnaires or ‘instruments’ in optometry and 
ophthalmology, which assess visual function or vision-related QoL in different 
diseases. Each instrument is designed to measure specific aspects of visual function 
and vision-related QoL, either in a specific disease (e.g. glaucoma, cataract and AMD) 
or in a group (adult or child with low vision). It is, therefore, important to evaluate and 
select the most appropriate instrument available for the participants and the aims of 
the study (Khadka, McAlinden and Pesudovs 2013).  
When evaluating these instruments, the psychometric properties, or the validity, 
reliability and responsiveness need to be considered (Khadka, McAlinden and 
Pesudovs 2013). Validity is the extent to which the instrument measures that which it 
was developed to measure. There are several types of validity: face, construct and 
criterion. Face validity refers to whether an instrument subjectively appears to 
measure what it is designed to. Construct validity assesses whether an instrument 
measures what it is designed to measure. Criterion validity can be subdivided into 
concurrent and predictive validity. Concurrent validity refers to how closely a new 
instrument correlates with an existing already validated measure. Predictive validity 
is the ability of an instrument to predict the results from an existing already validated 
measure (Bland and Altman 2002).  
 Reliability is the degree to which an instrument is free from random error, i.e. whether 
the same results are obtained a second time (Bowling and Ebradhim 2005). There 
are several tests for this, such as repeatability, reproducibility and internal 
consistency. Repeatability or test-retest reliability is the capability of an instrument to 
give the same measurement over a short period of time. Reproducibility is the ability 
to replicate an entire study. Internal consistency is usually measured by Cronbach’s 
alpha, which calculates the correlations between items (questions) of an instrument. 
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Responsiveness is the ability of an instrument to detect a known change in an 
individual (Bowling and Ebradhim 2005). 
Likert scales are commonly utilised to measure the responses for visual function 
instruments. Likert scales usually consist of a five point scale of answers, for example 
if the question was “how much difficulty do you have with watching the TV?” the 
answering categories might be: 0, “no difficulty”; 1, “a little difficulty”; 2, “some 
difficulty”; 3, “a lot of difficulty”; and 4, “unable to perform task”. The scores are then 
summed to give an overall score. This, however, does not take into account the 
difference in magnitude between the five points of the scale or the difference in 
difficulty between items (Elliott, Pesudovs and Mallinson 2007).  
The Rasch model addresses these problems by assigning items different weightings 
depending on the difficulty of the item and person ability. The Rasch model was 
originally developed by Georg Rasch and was based upon item response theory 
(IRT). IRT addressed the concept that additional to items having different difficulties, 
people also have different abilities, and therefore, IRT scaled these accordingly 
(Pesudovs et al. 2007). Rasch analysis is a probabilistic logistic function that 
separates items and the individuals, which enables the difficulty of items and an 
individual’s pattern of answers to be analysed. The pattern of answers for each 
individual is analysed and an item difficulty rating generated accordingly. A scale 
based upon the individual’s responses is then produced, and compared with the other 
individuals. This converts ordinal raw scores into true linear scales, scored in logits, 
which allows for parametric statistical testing (Khadka, McAlinden and Pesudovs 
2013). Additionally, Rasch analysis enables assessment of the overall fit of the items 
and persons to the Rasch model, which has been used to assess the validity and 
reliability of instruments (Massof and Rubin 2001; Pesudovs et al. 2007; Finger et al. 
2008).  
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1.5.1.1 Age-related macular degeneration. 
Age-related macular degeneration can cause difficulties with everyday activities such 
as self-care (Ivanoff et al. 2000) and leisure activities (Scilley et al. 2002), and also 
the ability to access local amenities (Hochberg et al. 2012), leading to a lack of 
freedom and independence (Williams et al. 1998; Bennion, Shaw and Gibson 2012). 
These difficulties can result in a subsequent decline in an individual’s QoL (Curriero 
et al. 2013).  
Many instruments assess different aspects of visual function and vision-related QoL 
including visual symptoms, socio-emotional well-being, participation in daily activities, 
and the effect of visual function on daily living. It is important that when measuring 
self-reported visual function or vision-related QoL, the chosen instrument has been 
validated within the intended population (Massof and Fletcher 2001). The five most 
commonly used instruments that have been evaluated within a population with AMD 
are described in the following paragraphs (Finger et al. 2008; Khadka, McAlinden and 
Pesudovs 2013).  
1.5.1.1.1 National Eye Institute’s Visual Function questionnaire 
Originally, the National Eye Institute’s Visual Function questionnaire (NEI VFQ) 
consisted of 52 items. It was designed to assess ‘vision-targeted functioning’ and how 
this influenced the vision-related QoL across a number of ocular conditions (Mangione 
et al. 1998). A survey of focus groups with a range of different ocular conditions was 
conducted, and it was concluded that to be clinically viable, the NEI VFQ would need 
to be shortened (Mangione 1998). The 25 item NEI VFQ (NEI VFQ-25) was one of 
several shorter versions (including 48, 39 and 36 items) created, which all had the 
same psychometric properties as the 52 item. However, these were more suitable for 
a clinical environment and more patient friendly (Mangione 2001; Matchar et al. 2006). 
The shorter versions are now widely used (Mangione 2001; Matchar et al. 2006), and 
the NEI VFQ-39 and the NEI VFQ-25 have been recommended for use due to a robust 
Rasch analysed construct (Pesudovs et al. 2010). 
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In CNV, the NEI VFQ-25 showed good reliability and internal consistency suggesting 
a good validity; however, Rasch analysis was not performed and this is a necessity in 
the psychometric testing of instruments (Orr et al. 2011; Khadka, McAlinden and 
Pesudovs 2012). In a population with low vision, the psychometric properties of the 
NEI VFQ-25 were assessed by Rasch analysis, and only 7 of the items were found to 
be sensitive to rehabilitation intervention (Stelmack, Stelmack and Massof 2002). In 
2008, this was developed to produce the seven-item NEI VFQ, which was shown to 
have acceptable person separation reliability and sensitivity to changes after a 
rehabilitation intervention (Ryan, Court and Margrain 2008; Dougherty and Bullimore 
2010). The floor and ceiling effects of the standard scoring of the NEI VFQ-25 were 
eliminated with the use of Rasch analysis, but the validity of the subscales needed 
reconsideration (Dougherty and Bullimore 2010). There are conflicting opinions on 
the use of the NEI VFQ and its various forms and subscales. A review of a number of 
instruments recommended several of the NEI VFQ subscales for use in a range of 
conditions, including refractive error and cataracts, but it was not recommended for 
use in AMD (Khadka, McAlinden and Pesudovs 2013). 
1.5.1.1.2 Impact of Vision Impairment scale 
The Impact of Vision Impairment (IVI) scale was established as a measure of vision-
related QoL based upon participation in daily activities, and has been suggested as a 
useful approach to evaluate visual rehabilitation (Hassell, Weih and Keeffe 2000; 
Weih, Hassell and Keeffe 2002; Lamoureux et al. 2007b). It was developed in 
accordance with the WHO’s statement on participation in daily activities (WHO 2001). 
Whereby, participation is affected by a number of factors including: eye disease, 
vision impairment, limitation of activities, individual characteristics and the 
environment  (WHO 2001). The development involved consultation with focus groups, 
in addition to input from existing instruments (Hassell, Weih and Keeffe 2000; Weih, 
Hassell and Keeffe 2002). The IVI, unlike other instruments, focuses on the 
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individual’s ability to participate within society, by assessing their visual capability in 
daily activities, rather than only what they are able to ‘see’. 
The IVI originally consisted of 32 items split into five domains: leisure and work, 
consumer and social interaction, household and personal care, mobility and emotional 
reaction to vision loss. Four of the 32 items IVI were demonstrated to deviate from the 
expected model when evaluated with Rasch analysis (Lamoureux et al. 2006). When 
these items were removed and the scoring altered, the instrument fitted to the Rasch 
model (Lamoureux et al. 2006). The revised 28 item IVI fitted to a three factor model 
divided into the subscales; “emotional well-being” (8 items), “reading and accessing 
information” (9 items) and “mobility and independence” (11 items) (Lamoureux et al. 
2007c). The revised IVI was determined to be sensitive to changes in visual 
impairment when evaluating the benefit of cataract surgery in early AMD, suggesting 
the ability to identify changes due to treatment (Lamoureux et al. 2007a). IVI results 
were associated with VA, reinforcing the relationship between functional impairment 
and vision-related QoL (Lamoureux et al. 2007b). In AMD, the 28 item IVI fitted well 
to the Rasch model and was able to identify differences in the disease severity, 
suggesting validity in this population (Lamoureux et al. 2008). Most recently, the IVI 
was further shortened to produce a ‘brief IVI’ consisting of 15 items: 9 visual function 
items and 6 emotional well-being items (Fenwick et al. 2017). The aim of this 
shortened version was to reduce the time commitment required by the full length IVI 
and, therefore, reduce the burden for the participants. 
In conclusion, the IVI is a vision-related QoL questionnaire that was developed to 
assess the effect of visual impairment on an individual’s ability to participate in daily 
activities and society, as well as the emotional effect. It has been shown to be valid 
for a population with AMD, and sensitive to the severity of disease, in addition to 
changes due to interventions. 
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1.5.1.1.3 Visual Function Index 
The Visual Function Index (VF-14) is an instrument that measures difficulty with visual 
tasks. It has fourteen items that are related to vision-specific daily activities and are 
scored on a Likert scale from 0 to 4; ranging from “no difficulty” to “unable to perform” 
respectively (Steinberg et al. 1994). It was designed for use within a population with 
cataracts, and when Rasch analysed within this population, there was concordance 
between the Rasch scores and traditional scoring (Steinberg et al. 1994; Valderas et 
al. 2004). The VF-14 was validated in retinal disease and AMD, in which it was found 
to be sensitive to changes in VA and progression of disease (Linder et al. 1999; 
Mackenzie et al. 2002). In late stage AMD, the VF-14 was shown to be a more useful 
predictor of subjective satisfaction with vision than VA (Riusala, Sarna and Immonen 
2003). Rasch analysis of the VF-14 gives improved precision over Likert scoring, 
especially for the use in longitudinal studies (Hewitt et al. 2006; Las Hayas et al. 
2011).  
1.5.1.1.4 Macular Disease Quality of Life questionnaire 
The Macular Disease Quality of Life (MacDQoL) instrument was originally developed 
to examine the impact that macular disease has on QoL (Mitchell and Bradley 2004). 
It was derived from a mixture of ideas from the ‘Schedule for the Evaluation of 
Individual QoL’ and the ‘Audit of Diabetes Dependant QoL’, then further developed 
using focus groups of individuals with macular disease (Mitchell and Bradley 2004). 
Once redundant items were removed, reducing the MacDQOL to 22 items, it was 
concluded that it had good face validity, construct validity, good test re-test 
repeatability and was sensitive to change in vision status (Mitchell et al. 2005; Mitchell 
et al. 2008). More recently, Rasch analysis was used to examine the psychometric 
properties of the MacDQOL and the answering categories were determined to have 
overlapping responses (Finger et al. 2012; Khadka, McAlinden and Pesudovs 2013). 
The instrument was also multidimensional; however, it could be split into two 
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subscales with simplified scoring which were psychometrically sound (Finger et al. 
2012; Khadka, McAlinden and Pesudovs 2013). A more recent study performed a 
semi-structured interview with individuals with AMD asking questions related to the 
applicability of the MacDQOL instrument (Ord et al. 2015). This study concluded that 
the MacDQOL was relevant to those with AMD (Ord et al. 2015), however the study 
was limited by the lack of robust statistical analysis. 
1.5.1.1.5 Daily Living Tasks Dependent on Vision 
The Daily Living Dependent on Vision (DLTV-22) instrument was specifically 
developed as a “vision specific functional index” for individuals with AMD (Hart et al. 
1999). Activities in which difficulties arise due to visual impairment were identified by 
individuals with AMD and healthcare professionals (Hart et al. 1999). Items were then 
derived from these activities and a Likert scale of responses was used (Hart et al. 
1999). The psychometric properties of the DLTV-22 were improved by identifying four 
domains and removing redundant items (DLTV-17) (Hart et al. 2005). Additional 
refinement reduced the items to 11, with a 7 item subscale, which was recommended 
for use with an AMD population (Denny et al. 2007; Khadka, McAlinden and Pesudovs 
2012).  
1.5.1.1.6 Utility measurement  
Utility measurements are most commonly utilised to provide an unbiased assessment 
of an individual’s health state (Redelmeier and Detsky 1995). One method of utility 
measurement is the time-trade off instrument (TTO) (Brown 2000). The TTO 
instrument, undertaken as a health-related metric, poses two hypothetical questions; 
firstly, how many years the individual expects to live and secondly, how many of those 
years the individual would trade in return for perfect health. A utility value can then be 
calculated, a value of 1.0 indicates perfect health state and 0.0 indicates death (Brown 
2000). 
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This instrument has been adapted for use with respect to vision, in which the wording 
of the hypothetical questions is altered to include perfect sight rather than perfect 
health state. This adapted TTO has been previously implemented in individuals with 
AMD (Brown 2000; Butt et al. 2013; Stein et al. 2003; van de Graaf et al. 2016) and 
is recommended for use in economic evaluations of AMD due to the association with 
VA (Butt, Tufail and Rubin 2017).  
To summarise, there are a number of vision-related instruments that have been 
evaluated in a population with AMD. Three instruments are appropriate for individuals 
with AMD: one measuring visual function (VF-14), one measuring utility (TTO) and 
one measuring vision-related QoL (IVI). The VF-14 provides a subjective 
measurement of visual function, which has been shown to be sensitive to AMD 
severity. The TTO gives an unbiased assessment of the individual’s visual impairment 
by calculating a utility value. The psychometric properties of the IVI have been 
examined both in a normal population and in individuals with AMD in numerous 
studies. Additionally, the face validity of the IVI shows a variety of items covering the 
three different domains, and thus, it provides a thorough assessment of vision-related 
QoL. 
1.5.2 Health-related instruments 
Physical and mental health have a larger impact on QoL than visual factors in 
individuals with low vision (Hernandez Trillo and Dickinson 2012), and it is therefore 
important to consider health-related measures when investigating vision-related QoL.  
1.5.2.1 Physical health 
Different chronic co-morbidities have varying effects on QoL. Since 75% of visually 
impaired adults have additional co-morbidities (Van Nispen et al. 2008), it is essential 
to take these into account when examining a population with visual impairment. As 
AMD is an age-related disease, additional co-morbidities are common and lead to an 
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increased risk of a reduced QoL (Van Nispen et al. 2009). The use of a well-
established generic health instrument is necessary, as validation in different 
populations has already taken place and, therefore, allows for meaningful 
comparisons (Mangione 1998).  
1.5.2.1.1 EQ-5D  
The EQ-5D is a generic health status instrument, developed by the EuroQOL group. 
The EuroQOL group aimed to develop an instrument that was non-disease specific 
and standardised, but described an individual’s health status (EuroQoL 1990). The 
EQ-5D has 5 domains: mobility, self-care, usual activities, pain and discomfort, and 
anxiety and depression. Each question has a three (EQ-5D-3L) or five level (EQ-5D-
5L) scale of answers. This allows for the classification of 243 health states (Rabin and 
de Charro 2001). The EQ-5D is recommended by the National Institute for Health 
Care and Excellence (NICE) in the UK and is thus one of the most commonly used 
health status instruments in clinical practice. Furthermore, it has been utilised in 
clinical and economic evaluations of health care, and in population health surveys 
(Rabin and de Charro 2001; Clemens et al. 2014; Rencz et al. 2016). The EQ-5D is 
also typically included in research in AMD (Chatziralli et al. 2016; Lotery et al. 2007; 
Payakachat et al. 2009). The EQ-5D score is reduced in individuals with AMD 
compared to controls (Chatziralli et al. 2016). 
1.5.2.1.2 Short Form Health Survey 
The Short Form 36 Health Survey questionnaire (SF-36) is a standardised measure 
of health status (Garratt et al. 1993), and has been widely used to measure the impact 
of interventions (Garratt et al. 1993). The SF-36 has 8 dimensions that can be 
combined into two summary measures: physical and mental health, and has been 
shown to have high internal consistency, reliability and validity (Stewart 2007). The 
36 item version has since been reduced to 12 items and the scoring altered to produce 
the 12-item Short-Form Health Survey (SF-12), which was found to be valid and 
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reliable in a sample of older adults (Resnick and Nahm 2001; Resnick and Parker 
2001). Additionally, the SF-36 was further developed into a six-dimensional 
questionnaire, the SF-6D, which consists of 10 items from the original questionnaire 
(Brazier, Roberts and Deverill 2002). The SF-6D differs from the other two versions 
as it estimates a single index of health using normative database values, and can 
subsequently be used in economic analysis (Brazier, Roberts and Deverill 2002).  The 
SF-36, SF-12 and SF-6D have all been utilised in AMD research (Hassell, Lamoureux 
and Keeffe 2006; Choudhury et al. 2016; Mathew et al. 2011; Espallargues et al. 
2005) . 
In conclusion, the EQ-5D and the SF-6D are both NICE recommended and have been 
implemented in those with AMD. However, a review by the NHS stated that the EQ-
5D was the preferred health status measure by NICE, showing good responsiveness 
for visual disorders (Longworth et al. 2014).  
1.5.2.2 Mental health 
In AMD, the prevalence of depression is approximately twice as high as in the general 
population (Brody et al. 2001), and is also associated with reduced visual function 
(Rovner, Casten and Tasman 2002; Brody et al. 2001). Dissatisfaction of performance 
in certain daily activities has been associated with an increased risk of depression in 
AMD (Rovner et al. 2007). However, the presence of depressive symptoms can also 
be associated with greater difficulty with daily tasks in individuals with a visual 
impairment (Jones et al. 2009), and reduced visual function in AMD (Rovner, Casten 
and Tasman 2002). Social status can also affect mental health; for example in AMD, 
depression was less likely to occur when cohabiting (Jivraj et al. 2013). Mental well-
being or positive mental health is defined as the positive aspects of an individual’s 
everyday functioning, and is a less explored area in those with AMD. The depression 
instruments recommended by NICE will be briefly described and an instrument to 
measure well-being will also be summarised.
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1.5.2.2.1 Patient Health Questionnaire-9  
The Patient Health Questionnaire-9 (PHQ-9) is a well-established instrument to detect 
depression (Kroenke, Spitzer and Williams 2001). The 9 items are established from 
the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition), which 
describes diagnoses of major or minor depressive disorders (Association 1994). The 
PHQ-9 measures the symptoms of depression. A Likert scale is used to grade the 
symptoms from 0, “not at all” to 3, “every day”. The score is the sum of the answers 
and the higher the score, the more severe the depressive symptoms. The PHQ-9 is 
the NICE recommended instrument to measure depression severity at baseline and 
after treatment (Smarr and Keefer 2011). 
1.5.2.2.2 Beck Depression Inventory 
The Beck Depression Inventory (BDI) was developed in 1961 to measure depression 
objectively and to enable change to be monitored (Beck 1961). It has been adapted 
several times. One of the most recent versions is the BDI-II, which was developed 
due to the changed diagnostic criteria for depression. It is a 21 item questionnaire with 
a 4 category Likert scale, except for two questions that have 7 category Likert scale.
The BDI-II is also one of the NICE recommended depression instruments (Smarr and 
Keefer 2011).
In conclusion, the PHQ-9 and the BDI are NICE recommended measures of 
depressive symptoms. Both instruments are well-established instruments, however 
the PHQ-9 is shorter than the BDI and therefore is more effective within a clinical 
research study. 
1.5.2.2.3 Warwick-Edinburgh Mental Well-being Scale 
Mental well-being can be broken down into two positive aspects; pleasure and life 
satisfaction (hedonic perspective) and positive cognitive functioning, healthy 
relationships with others and self-acceptance (eudaimonic perspective) (Ryan and 
Deci 2001; Berridge and Kringelbach 2011). Mental well-being is different to mental 
46 
health as it describes positive aspects of thinking and feeling, whereas mental health 
can include a range of conditions from excellent to poor mental health.  
The Warwick-Edinburgh Mental Well-being Scale (WEMWBS) was developed in 2006 
after being commissioned by Warwick and Edinburgh universities (Tennant et al. 
2007). It was developed as a scale to assess positive mental health by building on 
existing instruments and including both aspects of well-being; hedonic and 
eudaimonic (Tennant et al. 2007). The development of the WEMWBS combined 
expert advice from many disciplines including psychiatry, public health and focus 
group discussions. The final instrument consisted of 14 positively worded items with 
5 Likert response categories. Rasch analysis was subsequently used to evaluate the 
WEMWBS, and it was established to be multidimensional. Items were deleted until 
strict unidimensionality was obtained and 7 items remained, which became the 
shortened WEMWBS (SWEMWBS) (Stewart-Brown et al. 2009). Face validity of the 
SWEMWBS displayed bias towards eudaimonic well-being rather than hedonic, and 
it was concluded that the WEMWBS provided a less restricted assessment of well-
being (Stewart-Brown et al. 2009).  
In one recent publication in individuals with low vision, no change in WEMWBS was 
observed as a result of vision rehabilitation (Acton et al. 2016). However, the 
association between well-being and vision-related QoL has yet to be established. The 
already established relationship between QoL and depression in AMD (Rovner, 
Casten and Tasman 2002), may suggest that AMD would also be associated with a 
reduced level of well-being measured by the WEMWBS. 
To summarise, QoL is a multidimensional concept that is difficult to define and 
measure. Using a combination of health- and vision-related instruments will enable a 
thorough evaluation of QoL. AMD is associated with a reduced vision-related QoL and 
the ability to understand this relationship in respect to clinical findings and health-
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related measures may lead to improved identification of individuals at risk of reduced 
QoL within a clinical setting. 
In the evaluation of QoL and clinical outcomes in AMD, the overall aim of the thesis 
is to determine the factors that predict QoL in those with AMD, both at baseline and 
after 1 year follow-up. This section will describe the rationale behind this aim and the 
detailed aims of each chapter. 
Age-related macular degeneration is the leading cause of sight loss in the developed 
world (Klein et al. 2013), and owing to an ageing population is predicted to become 
an increasing economic and social burden (Saxena et al. 2016; Day et al. 2011). QoL 
outcomes are critical to the individual and AMD has detrimental effects on an 
individual’s QoL (Chatziralli et al. 2016), reducing independence (Wong et al. 2004), 
limiting activities (Scilley et al. 2002), and increasing the risk of falls and depression 
(Knudtson, Klein and Klein 2009; Rovner, Casten and Tasman 2002). AMD 
management should take these QoL changes into account. Additionally, as a result 
of the increasing economic burden, the ability to identify those at risk of a reduced 
QoL would allow more economically viable support mechanisms for those in need.  
QoL is a multidimensional concept and consequently, it is influenced by a number of 
aspects of daily living including physical and mental health, education, and social and 
economic status (WHOQOL 1995). Depression is also an important predictor of QoL 
(Moore et al. 2005). The prevalence of depression in individuals with low vision is 
twice that of those with normal vision (van der Aa et al. 2015). Furthermore, it is well 
established that depression has a high incidence within a population with AMD 
(Rovner, Casten and Tasman 2002).  
Clinical measures of visual function also represent a measure of the individual’s 
everyday functioning (West et al. 2002a), and are associated with QoL in those with 
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AMD (Cahill et al. 2005). VA is the most established outcome measure of visual 
function in AMD clinical trials, yet it has been suggested that VA is not sensitive to 
early functional loss in AMD (Parravano et al. 2010b; Midena et al. 2007). Other 
common measures of visual function include assessments of reading ability and CS, 
which have both previously been associated with self-reported visual performance 
and vision-related QoL (Hazel et al. 2000; McClure et al. 2000). However, CS 
(measured with a letter chart) and VA are typically limited to the measurement of 
foveal function. A topographical measure allows a more detailed assessment of visual 
function and may be more valuable in a disease such as AMD, which extends across 
the retina. Microperimetry is such a technique, and can identify both focal and 
generalised functional loss. Thus, the investigation of the microperimetry outcomes 
relative to QoL measures may yield stronger relationships with QoL than measures 
such as VA, CS and reading ability. 
In summary, when evaluating the factors that may predict a reduced QoL in those with 
AMD it is appropriate to consider clinical measures of visual function, AMD severity, 
metrics of depression and health status. The research presented herein will include 
VA, CS, reading speed and microperimetry outcomes to measure visual function, 
PHQ-9 to measure depressive symptoms and EQ-5D to measure health status. 
It is also of interest to investigate if a change in QoL over a period of 1 year could be 
predicted by either the baseline measures or by the change in the same factors. 
Potential implications of these findings would form an evidence base for a clinical tool 
to identify those with a change in QoL without the need for a time-consuming 
questionnaire interview. This would subsequently allow clinicians to make sound 
management decisions with economic and social benefits, and allow resources to be 
directed to those who require it. 
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1.6.1 Thesis aims 
The overall aim of this research was to investigate the relationship between clinical 
measures and vision-related QoL outcomes in individuals with AMD.  
The detailed aims are: 
 To provide a comprehensive systematic review of the current literature on the 
use of microperimetry as a measure of visual function in AMD. 
o This aim is addressed in Chapter 2: A systematic review evaluating the 
use of microperimetry in assessing visual function in age-related 
macular degeneration.  
 To derive a pointwise age-corrected normative database with a statistical 
model to perform global and localised probability analyses. Two secondary 
aims were: to examine over three visits the characteristics of the macular 
visual field (MVF), from microperimetry, with respect to age and eccentricity; 
and to compare two different methods of deriving the normative database.  
o In Chapter 4, it was necessary to develop a robust method to analyse 
the outcomes of microperimetry, prior to its use in the evaluation of 
AMD. 
 To evaluate the association between AMD-related retinal microstructure 
changes and microperimetry outcomes at 5° from fixation.   
o This aim is addressed in Chapter 5: The association between SD-OCT 
and microperimetry outcomes. The complex interrelationships 
between these outcomes are of interest due to their role as potential 
biomarkers in AMD. 
 To establish the relationship between vision-related QoL, as measured by the 
IVI questionnaire, in individuals with AMD and the following variables: AMD 
severity, VA, CS, reading speed and microperimetric outcomes; additional 
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vision-related self-reported outcomes, assessed by VF-14 and TTO; 
depression (PHQ-9); health status (EQ-5D-3L); and well-being (WEMWBS).   
o Chapter 6: Vision-related quality-of-life in individuals with age-related 
macular degeneration directly examined the primary aim of the thesis. 
 To examine the relationship between change in vision-related QoL and clinical 
outcomes over 1 year, in a subset of individuals with AMD. To achieve this, it 
was necessary to, firstly, quantify the change in vision-related QoL (IVI), 
clinical measures of visual function (CS, VA, reading speed and 
microperimetric outcomes), health status (EQ-5D), depression (PHQ-9) and 
well-being (WEMWBS) after a follow-up period of 1 year. Secondly, to 
evaluate the factors that determine change in vision-related QoL after 1 year.
o In Chapter 7, the relationship between change in vision-related QoL 
and clinical outcomes benefitted from the added insight of a 
longitudinal evaluation of QoL, and allowed the identification of those 
at risk of a change over time. 
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Chapter 2: The use of microperimetry in assessing 
visual function in age-related macular degeneration 
Microperimetry is a novel technique for assessing visual function and appears 
particularly suitable for AMD. Compared to SAP, microperimetry offers several unique 
features. It simultaneously images the fundus, incorporates an eye tracking system to 
correct the stimulus location for fixation loss, and identifies any preferred retinal loci.  
A systematic review of microperimetry in the assessment of visual function in AMD 
identified 680 articles; of these, 56 met the inclusion criteria.  
Microperimetry and AMD is discussed in relation to: disease severity; structural 
imaging outcomes; other measures of visual function; and evaluation of the efficacy 
of surgical and/ or medical therapies in clinical trials.   
The evidence for the use of microperimetry in the functional assessment of AMD is 
encouraging. Disruptions of the ellipsoid zone band and RPE are clearly associated 
with reduced DLS despite the maintenance of good VA.  Reduced DLS is also 
associated with outer segment thinning and RPE thickening in early AMD and with 
both a thickening and a thinning of the whole retina in CNV.  However, microperimetry 
lacks the robust diffuse and focal loss age-corrected probability analyses associated 
with SAP and the technique is currently limited by this omission. 
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Age-related macular degeneration is the leading cause of blindness in the developed 
world (W.H.O 2016) and accounts for the majority of registerable visual impairment in 
both the USA and the UK (Resnikoff et al. 2004; Bunce, Xing and Wormald 2010; 
Klein et al. 2013).  
Visual acuity is the most widely used outcome measure in ophthalmic research; 
however, VA is insufficiently sensitive to detect the early stages of functional loss in 
AMD (Parravano et al. 2010b; Midena et al. 2007). Various other tests of visual 
function, such as dark adaptation (Owsley et al. 2001), flicker threshold (Dimitrov et 
al. 2011) and photostress recovery time (Neelam et al. 2009), are more sensitive than 
VA in detecting early functional loss in AMD; however, such tests have limited clinical 
utility due to their time-consuming nature (Neelam et al. 2009). There is, therefore, a 
need for a robust and clinically appropriate technique to assess visual function across 
the macula that is more indicative of visual function than VA.  
Microperimetry is similar to SAP in that it measures the DLS, i.e. the minimum 
luminance of a white spot stimulus, superimposed upon a white background of 
uniform luminance, necessary to perceive the stimulus. However, microperimetry is 
novel in that it uses an eye tracking system to correct the position of the stimulus for 
any fixation loss. Such a correction is particularly appropriate in the later stages of 
macular disease where unsteady fixation and/ or a preferred retinal locus is common. 
Microperimetry offers the additional benefit of providing a real-time en-face image of 
the posterior pole. The latter is of value in macular disease as it enables direct 
comparison between the visual function outcome and the underlying fundal 
appearance (Acton and Greenstein 2013). 
The concept of microperimetry was initially illustrated clinically in 1981 (Webb and 
Hughes 1981). Currently, there are two commercially available microperimeters: the 
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Nidek MP-3 (Nidek Technologies, Padova, Italy) and the MAIA (CentreVue, Padova, 
Italy).  These instruments have an improved dynamic range of 34dB (differential 
luminance range of 4 to 10,000asb) for the MP-3 and 36dB (0.25 to 1,000asb) for the 
MAIA, compared to 20dB for the two immediately earlier commercially available 
instruments: the MP-1 (400asb) and the Optos OCT SLO (Optos, Dunfermline, 
Scotland, UK) (400asb). The background luminance for the MAIA is 4asb; while the 
MP-3 offers the option of either 4asb or 31.4asb. The technical specifications of the 
current and earlier microperimeters are reviewed in detail elsewhere (Markowitz and 
Reyes 2013). The eye-tracking systems automatically register the eye position at 25 
times per second relative either to given anatomic landmarks (MP-3) or to each pixel 
of the fundal image (MAIA). 
Mean Sensitivity is the most common outcome measure in microperimetry and is 
defined as the mean of the DLS obtained across all the designated stimulus locations. 
However, the MS is a summary measure and does not account for the decline in DLS 
with age. Less common, but more appropriate outcome measures for microperimetry 
are the TD which is defined as the difference between the DLS at a given stimulus 
location and the corresponding age-corrected normal value; and the MD which is 
defined as the weighted arithmetic mean of the TD obtained across all the designated 
stimulus locations. A worsening of visual function is indicated by an increasingly less 
positive MS and by an increasingly negative TD and MD.  
Given that microperimetry is novel, and that the design features appear particularly 
suitable for assessing visual function in AMD, a systematic review was undertaken to 
critically evaluate the literature relating to the use of microperimetry for assessing 
visual function in AMD. The published version of this review can be found in Appendix 
A (Cassels et al. 2018). 
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The Medline, Ovid, EMBASE and Web of science databases were each searched 
using the search terms in Table 2.1. The search extended from 1950 (Medline only) 
to July 2017. The search terms were divided into two groups: population and 
instrument (Table 2.1). Each selected article was required to match at least one 
search term from each group. Additional articles were identified from the references 
within the publications identified by the primary search. The abstracts of articles found 
from the database search were independently assessed by two of the authors (NC 
and JA) to identify those that met the inclusion criteria. 
Table 2.1 Terms used in the database search (*=truncation: includes various word endings 
into search). 
Eligible articles had to include microperimetry undertaken on at least twenty eyes with 
AMD to provide a minimum level of evidence. All articles were required to contain the 
DLS outcome obtained by microperimetry. Preferred retinal location and fixation 
studies were excluded. Only articles that discussed microperimetry in the context of 
the outcome from other commercially available instrumentation were included. 
Conference abstracts and case reports were excluded. Studies where the whole 
article was not written in English were also excluded. 
Population
AND
Instrument
Age-related Macul* Microperimet*
AMD Fundus controlled perimet*
ARMD
Macular degeneration
Dry Macular degeneration
Wet Macular degeneration
Senile Macular degeneration
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The search methods identified 687 primary articles. Six additional articles were 
obtained from the references within the primary retrieved articles.  The final number 
of included articles was 56 (Figure 2.1).   
Figure 2.1 A Flow diagram demonstrating the primary identified articles and those included 
and excluded at each stage of the literature review. Adapted from PRISMA (Preferred 
Reporting Items for Systematic Reviews and Meta-Analysis). 
The review was divided into four principle areas which reflected the content of the 
included articles: evaluation of the efficacy of microperimetry in distinguishing 
between the various stages of AMD severity (6 articles); the relationship between 
microperimetry outcomes and structural imaging outcomes (including SD-OCT) (23 
articles); the relationship between microperimetry outcomes and those of other 
measures of visual function (15 articles); and microperimetry outcomes in the 
evaluation of the efficacy of medical therapy and/ or surgical intervention in the 
treatment of AMD (17 articles).  
2.4.1 Quality of evidence 
The quality of each of the 56 included articles is described in Appendix B, which is 
ordered by quality of evidence. The studies were classified as either experimental or 
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observational. Within these two classifications, experimental studies were classified 
as either randomised control trial (RCT) or as non-randomised design, which will be 
referred to as quasi-experimental. Observational studies were classified as cross-
sectional, case-controlled or case series studies. None of the included studies were 
cohort studies. Assessment of the quality of reporting showed that over half the 
articles included in this review had limitations relating to the quality of the 
microperimetry outcome (19 articles) and/ or to the reporting of the SD-OCT methods 
and analysis (12 articles). The reporting of microperimetry stimulus parameters was 
also generally poor, particularly in regard to the description of the stimulus program 
(i.e., the number, the location and the separation, of the stimuli).  
The method of classification of AMD severity varied between the various studies and 
limited the extent of meaningful comparisons between studies. These comprised the 
AREDS grading system (AREDS 2001) (9 articles), the Beckman classification (Ferris 
et al. 2013) (10 articles), the Wisconsin Age-related Maculopathy Grading system 
(Klein et al. 1991) (1 articles), and the International Classification and Grading system 
(Bird et al. 1995) (2 articles). Consequently, the classification method utilised in each 
study is noted, where appropriate, throughout this review.  
Similarly, the difference in the stimulus parameters and also in the dynamic range 
between the various microperimeters used in the various studies hinder direct 
comparisons of DLS between studies (Acton, Bartlett and Greenstein 2011). 
Microperimetry was undertaken by the Nidek MP1 or MP1-S in 30 of the 57 included 
articles (Giacomelli et al. 2013; Grenga et al. 2013; Dinc et al. 2008; Dunavoelgyi et 
al. 2011; Huang et al. 2015; Iaculli et al. 2015; Iwama et al. 2010; Kiss et al. 2009; 
Lazzeri et al. 2015; Mettu et al. 2011; Munk et al. 2013; Ooto et al. 2015; Ozdemir et 
al. 2012; Parisi et al. 2007; Pilotto et al. 2011; Pilotto et al. 2016; Sabour-Pickett et al. 
2013; Sato et al. 2015; Sayegh et al. 2014; Steinberg et al. 2016; Sulzbacher et al. 
2012; Sulzbacher et al. 2013; Sulzbacher et al. 2015; Takahashi et al. 2016; Weigert 
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et al. 2013; Amore et al. 2013; Bolz et al. 2010; Chieh, Stinnett and Toth 2008; Acton 
et al. 2012b; Fragiotta et al. 2017a) by the Nidek MP3 in 1 (Hariri et al. 2016), by the 
MAIA in 16 (Wu et al. 2015b; Wu et al. 2015c; Wu et al. 2013; Wu et al. 2015a; Wu et 
al. 2014c; Wu et al. 2016; Wu, Guymer and Finger 2016; Wu et al. 2014a; Alexander 
et al. 2012; Anastassiou et al. 2013; Chandramohan et al. 2016; Vujosevic et al. 2011; 
Denniss et al. 2017; Vujosevic et al. 2017; Broadhead et al. 2017), by the Optos 
Spectral OCT/SLO in 7 (Landa et al. 2011; Querques et al. 2012; Forte et al. 2013; 
Cho et al. 2013; Hautamäki et al. 2014; Hartmann et al. 2011; Hartmann et al. 2015) 
and by the Rodenstock SLO microperimeter in 2 articles (Ergun et al. 2003; Fujii et 
al. 2003). The limited dynamic range of the previously available Optos OCT SLO and 
Nidek MP-1 microperimeters arising from the lower maximum stimulus luminance 
results in ceiling and floor effects compared to the MAIA and MP-3 microperimeters 
(Markowitz and Reyes 2013). In particular, the presence of a floor effect can result in 
underestimation of the depth of the field loss. Consequently, the type of 
microperimeter is specified whenever the perimetric outcome is given in terms of 
decibels (dB).
2.4.2 Microperimetry and AMD severity 
Six of the 56 included articles evaluated the efficacy of microperimetry in 
distinguishing between the various stages of AMD severity (Dinc et al. 2008; 
Vujosevic et al. 2011; Fujii et al. 2003; Wu et al. 2013; Denniss et al. 2017; Vujosevic 
et al. 2017).   
Microperimetry with the MAIA is able to discriminate between normality and early and 
intermediate stages of AMD (Age-related Eye Disease Study, AREDS (AREDS 2001), 
grades 2 and 3 respectively), when considered both in terms of the group mean MS 
and of the DLS derived at individual locations (Vujosevic et al. 2011; Vujosevic et al. 
2017). In the largest study of this kind to date, the group of 200 normal individuals 
exhibited the highest MS (mean 29.8dB; SD 1.7) whilst, within the group of 200 
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individuals with AMD, the MS for those with early AMD was larger (mean 24.9dB; SD 
3.9) than for those with intermediate AMD (mean 21.8dB; SD 5.4) (all p<0.001) 
(Vujosevic et al. 2011). A comparable, but earlier study, of 30 individuals noted a 
statistically significant worsening of both the group mean MS and the group mean MD 
for intermediate AMD (AREDS grade 3) compared to normal individuals (Dinc et al. 
2008). For both these studies, the magnitudes of the group mean MS reflected the 
severity of the structural classification of AMD. However, the magnitudes of the 
standard deviations associated with the group mean MS indicated overlap between 
groups. In addition, no criteria for microperimetry were given for the optimal 
differentiation, on an individual basis, between the AMD severities. The analysis of 
the DLS at each individual stimulus location enabled a localised assessment of 
function that was more descriptive of the AMD severity than that provided by the MS 
(Wu et al. 2013).  
A recent study examined DLS with respect to location specific normal values, in 185 
individuals with AMD, and subsequent TD and PD probability analysis was performed 
(Denniss et al. 2017). Within the central 5˚ of fixation, 95% of individuals with AMD 
had a TD worse than -2.0dB (measured by MAIA microperimetry), which increased to 
97% at fixation (Denniss et al. 2017). This suggests that despite the common adaption 
of a preferred retinal loci, a significant DLS loss remains surrounding and at the PRL 
(Denniss et al. 2017).   
The reduction in DLS varies with the location and severity of the AMD. Eyes with 
subfoveal nAMD that exhibit severe (absolute) localised parafoveal abnormality (0dB, 
as measured by an early commercially available Rodenstock SLO microperimeter; 
Rodenstock GmbH, Munich, Germany) manifest a normal foveal DLS enabling central 
fixation to be maintained (Fujii et al. 2003). The likelihood of a dense parafoveal 
abnormality increases as the duration of self-reported symptoms increases (Fujii et 
al. 2003). 
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In summary, the MS derived by microperimetry is reduced in those with AMD and is 
able to differentiate, on a group mean basis, at least, between levels of disease 
severity (Vujosevic et al. 2011; Dinc et al. 2008). However, the evidence is 
questionable as to whether microperimetry can correctly classify AMD disease 
severity. Characterising the reduction in DLS by location, area and depth enables the 
study of associations with other factors such as disease duration and maintenance of 
central fixation (Fujii et al. 2003).  
2.4.3 Microperimetry and structural imaging modalities. 
Twenty three of the 56 included articles were concerned with the relationship between 
visual function and retinal morphology in AMD (Forte et al. 2013; Acton et al. 2012b; 
Hartmann et al. 2011; Landa et al. 2011; Iwama et al. 2010; Forte et al. 2012; Ooto 
et al. 2015; Wu et al. 2015c; Wu et al. 2014c; Wu et al. 2015b; Pilotto et al. 2011; 
Iaculli et al. 2015; Sulzbacher et al. 2012; Hariri et al. 2016; Steinberg et al. 2016; 
Pilotto et al. 2016; Sayegh et al. 2014; Wu et al. 2016; Hartmann et al. 2015; 
Takahashi et al. 2016; Broadhead et al. 2017; Fragiotta et al. 2017a), most of which 
have used SD-OCT.  
This section of the review discusses microperimetry outcomes in relation to: specific 
retinal layer changes; retinal pseudodrusen; GA and outer retinal tubulations (ORTs).  
A typical SD-OCT horizontal line scan of an individual with AMD illustrating the retinal 
layers evaluated in the various studies is shown in Figure 2.2. The external limiting 
membrane (ELM) appears as a hyperreflective line, by SD-OCT, in the outer retina 
just above the ellipsoid zone (EZ). The EZ is also visible as a hyperreflective band, 
but is not synonymous with a single retinal anatomical feature (Tao et al. 2016). The 
photoreceptor outer segment layer appears below the EZ band and is visible as a 
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hyporeflective line. The RPE layer also appears as a hyperreflective line: it is 
continuous with Bruch’s membrane until disease processes cause their separation.
Figure 2.2 SD-OCT horizontal line scan of an eye with AMD. Right: The external limiting 
membrane, ellipsoid zone, photoreceptor outer segment and retinal pigment epithelium are 
highlighted by the three black lines which are continuous with the respective layers. 
Reticular pseudodrusen represent a build-up of material  below the RPE and, when 
viewed by SD-OCT, manifest as hyperreflective triangular shaped deposits located 
between the RPE and the EZ band (Figure 2.3) (Sohrab et al. 2011; Zweifel et al. 
2010).  
Figure 2.3 Top: Infra-red image and Bottom: SD-OCT horizontal line scan of an eye with AMD 
exhibiting a reticular pseudodrusen. 
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Geographic atrophy is the late stage of AMD and involves the loss of retinal structures 
including the RPE and photoreceptors, with the ensuing visibility of the underlying 
choroidal vessels (Figure 2.4) (Hariri et al. 2016).  
Figure 2.4 Colour fundus photograph of an eye with AMD exhibiting drusen and an area of GA 
(circled) with visible choroidal vessels. 
Nascent geographic atrophy as defined by Wu and colleagues(Wu et al. 2015b) 
occurs prior to drusen-associated atrophy and has similar risk factors to GA; it can be 
visualised by SD-OCT but not by colour fundus photography (Wu et al. 2015b). nGA 
appears by SD-OCT as a breakdown of the outer plexiform layer (OPL) and inner 
nuclear layer (INL) accompanied with a wedge-shaped hyporeflective area in the OPL 
(Wu et al. 2014d). Finally, ORTs can only be visualised by SD-OCT and appear as a 
hyperreflective ring with a hyporeflective centre located within the outer nuclear layer 
(Figure 2.5).  
Figure 2.5 SD-OCT horizontal line scan of an eye with AMD exhibiting outer retinal tubulations 
(highlighted). 
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2.4.3.1 Retinal layers 
The relationship between outer retinal layer thickness and DLS in early AMD 
(International Classification and Grading System (Bird et al. 1995)) has been 
investigated by comparing RPE and OS thicknesses at locations with and without an 
abnormal DLS (defined as a TD value with a probability of lying within the normal 
range of p≤ 0.05) (Acton et al. 2012b). The OS layer was thinner at locations with an 
abnormal TD (p<0.01). The OS layer thickness was also significantly correlated with 
both MS and MD, obtained using the MP-1 microperimeter (r=0.62 and r=0.63, 
respectively, both p<0.01) (Acton et al. 2012b). MS worsens with increased thickening 
of the RPE (Acton et al. 2012b; Wu et al. 2016; Wu et al. 2014c); a 10μm increase in 
RPE layer thickness is associated with a 0.29dB worsening of MS (p<0.001) obtained 
with the MAIA microperimeter (Wu et al. 2016).  
DLS and choroidal thickness was investigated in control eyes, and eyes with early to 
intermediate AMD (AREDS grade 2 and 3 (AREDS 2001)) (Broadhead et al. 2017). 
No significant difference in choroidal thickness was present between the control and 
AMD groups (p=0.36), and no association between DLS and choroidal thickness was 
found in the AMD group (p=0.08) (Broadhead et al. 2017). 
In eyes with early to intermediate AMD, the MS at locations overlying drusen is 
statistically significantly worse than that at adjacent locations without the presence of 
drusen (Hartmann et al. 2011; Iwama et al. 2010). EZ band disruption is the strongest 
predictor of DLS at locations with drusen (Hartmann et al. 2011) and the reduction in 
MS in the presence of EZ band disruption is worse than that in the presence of drusen, 
alone (Iwama et al. 2010). It should be noted that, in the former study, the stage of 
AMD was not classified; individuals exhibiting drusen (excluding nAMD) were 
included and, therefore, any stage of AMD may have been involved (Hartmann et al. 
2011). Additionally, a more recent study investigated the predictors of DLS in 
individuals with intermediate AMD (Fragiotta et al. 2017a). The integrity of the EZ 
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band, ELM and the presence of hyperreflective foci were each associated with DLS 
(r=-0.45, r=-0.7 and r=-0.66, respectively) (Fragiotta et al. 2017a). However, the stage 
of AMD was not classified prior to the grading of SD-OCT features. 
In early to late atrophic AMD, MS worsens as the EZ band disturbance increases 
(Landa et al. 2011; Querques et al. 2012; Wu et al. 2014c). In nAMD, a worsening of 
EZ band disruption and an increase in central retinal thickness are both associated 
with a reduction in MS (r=-0.79; p<0.001 and r=-0.51; p<0.01, respectively) (Landa et 
al. 2011; Sulzbacher et al. 2012). Similarly, in nAMD treated with bevacizumab, MS 
significantly worsened (p<0.01) with increase in EZ band disruption (Hartmann et al. 
2015).  The presence of nAMD, intra-retinal cysts and a focal/ localised absence either 
of the RPE or of the photoreceptor layer are each associated with an absolute loss of 
MS (<0dB) obtained with the MP-1 microperimeter (Sulzbacher et al. 2012). Sub-
retinal fluid, intra-retinal fluid, PED and pseudodrusen are each separately associated 
with relative visual field loss (defined as 1dB to 8dB) when measured with the MP-1 
microperimeter (Sulzbacher et al. 2012). 
2.4.3.2 Reticular pseudodrusen 
The presence of RPD in early to intermediate AMD (AREDS grade 2, 3 or 4 (AREDS 
2001)) is associated with a reduction in MS out to 10° eccentricity (Ooto et al. 2015). 
Such an association is absent in a cohort with intermediate stage AMD (Beckman 
classification (Ferris et al. 2013)) (Wu et al. 2015c). MS out to 4˚ eccentricity was 
associated with RPD on a univariate basis; however, in a multivariate analysis 
incorporating age, drusen volume and pigmentary disturbance, the association was 
no longer present (Wu et al. 2015c). One explanation for these findings may simply 
be the difference in classification systems used between the two studies. In early to 
intermediate AMD (Beckman classification (Ferris et al. 2013)), both scotopic and 
mesopic group mean MSs, obtained with a modified MP-1S microperimeter, were 
reduced in areas of RPD (mean 12.8dB; SD 3.3 and mean 17.2dB; SD 2.5, 
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respectively) compared to areas without (mean 18.2dB; SD 2.2 and mean 18.4dB; 
SD 2.5, respectively). The scotopic MS was reduced to a greater extent than the 
mesopic MS (Steinberg et al. 2016). These findings suggest that, in the presence of 
RPD, rod photoreceptor function is the most affected. However, it is not clear whether 
the greater reduction in the scotopic MS was due to differences in the measurement 
range resulting from the two different background luminance enabling scotopic and 
mesopic viewing conditions. Scotopic dysfunction also correlates with outer retinal 
thickness in eyes with RPD: a 1μm decrease in thickness corresponded to a 0.96dB 
reduction in scotopic MS (Steinberg et al. 2016). In another study, the MS was also 
reduced in the presence of pseudodrusen in atrophy free areas of eyes with GA 
(Takahashi et al. 2016).  
2.4.3.3 Geographic atrophy 
In GA, MS has been compared between areas with and without either RPE loss and/ 
or photoreceptor damage (Takahashi et al. 2016). The group mean MS, obtained with 
the MP-1 microperimeter, was markedly lower in areas of RPE loss (mean 1.84dB; 
SD 2.68; p<0.001) and also in areas with photoreceptor damage (mean 6.57dB; SD 
4.13; p<0.001) when compared to areas without (Takahashi et al. 2016). In GA, a 
thinning or an absence of the RPE, an absence of the external limiting membrane and 
a thickening of the EZ boundary are each associated with absolute field loss (0dB) 
obtained with the MP-1 microperimeter (Sayegh et al. 2014). The group mean MS, 
obtained with the MP-3 microperimeter, at the GA boundary is lower (mean 13.7dB; 
SD 4.7)  than the group mean MS in the area surrounding the GA (mean 20.8dB; SD 
3.8); however, the latter is lower than that in eyes without GA (mean 23.9dB; SD 2.6) 
(p<0.001) (Hariri et al. 2016). Another study utilised en-face OCT to identify GA 
boundaries at the choroidal and the outer retinal levels. When the MS was better than 
10dB, the mean area of GA was larger at the outer retinal level than at the choroidal 
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level; however, the areas were similar when the MS was worse than 10dB (Pilotto et 
al. 2016). 
In areas of nGA, the group mean MS measured by MAIA microperimetry is reduced 
(mean 20.4dB; SD 0.8) compared to areas without atrophy (mean 23.8dB; SD 0.7, 
p<0.01) and is greater than that obtained in areas with drusen associated atrophy 
(mean 16.4dB; SD 0.9; p<0.01) (Wu et al. 2015b). The area of drusen associated 
atrophy did not exhibit absolute loss as was the case in GA (Wu et al. 2015b).  
The monitoring of progression of GA can be undertaken by areas of GA appear hypo-
fluorescent. One study compared the outcome of MP-1 microperimetry to that from 
both NIR-FAF and short-wavelength FAF (Pilotto et al. 2011). The associations 
between severe relative loss (a DLS of not more than 5dB) and normal and hyper-
fluorescence outcomes were determined for each FAF technique. It was concluded 
that the outcome from MP-1 microperimetry, in combination with both FAF 
techniques, enabled effective detection and monitoring of GA (Pilotto et al. 2011). 
Another study used microperimetry to evaluate SD-OCT FAF and NIR-FAF (Forte et 
al. 2013).  As would be expected, DLS was substantially reduced in areas of GA and 
the imaging techniques were able to detect the presence of GA with differing 
capabilities. SD-OCT was considered to be the most appropriate imaging technique 
to examine GA (Forte et al. 2013). 
2.4.3.4 Outer retinal tubulations 
Outer retinal tubulations are not specific to AMD and are also seen more commonly 
in inherited retinal disorders such as  choroideremia and retinitis pigmentosa 
(Goldberg et al. 2013). In AMD, they are not a typical feature and can occur in eyes 
with previous nAMD. The identification of ORTs is clinically important due to their 
misinterpretation as either intraretinal or subretinal fluid with the resultant 
unnecessary treatment (Iaculli et al. 2015; Zweifel et al. 2009).  In a study of 
individuals without ORTs who were treated for nAMD, the improvement in MS, 
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obtained with the MP-1 microperimeter, after 12 months was less pronounced in those 
that developed ORTs (mean 6.31dB, SD 2.5) compared to those that did not (mean 
9.89dB, SD 5.43; p<0.01). However, this latter study did not fully describe the stimulus 
parameters for the microperimetry. 
In summary, focal areas of reduced DLS in AMD can be identified by microperimetry 
and are associated with a disruption of the EZ band and/ or changes to the RPE 
(Iwama et al. 2010; Landa et al. 2011; Querques et al. 2012; Wu et al. 2014c).  The 
association between RPD and MS is equivocal. In early to intermediate AMD (AREDS 
2, 3 and 4 (AREDS 2001)), the presence of pseudodrusen is associated with a 
reduction in MS at the macula (Ooto et al. 2015). However, there was no such 
association in a different cohort with intermediate AMD (Beckman classification(Ferris 
et al. 2013)) (Wu et al. 2015c). The differences between areas with and without 
pseudodrusen, for early and intermediate AMD (Beckman classification (Ferris et al. 
2013)), combined, are seemingly most profound under scotopic conditions (Steinberg 
et al. 2016). The reduction in MS is, in general, consistent with the presence of retinal 
lesions apparent by OCT. In the presence of a normal retinal appearance by fundus 
photography, alone, microperimetry detects functional loss arising from nGA (Wu et 
al. 2015b; Takahashi et al. 2016; Hariri et al. 2016).  
2.4.4 Microperimetry and other measures of visual function. 
Fifteen included studies used microperimetry alongside other measures of visual 
function in individuals with AMD  (Acton et al. 2012b; Munk et al. 2013; Wu et al. 
2014b; Wu et al. 2015a; Ozdemir et al. 2012; Hautamäki et al. 2014; Sato et al. 2015; 
Amore et al. 2013; Ergun et al. 2003; Chandramohan et al. 2016; Ooto et al. 2015; 
Wu, Guymer and Finger 2016; Giacomelli et al. 2013; Wu et al. 2014a; Parisi et al. 
2007). 
In early AMD (International Classification and Grading System(Bird et al. 1995)) with 
distance VAs ranging from 20/20 to 20/40, the corresponding MS varied between 
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19.5dB (SD 0.4dB) and 14.9dB (SD 2.4dB) (Acton et al. 2012b). Similarly, in early to 
intermediate AMD (Beckman classification (Ferris et al. 2013)) with a distance VA 
better than 20/40, MS exhibited a greater reduction compared to VA and to LLVA by 
3.0 and 1.9 fold, respectively (Wu et al. 2014b). A prospective longitudinal study of 
intermediate AMD (Beckman classification (Ferris et al. 2013)) (Wu et al. 2015a), 
compared two groups: those graded as progressed, defined as the development of 
additional structural abnormality visible by colour fundus photography, and those 
graded as stable with unchanged features. No deterioration from baseline in either 
VA or LLVA was present in either group at 12 months; however, small but statistically 
significant reductions in group mean MS (obtained with the MAIA microperimeter) 
were present in both groups (mean 0.42dB; SE 0.12 and mean 0.31dB; SE 0.10, 
respectively) (Wu et al. 2015a). However, it should be noted that microperimetry is 
only able to measure DLS to a resolution of 1dB and, therefore, the clinical 
significance of these findings is limited. An additional finding of this latter study was 
that eyes identified as improved, defined as a disappearance of structural abnormality 
on colour fundus photography, showed a statistically significant increase in the group 
mean MS (mean 1.13dB; SE 0.23, p<0.001) at 12 months (Wu et al. 2015a). Another 
study, which compared the outcomes in early AMD (AREDS grade 2 (AREDS 2001)) 
and in intermediate AMD (AREDS grade 3 (AREDS 2001)) to those in normal 
individuals, found a significant worsening in LLVA for each AMD group compared to 
the normal individuals (p<0.05) (Chandramohan et al. 2016). The reduction in LLVA 
was associated with a reduction in foveal DLS (r²=0.60, p<0.01) (Chandramohan et 
al. 2016). In early to intermediate AMD (AREDS grade 2 and 3 (AREDS 2001)), a 
reduction of parafoveal MS is associated with a reduction in VA and in CS (r=0.59 
and r=0.35 respectively, p<0.01)(Ooto et al. 2015).  
In a separate study of individuals with intermediate stage AMD (Beckman 
classification (Ferris et al. 2013)), neither MS nor foveal DLS were associated with a 
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LLD, defined as the difference between VA and LLVA, or with the self-reported 
outcome to a 10-item night vision questionnaire.  Nevertheless, LLD was significantly 
associated with difficulty under low luminance levels (Wu, Guymer and Finger 2016). 
In individuals with nAMD who had previously received anti-VEGF therapy, MS (out to 
20˚ eccentricity) was moderately correlated with both VA (r=0.54) and CS (r=0.53) 
separately; and to a lesser extent with reading speed (r=0.37) (all p<0.001) (Sato et 
al. 2015). However, in those undergoing anti-VEGF treatment, no association was 
present between the MS and either VA or CS (Munk et al. 2013; Hautamäki et al. 
2014). Other studies have shown that both DLS and VA improve up to either 6 months 
(Ozdemir et al. 2012) or 12 months (Munk et al. 2013) of anti-VEGF therapy; however, 
the association between DLS and VA was not determined. In subfoveal CNV, an 
increase in the area of absolute DLS loss is associated with a decline in both reading 
acuity (r=0.52; p=0.01) and reading speed (r=-0.48; p=0.02) (Ergun et al. 2003). 
In GA manifesting absolute loss of DLS and a central island of residual vision (foveal 
sparing), the MS out to 20° eccentricity was moderately associated with reading 
speed (r²=0.5) (Amore et al. 2013). An improvement in reading is a major goal of 
visual rehabilitation; microperimetry enables additional information about the location 
and size of the area(s) of residual function, allowing for a realistic estimation of reading 
ability and the likely outcome of rehabilitation (Amore et al. 2013; Giacomelli et al. 
2013).  
The multifocal electroretinogram (mfERG) provides objective, topographical, 
electrophysiological information about central retinal function. Two studies compared 
microperimetry and mfERG (Parisi et al. 2007; Wu et al. 2014a). In early AMD 
(Wisconsin Age-related Maculopathy Grading system (Klein et al. 1991)), a significant 
correlation was present between the mfERG response amplitude density (N1-P1) and 
MS (r=0.69, p<0.01) (Parisi et al. 2007); however, there was no association for 
intermediate AMD (Beckman classification (Ferris et al. 2013)) (Wu et al. 2014a). This 
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latter study found a greater reduction in the MS than in the mfERG (p<0.001), 
suggesting that the two measures assess different aspects of retinal dysfunction (Wu 
et al. 2014a). 
In summary, VA, CS and reading ability have, historically, been used as outcome 
measures in ophthalmic clinical research. Microperimetry has more recently become 
an additional outcome measure. MS exhibits a wide range of values in the presence 
of relatively good VA in early to intermediate AMD (Acton et al. 2012b) (International 
Classification and Grading System (Bird et al. 1995)).  It is able to detect progressive 
improvements in AMD, consistent with colour fundus photographs, when no change 
is observed in VA or LLVA. There is conflicting evidence as to the strength of the 
associations between DLS and VA, CS and reading ability (Munk et al. 2013; Wu et 
al. 2014b; Wu et al. 2015a). Reading ability is an important factor when considering 
visual rehabilitation: microperimetry gives additional relevant information with respect 
to the area and location of residual function.  
2.4.5 Microperimetry as an outcome measure in clinical trials of 
medical or surgical intervention 
Microperimetry has been included as an outcome measure in 17 included articles 
describing clinical trials of medical and/ or surgical interventions for AMD. In 
individuals undergoing treatment with ranibizumab for AMD, MS, measured with the 
MAIA microperimeter, was at a maximum of 17dB for a central retinal thickness of 
210μm. MS declined as the thickness increased, reaching a minimum of 7dB at a 
thickness of 320-339μm, and declined as the thickness decreased, reaching a 
minimum of 15dB at a thickness of <160μm (Alexander et al. 2012). However, these 
findings cannot be compared with other studies as both the microperimetry and the 
method of measuring retinal thickness were not reported. A similar finding was noted 
with bevacizumab therapy: MS increased following a reduction in retinal thickness 
(Hartmann et al. 2015) and decreased with increasing retinal thickness (r=-0.54, 
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p<0.01) (Sabour-Pickett et al. 2013). However, neither of these latter studies specified 
the thickness boundaries used in the retinal thickness measurements. It has been 
suggested that the improvement in MS occurs from the reduction in RPE lesion area 
with treatment rather than from a reduction in the retinal thickness, as a whole (Kiss 
et al. 2009).  
The relationship between DLS and specific AMD morphology, as identified by SD-
OCT, has been studied in previously untreated patients with nAMD who subsequently 
received aflibercept (Sulzbacher et al. 2015). The greatest improvement in DLS 
(measured with the MP-1 microperimeter), occurred 3 months after the start of 
therapy; areas exhibiting a reduction in either a serous PED or subretinal fluid 
exhibited the greatest improvement in group mean MS of 5.5dB and 4.0dB 
respectively (p<0.001). Areas with fibrovascular PED or with an intra-retinal cystoid 
space also improved, but to a lesser extent (group mean improvements 2.3dB and 
1.7dB; respectively) (Sulzbacher et al. 2015). In an earlier study, DLS improved 
following ranibizumab therapy in previously untreated patients with nAMD. The most 
marked improvement occurred at stimulus locations which were associated with a 
reduction in subretinal fluid, intraretinal fluid or intraretinal cystoid space (Sulzbacher 
et al. 2013).  
Although all trials of anti-VEGF therapy involving microperimetry report an 
improvement in DLS from baseline, the results of these studies are equivocal with 
respect to the duration of therapy beyond which the DLS ceases to improve. A number 
of studies have reported that DLS continues to improve up until 12 months, the time 
at which the studies ended (Cho et al. 2013; Munk et al. 2013; Sulzbacher et al. 2013; 
Grenga et al. 2013; Lazzeri et al. 2015). However, two studies suggest that DLS does 
not improve beyond that recorded after one week of treatment (Bolz et al. 2010; Kiss 
et al. 2009). DLS can also decline following withdrawal of anti-VEGF therapy. 
Individuals with stable nAMD, who ceased anti-VEGF therapy, exhibited a reduction 
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in DLS during the follow-up period (at least 3 visits over 7 months) when compared 
with those that continued to receive treatment (Alexander et al. 2012). It was 
speculated that the reduction in DLS may have resulted either from photoreceptor 
atrophy over time that was too subtle to be identified by VA or that CNV could be 
occurring at a subclinical level below that required by the United Kingdom NICE 
guidelines for an anti-VEGF injection (Alexander et al. 2012).  
Two trials with an unsuccessful outcome utilised microperimetry as an outcome 
measure; one trial assessed the outcome of transpalpebral electrotherapy as a 
treatment for early to intermediate AMD (AREDS grade 2, 3 and 4(AREDS 2001)) and 
the another evaluated the outcome of photodynamic therapy combined with 
intravitreal triamcinolone as a treatment for nAMD (Dunavoelgyi et al. 2011; 
Anastassiou et al. 2013). Neither study found a sustained improvement in either DLS, 
VA or CS, following treatment.  
Macular translocation surgery (MT360) involves a peripheral retinectomy of 360˚ at 
the ora serata following which the subfoveal CNV is removed and the whole retina is 
rotated such that the fovea is located away from the removed CNV. The retina is then 
reattached. In one study, VA, near VA and reading speed improved post-operatively 
(Chieh, Stinnett and Toth 2008). DLS was specified in terms of the median retinal 
sensitivity score (MRSS) obtained with the MP-1 microperimeter. The 12 month post-
operative group mean MRSS was better (2.5dB, SD 4.3) in the foveal surgical area 
compared to the retinal area where the CNV had been removed (<0dB) (Chieh, 
Stinnett and Toth 2008). However, the MRSS had not been evaluated prior to surgery; 
therefore it is not possible to evaluate whether the surgery improved visual function. 
Another study found that the MRSS only improved in lesions greater than 4 disc areas 
(Mettu et al. 2011). However, the two studies evaluated the outcome of the 
translocation surgery by differing methods. The first determined the MRSS at areas 
of healthy retina compared to that at the surgical sites (Chieh, Stinnett and Toth 2008), 
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whereas the second compared the difference in the MRSS for the pre- and 12-month 
post-operative areas (Mettu et al. 2011). 
Two RCTs examined the effect of lutein supplementation on macular pigment optical 
density and the subsequent effect on visual function. One RCT found that, although 
lutein supplementation increased the macular pigment density, there was no 
improvement in MS after 6 months of lutein supplementation (Weigert et al. 2013).
Macular pigment density was also weakly correlated with DLS (r =0.25, p =0.027) 
(Weigert et al. 2013). The second RCT examined differing levels of lutein 
supplementation (10mg, 20mg and a combination of lutein with zeaxanthin) with 
placebo. After two years of supplementation, the group mean MS, obtained with the 
MP-1 microperimeter, was greater for the groups receiving 10mg (13.37dB) or 20 mg 
of lutein (12.55dB) compared to the control group (10.32dB, p<0.05) (Huang et al. 
2015).  
It is clear that microperimetry has the ability to detect changes in visual function arising 
from a variety of interventions for AMD. All studies suggest that MS improves, 
following anti-VEGF treatment, as retinal thickness reduces and nAMD-associated 
lesions improve. The extent of any such improvement in MS beyond 12 months is 
unknown. 
The quality of evidence varied between the 56 articles. Overall, none of the RCTs 
directly analysed the utility of microperimetry in the assessment of visual function in 
AMD but, as would be expected, evaluated a specific medical therapy using 
microperimetry as one of the various outcome measures. Over half of the studies 
included in this review were observational in design and, therefore, have a 
consequent risk of selection bias, information bias or confounding bias (Grimes and 
Schulz 2002). Many studies had limitations in the quality of reporting of the 
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microperimetry outcomes and/ or of the SD-OCT methods and analysis (Appendix B). 
Comparison between studies was also confounded by the differences in the 
classification systems for early and intermediate AMD. Four studies did not include 
the classification method (Amore et al. 2013; Giacomelli et al. 2013; Hartmann et al. 
2011; Landa et al. 2011) . An additional difficulty in comparing studies arose from the 
differences in the dynamic range between the various microperimeters used in the 
studies. 
The majority of studies used the summary statistic MS, which is not age-corrected, 
and many of the studies did not report either the number or the spatial location of the 
stimuli upon which the MS was based (Alexander et al. 2012; Iaculli et al. 2015; Ooto 
et al. 2015; Anastassiou et al. 2013; Fujii et al. 2003; Huang et al. 2015; Lazzeri et al. 
2015; Mettu et al. 2011; Pilotto et al. 2011; Dinc et al. 2008; Fragiotta et al. 2017b). 
Only 14 of the studies analysed the DLS at each given stimulus location (Vujosevic et 
al. 2011; Wu et al. 2015a; Wu et al. 2015b; Wu et al. 2014c; Takahashi et al. 2016; 
Sulzbacher et al. 2013; Sulzbacher et al. 2015; Sulzbacher et al. 2012; Querques et 
al. 2012; Landa et al. 2011; Hartmann et al. 2011; Sayegh et al. 2014; Denniss et al. 
2017; Vujosevic et al. 2017). From the 56 included studies, three of the studies (Acton 
et al. 2012b; Dinc et al. 2008; Denniss et al. 2017) utilised location-specific probability 
analysis of the measured DLS compared to the corresponding age-corrected normal 
value, as is conventional practice in SAP. Despite the latter probability analysis 
enabling separation of focal from diffuse defects (Heijl, Lindgren and Olsson 1987a), 
such an approach was only used in one of these studies (Denniss et al. 2017).  
The absence of a robust statistical analysis software package for microperimetry, 
which separates focal from diffuse loss and which is comparable to that widely used 
in SAP, currently limits the technique. Such analysis would have enabled a more 
clinically relevant evaluation of the microperimetry outcomes, particularly their 
association with structure. The various microperimeter manufacturers should be 
74 
encouraged to develop such a package to enable this more comprehensive method 
of assessing abnormal visual function. In late stage AMD, this type of analysis would 
also need to be corrected for the presence for any retinal locus (Denniss and Astle 
2016).  
The clinical value of microperimetry has not yet been assessed against other 
functional biomarkers of AMD, such as flicker sensitivity and dark adaptation, known 
to be sensitive to AMD disease severity (Dimitrov et al. 2011; Owsley et al. 2007)
Microperimetry offers detailed topographical information relative to traditional 
measures of foveal function such as VA and CS. In addition, microperimetry was 
superior to VA in detection of subtle AMD changes in a longitudinal study over one 
year (Wu et al. 2015a). The investigation of microperimetry in comparison with dark 
adaptation in early AMD would be of value and enable clearer clinical 
recommendations for microperimetry. 
Notwithstanding the above limitations, it is clear that there is a strong association 
between the magnitude of the DLS and a number of classic signs associated with 
AMD. Disruptions of the EZ band and RPE are associated with reduced DLS despite 
the maintenance of good VA (Landa et al. 2011; Hartmann et al. 2015; Iwama et al. 
2010; Parisi et al. 2007; Wu et al. 2014c). OS thinning and RPE thickening are both 
associated with reduced MS, in early AMD (Acton et al. 2012b). A thickening and a 
thinning of the whole retina in CNV are each associated with a reduced MS (Alexander 
et al. 2012; Hartmann et al. 2015; Sabour-Pickett et al. 2013).   
To conclude, the current microperimetric literature is of varying quality, but has been 
improving in recent years. The current lack of consistency in the microperimetric 
techniques and in the analysis of DLS, limits the conclusions regarding the use of 
microperimetry in AMD. Recommendations for good clinical practice are, therefore, 
currently not possible; however, microperimetry provides information beyond that of 
VA and CS in the functional assessment of AMD. When combined with SD-OCT, it 
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gives a multimodal representation of AMD morphology and associated visual function. 
Statistical analysis software similar to that used in SAP would render microperimetry 
a more robust procedure. The development of a multimodal topographical 
classification system for all stages of AMD, based upon combined microperimetry and 
SD-OCT outcomes, represents an exciting prospect. 
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Chapter 3: Methodology 
This chapter will address in detail the experimental methodology implemented in the 
research presented in this thesis. Firstly, the methodology for the development of a 
normative database using the MAIA microperimeter will be described. Secondly, the 
methodology for the studies that involve individuals with AMD will be presented.  
This study was funded by Fight for Sight (grant number 1463/64). 
3.2.1 Recruitment 
3.2.1.1 Sample size 
A sample size of 80 healthy individuals was determined on the basis of the number of 
individuals required by international standards to produce a perimetric normative 
database (ISO 12866), including an allowance for 20% of individuals who may 
withdraw from the study.  
3.2.1.2 Inclusion and exclusion criteria 
Each individual conformed to rigid inclusion criteria comprising: a refractive error of 
≤5D sphere and ≤3D cylinder; VA of better than 0.10 logMAR for those aged up to 60 
years, and better than, or equal to, 0.18 logMAR for those aged greater than 60 years 
and lenticular changes no greater than grade two in any category of the Lens Opacity 
Classification System (LOCS III) (Chylack et al. 1993). Exclusion criteria included 
glaucoma or suspect glaucoma; any severity of AMD; any previous or current ocular 
history of significant eye disease, trauma or surgery; history of diabetes mellitus, or 
systemic medication known to affect the visual field. 
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3.2.1.3 Recruitment 
The individuals were recruited from the staff and student population at Cardiff 
University, and their family and acquaintances. All individuals were given information 
sheets regarding the study prior to the initial visit, which they attended at the School 
of Optometry and Vision Sciences, Cardiff University. Recruitment resulted in a cohort 
of 80 consecutive individuals with a median (IQR) age of 43 years (26, 65). 
3.2.2 Ethics 
The study adhered to the tenets of Declaration of Helsinki for research involving 
human participants and the protocol was approved by the School of Optometry and 
Vision Science Research and Audit Ethics Committee, Cardiff University. Each 
individual gave informed consent at Visit 1 before any procedures were performed. 
3.2.3 Procedures 
The individuals were required to attend three visits at the School of Optometry and 
Vision Sciences, Cardiff University, each visit was separated by a median (IQR) of 7 
days (5, 10).  
3.2.3.1 Visit 1 
The initial study visit consisted of taking written consent and a standard ophthalmic 
examination including an ocular and medical history. VAs, anterior eye examination, 
non-contact tonometry (NCT) and imaging data were also performed (Figure 3.1). 
This was to ensure the individuals adhered to the inclusion and exclusion criteria. The 
first examination on the MAIA microperimeter and on the HFA 30-2 examination also 
took place, which were implemented in a randomised order with rest periods between 
them. The procedures were performed by a research assistant (AN), under the 
supervision and guidance of the author who was then solely responsible for the 
analysis.  
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Figure 3.1 The sequence of procedures for each of the three visits, the HFA and MAIA 
examinations were performed in a randomised order for each individual. 
3.2.3.1.1 Medical and ocular history 
A comprehensive ocular history was obtained, which included previous hospital visits 
due to ocular-related causes, for example, diagnosed ocular conditions, or previous 
ocular surgery or trauma. A complete medical history was also taken including specific 
questions relating to diabetes, neurological conditions or systemic medication. 
3.2.3.1.2 Visual acuity 
Visual acuity was measured using the ETDRS LogMAR chart according to the 
standardised protocol (Ferris and Bailey 1996).The instructions to the individual were 
to read the letters on the chart from left to right and from the top to bottom. The 
individuals were encouraged to guess if unsure and scoring was based upon a 
standardised procedure in which a score of 0.1logMAR is assigned to one line and a 
score of 0.02logMAR is assigned to each letter (Ferris and Bailey 1996). The test was 
performed monocularly, with the distance refractive correction in place. 
3.2.3.1.3 Anterior eye examination 
A detailed anterior eye examination of both eyes by slit-lamp biomicroscopy was 
performed. This included grading of lens opacities and the anterior chamber angle, 
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using LOCS III grading (Chylack et al. 1993) and the Van Herick technique, 
respectively. Intraocular pressures (IOPs) were measured in both eyes, using the 
NT2000 non-contact tonometer (NCT, Nidek Co., Ltd., Aichi, Japan). 
3.2.3.1.4 Microperimetry 
MAIA microperimetry was performed on the study eye with the fellow eye occluded 
using an opaque patch. Prior to the examination, each individual underwent 10 
minutes of adaption to a darkened room. All individuals received identical instructions. 
Stimuli were presented using a custom stimulus pattern (Figure 3.2), extending to an 
eccentricity of 7°, with an inter-stimulus separation of 2°, offset by 1° from fixation. 
This stimulus pattern was selected on the basis of frequency of defect maps in 
individuals with AMD (Acton, Gibson and Cubbidge 2012), and resembles the HFA 
10-2 stimulus pattern, excluding the outermost radial locations. These stimulus 
locations have been previously examined in studies of individuals with AMD, but they 
were evaluated as part of larger grids, using different microperimeters (Meleth et al. 
2011; Chen et al. 2011).  
Figure 3.2 The stimulus locations used for the microperimetry examination. The inter-stimulus 
separation was 2° the stimuli were offset by 1° from fixation and extending to 7°. 
The stimulus parameters for the MAIA microperimeter are a white Goldmann size III 
stimulus presented for 200ms on a uniform white background of 1.27cd/m2 luminance. 
A 4-2dB threshold staircase algorithm was implemented, which uses a double 
crossing in 4dB and then 2dB steps. The MAIA tracks the eye position by monitoring 
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each pixel of the infrared retinal image at 25Hz throughout the examination. Reliability 
was determined by the Heijl-Krakau method (Heijl and Krakau 2009), whereby false-
positive responses to a stimulus presented to the blind spot were calculated (<15% 
was considered acceptable). False-negative responses are not determined on the 
MAIA. All individuals had experience of standard perimetry, but had no experience of 
microperimetry. 
3.2.3.1.5 Standard automated perimetry 
A SAP examination was performed on the study eye using the HFA 740i (Carl Zeiss 
Meditec, Dublin, CA), to identify any existing visual field defects. The fellow eye was 
occluded using an opaque patch and all individual received identical instructions. The 
Program 30-2 was used, with the SITA Fast algorithm, and the Goldmann III white 
stimuli presented for 200ms on a white background of 10cd/m2 luminance. The stimuli 
extend to an eccentricity of 30°, with an inter-stimulus separation of 6°. Fixation losses 
were identified by the Heijl-Krakau method and the gaze was monitored throughout 
the examination. False positives were identified as the number of responses when no 
stimulus is presented, and false negatives, as no response when a stimulus is 
presented at a previously visible level. A maximum criterion of 15% was considered 
acceptable for false positive and false negative responses, and fixation losses. 
3.2.3.1.6 Imaging techniques 
Colour fundus photographs and SD-OCT scans were acquired in the study eye for 
those over the age of 40 years. Forty-five degrees CFPs centred at the fovea (2048 
x 1536 pixels) were acquired using the non-mydriatic 3D-OCT 1000 (Topcon Corp, 
Tokyo, Japan), which has a field angle of 45° and uses an 840nm superluminescent 
diode.  
For the SD-OCT images, a single high-density 6mm horizontal foveal line scan 
consisting of 1024 A-scans was captured at the fovea, using the Cirrus HD-OCT (Carl 
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Zeiss Meditec, Dublin, CA). To ensure high quality images, the quality of the SD-OCT 
images was at least 5/10, or better. 
3.2.3.2 Visit 2 and 3 
The second visit consisted of the MAIA microperimetry examination and the HFA 30-
2 examination, which were performed using the identical method described in Section 
3.2.3.1.4 and Section 3.2.3.1.5 respectively. The third visit consisted of only the MAIA 
microperimetry examination.  
3.3.1 Recruitment  
3.3.1.1 Sample size 
A sample size of 52 was based upon a linear multiple regression analysis to obtain 
an effect size of 0.4 (Mangione et al. 1999) with a power of 90% and a 0.05 probability 
of a Type 1 error, and a 15% allowance for individuals who may withdraw from the 
study. This estimate was used for the recruitment targets for the cross-sectional 
studies presented in Chapters 5 and 6. 
For the 12 month follow-up study (Chapter 7), a separate sample calculation was 
necessary. A sample size of 32 was calculated, based upon a linear multiple 
regression analysis to obtain an effect size of 0.4 (Medeiros et al. 2015) with a power 
of 80% and a 0.05 probability of a Type 1 error, and a 15% allowance for individuals 
who may withdraw from the study.  
3.3.1.2 Inclusion and exclusion criteria 
The rigid inclusion criteria included VA of better than 0.6 logMAR; a refractive error of 
≤5D sphere and ≤3D cylinder; lenticular changes of an average of grade 2 or better 
using the LOCS III (Chylack et al. 1993). Exclusion criteria consisted of glaucoma or 
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suspect glaucoma; previous or current history of significant eye disease other than 
AMD; previous eye trauma or surgery excluding phacoemulsification; systemic 
medications known to affect the visual field; and any systemic or neurological 
condition known to significantly affect visual function.  
3.3.1.3 Recruitment 
Individuals were recruited from the Cardiff Eye Unit at the University Hospital of 
Wales. Patients attending the medical retina clinic, and the nAMD clinics were 
recruited for the study. At these weekly clinics, the ophthalmologist (Mr Chris Blyth 
and/or Prof Marcela Votruba) identified those who appeared suitable based on the 
inclusion/exclusion criteria (see Section 3.3.1.2). These individuals were then 
contacted by telephone and given verbal information regarding the study. Those who 
were interested in participating received a written information sheet by post (Appendix 
C). A subsequent telephone conversation confirmed that the individuals had read the 
information sheet, wished to partake in the study and a date was arranged for the 
initial study visit.  
3.3.2 Ethics 
The study adhered to the tenets of Declaration of Helsinki for research involving 
human participants and the protocol was approved by the National Health Service 
South East Wales Research Ethics Committee (13/WA/0339).  
3.3.3 Procedures 
The individuals attended two visits at the School of Optometry and Vision Sciences, 
Cardiff University. A subset of individuals who attended for the initial two visits, also 
attended an additional follow-up visit after 1 year (Visit 3) (Figure 3.3). Visit 1 and 2 
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were separated by a median (IQR) of 14 days (9, 24). Visit 3 took place approximately 
1 year after Visit 2, median (IQR) of 13.6 months (12.5, 14.6).  
Figure 3.3 Study visit timeline. 
3.3.3.1  Visit 1 
The purpose of Visit 1 was to firstly confirm adherence to the inclusion and exclusion 
criteria by obtaining an ocular and medical history, the mini-mental state examination 
(MMSE) and refraction. 
Secondly, a microperimetry examination was performed to reduce the perimetric 
learning effect at Visit 2 (Wu et al. 2013; Heijl, Lindgren and Olsson 1989). Also, SD-
OCT and fundus photography images were acquired at Visit 1. The procedure for Visit 
1 was identical for all individuals. Rest periods were given between tests and the test 
order was maintained the same for every individual (Figure 3.4). This order was 
chosen to minimise possible effects of fatigue (Hudson et al. 1994) on the 
microperimetry examination, and to avoid the bleaching effects of the slit lamp and 
imaging examinations prior to microperimetry. Those with AMD have reduced 
photoreceptor recovery after stimulation by a bright light (Curcio, Owsley and Jackson 
2000). 
Written consent was obtained prior to performing any examinations (Appendix D).  
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Figure 3.4 The ordered procedure for Visit 1. 
3.3.3.1.1 Medical and ocular history 
A structured record sheet was used to ensure commonality between the recorded 
responses from all individuals (Appendix E). Medical history included an open 
question regarding the individual’s general health, an open question concerning 
current medications and closed questions about the presence of breathing disorders, 
diabetes, hearing impairment, heart conditions, hypertension and musculoskeletal 
conditions.  
Any relevant ocular history concerning referrals to hospital eye services and any 
ocular diseases were recorded. More specific questions were posed relating to AMD: 
the type of AMD; the length of diagnosis; and the affected eye. The individual was 
also asked to grade their own AMD condition as early, moderate or late. The anti-
VEGF injection history was also recorded. Specifically, the number of injections, the 
treated eye, last injection date and last appointment date.  
Information about activities of daily living was also documented. This included: 
difficulties performing tasks such as reading, cooking and watching television; the use 
of visual aids (magnifiers and additional aids); sight impairment registration; and 
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previous access to social service. Direct questions were used to enquire about the 
individual’s living situation and driving status. Hobbies and any current difficulties with 
performing these activities were noted. Fall history from the past year was also 
obtained. Finally, experience of visual hallucinations was probed and Charles Bonnet 
syndrome was explained briefly. 
3.3.3.1.2 Mini-mental state examination 
The shortened version of the MMSE (Schultz-Larsen, Lomholt and Kreiner 2007) is a 
cognitive screening tool involving 5 memory tasks (Appendix F). Firstly, three words 
were read aloud (“apple”, “penny” and “table”) and repeated until the individual had 
remembered the words. Three questions were then asked: “What is the day?”, “What 
is the month?” and “What is the year?”. The fourth task required the word “world” to 
be spelt backwards and finally the individual was asked to recall the words memorised 
at the beginning. 
To pass the MMSE an individual was required to answer the three questions 
appropriately, to correctly order three letters from “world” and to repeat two words of 
the memorised words correctly. Those that failed the MMSE were excluded. 
3.3.3.1.3 Refraction 
The habitual correction was recorded and both eyes were refracted to ascertain the 
BCVA measured by the Snellen chart. In cases where current spectacle correction 
was less than 6 months old, refraction was not performed. 
3.3.3.1.4 Microperimetry 
The detailed protocol for MAIA microperimetry is described in Section 3.3.3.1.4. MAIA 
microperimetry was performed on only one eye, as this was considered a training 
examination for microperimetry. 
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3.3.3.1.5 Anterior eye examination 
An examination of anterior ocular health was performed on both eyes using slit lamp 
biomicroscopy and included the Van Herick technique to grade the anterior chamber 
depth and LOCS III grading (Chylack et al. 1993). 
3.3.3.1.6 Fundus photography 
CFPs were obtained for both eyes, using the identical procedure described in Section 
3.3.3.1.6.  
3.3.3.1.7 SD-OCT 
SD-OCT images were acquired in each eye using the Cirrus HD-OCT (Carl Zeiss 
Meditec, Dublin, CA). Volume scans were centred on the fovea with a scan angle of 
20° x 20°, comprising 512 A-scans x 128 B-scans. A single high-density 6mm 
horizontal foveal line scan consisting of 1024 A-scans was also captured at the fovea. 
To ensure high quality images for grading and segmentation purposes, the quality of 
the SD-OCT images was at least 5/10, or better, and between 1 and 3 images were 
obtained. If SD-OCT was not possible due to a small pupil, one drop of Tropicamide 
0.5% was instilled in each eye. 
3.3.3.1.8 Colour fundus photograph grading 
Colour fundus photographs were graded using the AREDS 2 classification (Danis et 
al. 2013), which was based on the AREDS classification system (AREDS 2001) for 
the use with digital photographs. CFPs were graded and classified in PowerPoint 
(Microsoft Office, Washington, U.S) using a digital scaling of the AREDS grid, 
according to the method by Danis et al. (2013) adapted for a 45° CFP. To ensure 
consistency of grading, each of the CFPs was resized according to the PowerPoint 
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equivalent size (Figure 3.5) and the grading circles were sized accordingly to ensure 
the correct ratios (Figure 3.5).  
Figure 3.5 Left: A Colour fundus photograph of an individual with AMD with an overlay of the 
standard ETDRS grid and the standardised circles used for AREDs grading. Right: Table of 
equivalent sizes used to grade the colour fundus photographs (Adapted from Danis 2013 by 
[Terry, 2017]) 
A standard ETDRS grid was centred at the fovea for each of the images and retinal 
features were graded using the standard AREDS circles (Figure 3.5). Each CFP was 
graded for the presence of GA, drusen and pigmentation. An overall AREDs disease 
severity grade of 1 to 4 was assigned based upon the presence, size and location of 
AMD features (Table 3.1). As with AREDS 2 classification (Danis et al. 2013), history 
of injection was used to aid the classification of nAMD. 
Once the AREDS classification had been performed, SD-OCT volume scans were 
used to confirm or identify the presence of intraretinal fluid, PED and other retinal 
features at the macula. The presence of RPD was confirmed or identified by the IR 
images, acquired by the MAIA microperimeter. 
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AREDS 
classification Criteria
1 Drusen maximum size <C-0 (63µm diameter) and total area <C-1 
(125µm diameter)
2 Presence of one or more of the following:
•Drusen max size ≥C-0 but <C-1 
•Drusen total area ≥C-1 
•Pigment abnormalities consistent with AMD, defined as one or 
more of the following in the central or inner subfields:
a) Depigmentation
b) Increased pigment >C-1 
c) Increased pigment present and depigmentation at least 
questionable
3 Presence of one or more of the following:
•Drusen maximum size ≥C-1 
•Drusen maximum size ≥C-0 and total area >I-2 and type is 
soft indistinct
•Drusen maximum size >C-0 and total area >O-2 and type is 
soft distinct
•GA within grid but none in centre of macula
4 (Late) Presence of one or more of the following:
•GA in central subfield with at least questionable involvement 
of centre of macula
•Evidence of nAMD:
a) Fibrovascular/serous PED
b) Serous (or haemorrhagic) sensory retinal detachment
c) Subretinal pigment epithelial haemorrhage
d) Subretinal fibrous tissue
e) Photocoagulation for AMD
Table 3.1. AREDS classification with criteria (AREDS 2001) © from Elsevier. 
3.3.3.1.9 SD-OCT segmentation 
The SD-OCT 512x128 volume scans were segmented into 10 layers (11 surfaces), 
using a fully automated three-dimensional segmentation algorithm (OCTSeg), a 
module of OCT Explorer, which is part of the Iowa Reference Algorithms (Retinal 
Image Analysis Lab, Iowa Institute for Biomedical Imaging, Iowa City, IA) (Garvin et 
al. 2009; Abràmoff, Garvin and Sonka 2010). Nine retinal layer outcomes were 
evaluated: the retinal nerve fibre (RNFL, boundaries 1-2), the ganglion cell layer 
(GCL, boundaries 2-3), the inner plexiform layer (IPL, boundaries 3-4), the inner 
nuclear layer (INL, 4-5), the outer nuclear (ONL, boundaries 5-6), the outer segment 
layer (OS, boundaries 8-10), the RPE (boundaries 10-11) and, additionally, the total 
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receptor layer plus RPE (boundaries 5-11) and the total retina (boundaries 1-11) 
(Figure 3.6).   
Figure 3.6 OCT Explorer segmented SD-OCT with the 8 retinal layers utilised for further 
analysis shown, plus the additional grouped layers of total receptor and total retina. 
The pointwise retinal thickness was calculated at 40 retinal locations. Forty squares 
of 0.13 x 0.13mm in size, corresponding to the Goldmann III stimulus size (0.43° 
diameter) were identified on the en-face SD-OCT image. Stimulus sizes were 
converted to retinal sizes using 0.3mm equivalent to 1° (Blaker 1980; Carl Zeiss 
Meditec 2013; Lee et al. 2014). Each square was positioned on the en-face image, to 
align with the MAIA grid pattern extending to an eccentricity of 7° (Figure 3.7). This 
was achieved by programming coordinates for each stimulus location in the 
segmentation software (OCT Explorer), by writing .xml files in Notepad (Microsoft, 
Washington, U.S.) (Appendix G).  
A second grid to account for the displacement of the retinal ganglion cell layer at the 
macula (Hood and Raza 2011) was applied to the thicknesses for the RNFL and GCL 
layers (Figure 3.7).  
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Figure 3.7 A and B: Screenshot from OCT Explorer (left) and IR image from MAIA 
microperimeter (right), showing the matching layout of the retinal thickness measurement 
locations and DLS locations. C: Realigned 40 locations in degrees from the fovea 
corresponding to retinal ganglion cell displacement. D: Screenshot from OCT explorer of the 
layout of the RNFL and GCL retinal thickness measurements. 
The output of OCT Explorer takes the form of a Microsoft Excel comma separated 
value (.csv) file that contains the individual layer thickness for each location. From 
this, the mean retinal thickness outcomes at each of the stimulus locations, was 
calculated. 
3.3.3.1.10  SD-OCT grading 
SD-OCT B-scans corresponding to each of the 40 MAIA locations were examined for 
the presence of retinal features associated with AMD.  Key retinal features associated 
with AMD were identified: drusen, ORTs (Figure 3.8, B), RPD (Figure 3.8, D), EZ band 
disruption (graded 1, 2 or 3) (Figure 3.8, A)(Wu et al. 2014c), absent RPE and/or 
photoreceptor layer (Figure 3.8, E), sub-retinal and intra-retinal fluid (Figure 3.8, C), 
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PED (fibrovascular, serous or drusenoid) and presence of fibrovascular region (Figure 
3.8, C).  
Figure 3.8 AMD associated retinal features identified by SD-OCT. A: Ellipsoid zone disruption 
graded from 1-3 (Wu et al. 2014c), B: Outer retinal tubulations, C: Fibrovascular PED with 
additional subretinal fluid, D: Reticular pseudodrusen with additional large drusen, E: Atrophy 
of the RPE and photoreceptor layers 
3.3.3.2 Visit 2 
Visit 2 was scheduled for approximately 2 weeks after the Visit 1. It consisted of VA, 
CS, reading speed, MAIA microperimetry and a questionnaire interview comprising a 
number of vision-related and health-related instruments (questionnaires). The 
procedure for Visit 2 was identical for all individuals. Rest periods were given between 
procedures and the procedure order was maintained the same for each individual 
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(Figure 3.9). This order was chosen to reduce the effects of fatigue in the 
microperimetry examination and in the questionnaire interview. 
Figure 3.9 The ordered procedure for Visit 2. 
At the start of Visit 2, an injection history for the two weeks between Visit 1 and 2 was 
recorded.  
3.3.3.2.1 Visual acuity 
Visual acuity was measured using the ETDRS LogMAR chart according to the 
standardised protocol (Ferris and Bailey 1996) using an identical method described 
in Section 3.2.3.1.2. The test was performed monocularly and then binocularly. This 
was repeated with habitual correction (VA) and best correction in place (BCVA). 
3.3.3.2.2 Microperimetry 
Microperimetry was performed in an identical manner to that described in Section 
3.2.3.1.4 and to that in Visit 1. However, microperimetry was performed on both eyes 
where possible.  
3.3.3.2.3 Questionnaire outcomes 
Three vision-related instruments and three health-related instruments were utilised in 
this study. The IVI questionnaire (Lamoureux et al. 2006), the VF-14 (Steinberg et al. 
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1994), and the modified TTO (Brown 2000) were used to measure vision-related QoL, 
visual function and vision-related utility, respectively. The health-related instruments 
were the EQ-5D-3L (EuroQoL 1990), the PHQ-9 (Kroenke, Spitzer and Williams 
2001) and the WEMWBS (Tennant et al. 2007). The primary questionnaire outcome 
was the IVI. The secondary outcomes were the modified TTO utility value, the VF-14, 
the EQ-5D-3L, the PHQ-9 and the WEMWBS. Each of the questionnaires were 
administered verbally and in person. The individuals could view a prompt sheet as a 
reminder of each of the possible Likert scale responses for the IVI, VF-14, PH-Q9 and 
WEMWBS (Appendix H). 
The order within the questionnaire interview was the same for each individual 
beginning with the IVI, followed by the EQ-5D and then the WEMWBS. The individual 
then received a short break of between 5 and 10 minutes, in which refreshments were 
provided (Figure 3.10). After the break and before the next questionnaire, CS and 
reading speed were measured. Finally, the VF-14, followed by the PH-Q9 and 
concluding with the modified TTO, were administered (Figure 3.10). 
Figure 3.10 The sequence of administered questionnaires. 
The IVI, VF-14 and the WEMWBS logit scores were converted into a linear scale 
using Rasch analysis. 
Rasch analysis
Rasch analysis uses item response theory to transform ordinal categories into 
estimates of linear interval measures, expressed in logits (Rasch 1993). It is 
recommended for studies that include questionnaires as it allows for parametric 
statistical testing (Lamoureux et al. 2008). Rasch analysis also assesses the 
psychometric properties of a questionnaire, including: suitable response categories; 
item fit; unidimensionality; differential item functioning (DIF); and the range of item 
difficulty to individual ability (Lamoureux et al. 2008; Rees et al. 2013). 
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Rasch analyses was performed according to Andrich Rating Scale model (Andrich 
1978) using Winsteps software (Version 3.90.0) (Linacre 2006). The full methods to 
perform Rasch analyses and the associated output tables required are included in 
Appendix I. The psychometric properties of each questionnaire were assessed, firstly, 
by examining the person and item reliability and separation, where reliability estimates 
closer to 1 are the most reliable and separation over 2 is satisfactory (Court, 
Greenland and Margrain 2010). Secondly, the infit and outfit statistics were examined, 
which assesses how well the items measure that which the questionnaire aims to 
measure. Low values indicate the item correlates well with the targeted goal, values 
of 1.5 to 2.0 are considered as less acceptable, yet will not degrade the data, and any 
value greater than 2 indicated that the item is not measuring what it aims to (Court, 
Greenland and Margrain 2010). Thirdly, the response categories were evaluated, 
whereby each category required an ordered structure calibration threshold (Khadka 
et al. 2012). Following this, evaluation of the unidimensionality was performed, 
according to the infit and outfit cut-off guidelines (Smith, Schumacker and Bush 1998), 
whilst also taking into account the more lenient cut-offs that suggest the items are still 
productive for measurement (Linacre 2006). This concluded the assessment of the 
psychometric properties. Providing all these measures were adequate, according to 
the above criteria, a scoring table was produced for each questionnaire to convert raw 
scores to logit scores. 
The logit scoring tables were constructed by combining the item measures (for each 
question) and the category measures (for each scoring category). The sum of these 
numbers provides a scoring table for each item of the questionnaire. The baseline 
scoring tables for each questionnaire were used to convert the raw scores, obtained 
at the follow-up visit, to logit scores.  
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Impact of Visual Impairment questionnaire
The IVI is a 28 item questionnaire which utilises a Likert scale for responses 
(Lamoureux et al. 2006) (Table 3.2). The IVI procedure is summarised in Table 3.2
and is scored using Rasch analysis (Section 3.3.3.2.3.1) as the mean logit score for 
the total questionnaire and for each subscale: reading, mobility and emotional. 
IVI Questions Responsecategories Subscale
“In the past month 
how much has your 
eyesight interfered 
with the following 
activities?”
1-15
0 – not at all
1 – a little
2 – a fair amount
3 – a lot
8 – don’t do for 
other reasons
1,3,4,6-11Reading
2,5,12-15 Mobility
“In the past month 
how often has your 
eyesight made you 
concerned about 
the following?”
16-20
0 – not at all
1 – a little
2 – a fair amount
3 – a lot
8 – don’t do for 
other reasons
Mobility
Think about how 
your eyesight has 
made you feel in 
the past month”
21-28
0 – not at all
1 – a little
2 – a fair amount
3 – a lot
8 – don’t do for 
other reasons
Emotional
Note. Reduced answering category for question 4 and 7: 0, not at all; 1, fair amount; and 
2, a lot.
Table 3.2. The question wording for the Impact of Vision Impairment questionnaire with the 
associated response categories and subscales: mobility, emotion and reading. 
Although the IVI has been Rasch analysed for AMD previously (Lamoureux et al. 
2008), the published scoring system for the IVI was not established specifically for 
those with AMD (Lamoureux et al. 2006). Therefore, Rasch analysis for the IVI was 
performed within this research to produce a logit scoring table for the total score of 
the IVI, specifically for those with AMD. Prior to Rasch analysis, the IVI questionnaire 
scores were reversed and combined (Lamoureux et al. 2006), which allowed more 
logical interpretation, whereby a more negative logit score represents a worse vision-
related QoL. 
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EQ-5D-3L
The EQ-5D-3L instrument includes five questions with a choice of 3 responses for 
each question (EuroQoL 1990). The questions are related to mobility, self-care, ability 
to perform everyday activities, pain, and anxiety and/or depression. The individuals 
were required to rate each category as having no problems, 1; moderate problems, 
2; or extreme problems, 3, in each case. The published country specific value sets to 
calculate an index (van Reenen and Oppe 2015) were used to estimate the EQ-5D 
index value (Rabin and de Charro 2001).  
The EQ-5D also includes a visual analogue scale in which the individual was asked 
to rate their overall health state on the day of the visit using a scale of 0-100, with 0 
being the worst imaginable health state and 100, the best. 
Warwick-Edinburgh Mental Well-being scale
The authors of the WEMWBS require the following copyright statement to be given 
when using this questionnaire: 
“The WEMWBS was funded by the Scottish Government National Programme for 
Improving Mental Health and Well-being, commissioned by NHS Health Scotland, 
developed by the University of Warwick and the University of Edinburgh, and is jointly 
owned by NHS Health Scotland, the University of Warwick and the University of 
Edinburgh ) (Tennant et al. 2007).  
The WEMWBS includes 14 statements about positive thoughts and feelings. The 
individual is asked to provide the response that best describes their experience over 
the last two weeks (Table 3.3). The WEMWBS was scored using a Rasch analysed 
scoring table (Section 3.3.3.2.3.1). 
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Table 3.3 Warwick-Edinburgh Mental Well-Being scale question wording and the response 
categories. 
It was necessary to undertake Rasch analysis of the WEMWBS, as a scoring table 
has not previously been published for individuals with AMD. The psychometric 
properties were assessed and a scoring table was produced.  
VF-14
The VF-14 consists of 14 items each with a 5 category Likert scale (Steinberg et al. 
1994). The individuals were required to classify the level of difficulty experienced with 
14 different tasks by means of the categories Table 3.4. If any of the questions were 
not relevant to the individual, they were excluded. The VF-14 was scored using a 
Rasch analysed scoring table. 
Table 3.4 Visual function-14 question wording and response categories. 
The VF-14 has been Rasch analysed in individuals with cataracts (Las Hayas et al. 
2011) and with AMD (Hewitt et al. 2006), but to the authors knowledge, no scoring 
table has been published for individuals with AMD. Rasch analysis was, therefore, 
performed on the VF-14 to assess the psychometric properties and derive a scoring 
table for individuals with AMD. 
PHQ-9 
The PHQ-9 consists of 9 questions relating to symptoms of depression (Kroenke, 
Spitzer and Williams 2001). The individual was asked “how often over the last 2 weeks 
WEMWBS Questions Response categories
“Please give the response 
that best describes your 
experiences of each over 
the last 2 weeks”
1-14
1 – None of the time
2 – Rarely
3 – Some of the time
4- Often
5- All of the time
VF-14 Questions Response categories
“Do you have difficulty, 
even with glasses,….” 1-14
0- Not possible
1- a lot of difficulty
2- some difficulty
3- a little difficulty
4- no difficulty
98 
have you been bothered by any of the following problems?”. The choice of responses 
is: 0, not at all; 1, several days; 2, more than half the days; and 3, nearly every day. 
The individual scores were totalled to produce the overall score, which determined 
the individual’s level of depressive symptoms (Table 3.5). 
Total 
score Depression Severity
1-4 Minimal
5-9 Mild 
10-14 Moderate
15-19 Moderately severe
20-27 Severe
Table 3.5 Interpretation of the Patient Health Questionnaire-9 (PHQ-9) total score to establish 
the severity of depressive symptoms 
To identify individuals that were considered at risk of harm related to depressive 
symptoms, a protocol was adopted (Figure 3.11). A score of 5-27 led to the individual 
being offered referral to their GP, and completion of a consent form was required 
(Appendix J). Individuals identified as being at risk of suicide (score 2-3 on question 
9 of the PHQ-9) were referred to their GP without consent being required and were 
excluded from the study. 
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Figure 3.11 Protocol for identification of depressive symptoms from the PHQ-9 
Modified TTO
The modified TTO consists of two hypothetical questions (Brown 2000). Firstly: “How 
many years do you expect to live?” and secondly: “How many of those years would
you trade for perfect vision?” A utility value was then calculated from the equation: 
Utility value = (Number of expected life years - Number of years trade-off)Number of expected life years
3.3.3.2.4 Contrast sensitivity 
Monocular and binocular CS was measured using the Mars contrast sensitivity test 
(Haymes et al. 2006). Near visual correction was worn and the test undertaken at a 
working distance of 50cm. This was undertaken using the habitual correction and if 
applicable, repeated with the best correction in place. The chart was uniformly lit at 
an average of 85cd/m2, measured by a photometer (LS-110; Konica Minolta., Osaka, 
Japan), according to the manufacturer’s guidelines. Identical instructions were given, 
to read from left to right and top to bottom. Only a response of a letter included in the 
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chart was accepted. The LogCS was calculated as the LogCS value of the final correct 
letter minus the errors (-0.04 per incorrect letter).  
3.3.3.2.5 Reading speed 
The IResT (Trauzettel-Klosinski and Dietz 2012) was used to quantify reading speed 
binocularly. The text was held at the habitual working distance with the habitual near, 
and if appropriate with the best correction in place. The text was illuminated by 
overhead fluorescent lighting, with equal lumination (average of 85cd/m-2) over the 
page, using the same luminance for each individual. Identical instructions were given, 
to read the entire paragraph of text aloud from start to finish, as quickly as possible 
without making corrections.  
The text was initially covered and timing began when it was uncovered. The speed 
was measured using a stopwatch in seconds to the nearest 1/10th, consistent with the 
researcher’s reaction time. The words read incorrectly or missed were subtracted 
from the total number of words in the text. Reading speed in words per minute (wpm) 
was calculated by the equation: 
wpm= number of correctly read wordsreading time x 60
3.3.3.3 Visit 3 
Visit 3 was undertaken approximately 1 year after Visit 2 and involved the collection 
of follow-up outcomes in a subset of individuals. The procedure for Visit 3 was 
identical for all individuals, rest periods were given between tests and the test order 
was maintained the same for every individual (Figure 3.12).  
An updated ocular and medical history was taken in the same manner as Visit 1 
(Section 3.3.3.1.1). The habitual correction was recorded and both eyes were 
refracted, except in cases where current correction was less than 6 months old. 
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Monocular and binocular ETDRS VAs were recorded with both the habitual and best 
correction in place, as in Visit 2 (Section 3.3.3.2.1).  
Figure 3.12 The ordered procedure for Visit 3 
Microperimetry was performed using the identical protocol adopted in Visit 1, and 
performed on both eyes where possible (Section 3.3.3.1.4).  
The questionnaire interview was performed in an identical manner to Visit 2 (Section 
3.3.3.2.3). 
A full anterior ocular health evaluation was performed and imaging data was collected 
in an identical manner to Visit 1 (Section 3.3.3.1.5 and Section 3.3.3.1.6, respectively).  
This chapter described the methodology that was used for the subsequent studies 
presented in Chapters 4, 5, 6 and 7.  
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Chapter 4: Development of a normative database 
using the Macular Integrity Assessment 
microperimeter and the application in age-related 
macular degeneration 
Purpose: The primary aim of this study was to derive a pointwise age-corrected 
normative database and to determine the 95%, 98% and 99% limits of normality. The 
secondary aims were twofold: to examine over three visits the characteristics of the 
macular visual field (MVF), with respect to age and eccentricity; and to compare two 
different methods of deriving the normative database with the addition of a clinical 
case study. 
Methods: Sixty-five normal individuals (median age 43 years, IQR 26.0, 65.0) met 
the inclusion criteria and attended for three visits. The DLS for each individual was 
measured using a custom program (40 stimulus locations within 7° from fixation) on 
the MAIA microperimeter, at each of the visits. Two normative databases were 
derived, one using an adjusted age method (Method 1), that has previously been used 
with the Humphrey Visual Field Analyser, and the other using an age-specific method 
(Method 2) to derive the TD and PD probability levels at each of the 40 stimulus 
locations for each visit.
Results: Mean Sensitivity declined with age for each of the three visits (p<0.001). 
The pointwise normal DLS values and the magnitude of DLS at which the TD and PD 
95%, 98% and 99% probability limits occurred for Method 1 all declined with 
eccentricity and increased with visit (all p<0.05) as did those for Method 2, which also 
declined with age (p<0.05). The pointwise values of TD and PD prediction limits 
103 
between corresponding visits were higher for Method 1 than Method 2 in all cases (all 
p<0.01). 
Conclusion: The derivation of a normative database is essential for the quantification 
of functional deficits in AMD, detected using MAIA microperimetry. Method 2 will be 
employed throughout all subsequent chapters due to a robust statistical methodology.
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Normative databases for medical equipment are required to enable appropriate 
diagnosis and management of diseases. This chapter will develop a normative 
database for the MAIA microperimeter as a prerequisite for the analysis of 
microperimetry outcomes in individuals with AMD in the following chapters. Firstly, 
the relevant literature will be summarised, prior to a detailed explanation of the 
database derivation. 
In SAP, the standard approach is to use software that incorporates normal values to 
allow probability analyses of the DLS results, in order to identify abnormality (Heijl et 
al. 1989). This includes pointwise probability analysis of TD and PD, and summary 
measures such as MD and mean PD (MPD). TD refers to the difference between the 
measured value and the corresponding age-corrected normal value at each stimulus 
location, with MD being the mean weighted TD and mean TD (MTD) the unweighted 
equivalent. PD is adjusted according to the general height of the visual field and 
provides information about localised loss (Heijl, Lindgren and Olsson 1987a).  
The international standards for ophthalmic instruments (ISO 12866) provide a number 
of minimum requirements of a normative database for perimeters. Firstly, that the 
definition of healthy eyes must be predefined including a minimum level of VA, a 
maximum spherical and cylindrical optical correction and exclusion of individuals with 
conditions that affect the visual field. Secondly, the method of perimetric examination 
should be predefined including the eye to be tested, as only one eye of each subject 
can be included. Finally, the normative database must include at least 60 eyes, of 
which ten individuals are required to be younger than 30 years and ten individuals 
older than 60 years. 
Normative databases in SAP are usually obtained across multiple research sites, with 
a large number of individuals (typically more than 200), who undertake perimetry on 
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two or more visits, where data was randomly selected from one of the visits to be 
included in the database (Heijl, Lindgren and Olsson 1987a). This random selection 
attempts to reduce the impact of the perimetric learning effect i.e. where DLS results 
improve with experience, and are most pronounced from the first to the second visit 
(Wild et al. 1989; Heijl and Bengtsson 1996). This has led to the current practice of 
repeating the initial perimetry examination (Wood et al. 1987; Heijl, Lindgren and 
Olsson 1989; Fredette et al. 2015).
Microperimetry is a relatively recent technique with two main advantages over SAP. 
Firstly, tracking of the fundus allows correction of unstable fixation and/or loss of 
fixation, which is associated with late stage AMD (Whittaker, Budd and Cummings 
1988).  Secondly, the DLS at each stimulus location is overlaid onto the fundus image. 
The MAIA (Centervue, Padova, Italy) utilises a SLO to acquire a fundal image and 
tracks each pixel within the image. A correction of the stimulus projection is made 
according to the gaze position (gaze-contingency). A full description of the technical 
specification of the MAIA microperimeter can be found in Chapter 1 (Section 1.4.4.1) 
and a review of microperimetry is presented in Section 1.4.4. 
Similar to SAP, the plateauing of the learning effect after the second visit, is also 
evident in microperimetry as determined in a study of pointwise sensitivity on the 
MAIA (Wu et al. 2013). In contrast, another study found no learning effect, when 
examining an average index, MS (Weingessel et al. 2009). However, an average 
index might not be the most relevant method to analyse this due to the topographical 
nature of microperimetry. It is, therefore, still beneficial to have several separate 
examinations on different days to reduce the learning effect (Heijl and Bengtsson 
1996; Wu et al. 2013). 
The MAIA microperimeter does not derive TD or PD analysis and merely displays the 
measured DLS, in decibels, at each stimulus location. The DLS value is colour coded, 
using a continuous scale of colour change, to arbitrarily indicate normal, borderline 
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and abnormal outcomes (Midena 2013) (Figure 4.1). Although a schematic histogram 
of normality is presented, it does not consider the variation of DLS in the normal eye 
with age and with eccentricity (Figure 4.1). The lack of probability analysis, by TD and 
PD, may limit the ability to detect generalised and localised early functional losses in 
AMD and also to monitor functional deficits accurately.   
Figure 4.1 MAIA microperimetry output: 40 location stimulus pattern (top left) for an individual 
with AMD. The colour coding represents the different decibel values for sensitivity as shown 
on the frequency histogram for the same individual (bottom). The normal population 
distribution shown is the same for all ages and eccentricities. 
DLS results and spatial characteristics in normal individuals have been previously 
described for the MAIA microperimeter (Vujosevic et al. 2011; Fujiwara et al. 2014). 
However, these studies describe MS only, did not take into account age and did not 
derive TD or PD probability analysis i.e. the parameters that clinicians would find most 
useful. Two recent studies have examined normal values of the MAIA microperimeter 
with respect to age (Denniss and Astle 2016; Molina-Martín, Piñero and Pérez-
Cambrodí 2017). The first derived a computational model of DLS measurements 
enabling the derivation of TD and PD probability analyses independent of fixation 
(Denniss and Astle 2016). However, given the large number of stimulus locations 
examined, 237 locations over 1 or 2 sessions, this study did not reflect a typical 
perimetric situation in clinical practice. A more recent study examined median DLS 
values with respect to age, but did not include calculation of probability analyses 
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(Molina-Martín, Piñero and Pérez-Cambrodí 2017). Hence, the study presented 
herein will produce clinically relevant normative database values with the inclusion of 
probability analysis to define abnormality. 
There are different methods of deriving normative databases. A long established 
method of normative database derivation, used for the HFA, involves the adjustment 
of DLS values to that of the mean age of the cohort (Bengtsson and Heijl 1999; Heijl, 
Lindgren and Olsson 1987a). Yet, little is known or has been published to explain the 
methodology and statistical reasoning behind it. Other studies have derived normative 
databases for microperimetry (Acton, Bartlett and Greenstein 2011) and SD-OCT 
(Topcon Medical Systems I 2011) using linear regression analysis. Due to the 
equivocal nature of the current literature, both methods will be performed and 
subsequently compared to establish the most appropriate method to continue forward 
in all future studies. 
The primary aim of this study was to derive a pointwise age-corrected normative 
database and to determine the 95%, 98% and 99% limits of normality. The secondary 
aims were twofold: to examine over three visits the characteristics of the MVF, from 
microperimetry, with respect to age and eccentricity; and to compare two different 
methods of deriving the normative database with the addition of a clinical case study.
The cohort comprised 80 consecutive individuals with a median (IQR) age of 43 years 
(26, 65). The detailed methodology is presented in Chapter 3: and is summarised in 
Figure 4.2. 
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Figure 4.2 The sequence of procedures for the normative data collection. The three visits were 
each separated by an average of 2 weeks. 
The study eye was chosen as that with the better VA, and when both eyes had equal 
VAs the study eye was chosen at random.  
4.3.1 Analysis 
4.3.1.1 Regression 
MAIA DLS values from all visits were transformed to a right eye format. The 
distribution was examined using the Kolmogorov-Smirnov test.  
Two methods of deriving a normative database were investigated in this study. Both 
methods required regression analysis, therefore the assumptions of linear regression 
were tested prior to database construction. The assumptions of linear regression are 
that: 
 the outcome variable should have a normal distribution for each value of the 
predictor variable (Altman 1991). 
 the variability of the outcome variable should be the same for each value of 
the predictor variable (Altman 1991). 
 the relation between the two variables should be linear (Altman 1991). 
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Plotting the residuals allows subjective visual assessment of these assumptions, 
whilst the “gvlma” package in the open source statistical software, R (R Core Team 
2017), provides statistical testing (kurtosis, skewness, heteroscedasticity and a global 
statistic) with p-values to ensure the assumptions are met. The relationship between 
age and DLS, both as a mean and for each of the 40 stimulus locations, was 
determined using a linear regression model and the assumptions were assessed 
(Altman 1991). In all 40 locations, for each visit, the assumptions were met (all p>0.05) 
and each plot of residuals was acceptable (Figure 4.3). Therefore, it was concluded 
that linear regression was an appropriate method with which to construct the 
normative databases. 
Figure 4.3 Example of residual plots for linear regression of differential light sensitivity with 
age for location 3 and visit 3. The residuals (top left) and standardised residuals (bottom left) 
plotted against the fitted values, the normal Q-Q plot (top right) and the standardised residuals 
plotted against the leverage (bottom right). 
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4.3.1.2 Database derivation 
Two methods to derive the normative databases were used, the adjusted age method 
(Method 1) and age-specific method (Method 2). For each of these methods three 
databases were derived corresponding to each of the three visits (Figure 4.4). 
The adjusted age method (Method 1) involves the conversion of each individual from 
their own age to the mean age of the cohort and subsequently the appropriate 
adjustment of the DLS. The age-specific method (Method 2) utilises linear regression 
of DLS versus age of each individual. Both databases were derived using the open 
source environment R (R Core Team 2015) (Appendix K).  
Figure 4.4 Flow diagram of derivation the normative databases for Methods 1 and 2. Three 
databases are derived from each of the visits and TD and PD probability analyses will be 
derived for each of the databases. 
4.3.1.2.1 Adjusted age method (Method 1) 
The rationale for the current method to calculate the prediction limits in SAP is not 
well documented. However, this method was used as it is similar to that used by Zeiss 
for the HFA normative database as can be assumed from the current literature 
(Bengtsson and Heijl 1999; Heijl, Lindgren and Olsson 1987a). 
Normative database derivation
Linear regression was used to determine the relationship between age and DLS at 
each stimulus location. The pointwise DLS values were then adjusted to the mean 
age adjusted DLS using the equation: 
Mean age adjusted DLS = DLS + ( 45.97 - individual s age  x slope)
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Total Deviation derivation
Mean age (45.97 years) DLS values provide a ‘normal’ individual dataset for 
comparison with the mean age adjusted measured DLS values.  
The difference between mean age DLS and the age adjusted DLS were calculated to 
derive the TD values, for each location. The distribution of the TD values was 
examined using the Shapiro-Wilk test. The TD probability limits were calculated using 
the 95th, 98th and 99th percentiles of the TD values at each stimulus location (Figure 
4.5). 
Pattern Deviation derivation
The 85th percentile of the TD values across all the stimulus location, for each 
individual, was calculated. This was then subtracted from the mean age adjusted DLS 
values to produce the 85th percentile corrected DLS values for each individual. The 
difference between the pointwise 85th percentile corrected DLS and the mean age 
DLS were calculated to produce the PD values for each stimulus location. The 
distributions of the PD values were examined using the Shapiro-Wilk test. The PD 
probability limits were calculated using the 95th, 98th and 99th percentiles of the PD 
values at each stimulus location (Figure 4.5). 
Figure 4.5 Schematic diagram of the adjusted age method (Method 1). A theoretical 
distribution of the TD and PD values for a single stimulus location are shown. The 5%, 2% and 
1% probability limits of the normative database are derived from the 95th, 98th and 99th
percentiles of the distribution. 
Database use with clinical data
When using this database to examine new DLS values, the measured DLS values 
were age adjusted. These age adjusted values were then subtracted from the mean 
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age DLS database values to calculate the TD values for an individual. These values 
were then compared to the database probability limits to identify locations exhibiting 
a probability value at ≤5%, ≤2% and ≤1%. The 85th percentile of the individual’s TD 
values was then calculated and subtracted from the TD values to derive the PD 
values. Finally, the PD values were compared to the database PD probability limits to 
identify locations exhibiting a probability value at ≤5%, ≤2% and ≤1% (Figure 4.6). 
Figure 4.6 Flow diagram of the use of Method 1 database with a new individuals DLS values 
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4.3.1.2.2 Age-specific method (Method 2) 
Normative database derivation
The age-specific method used regression analysis of DLS as a function of age for 
each of the stimulus locations to create the normative database. The linear regression 
line was used for the normative DLS values of the database (Figure 4.7).  
Figure 4.7 Left: Linear regression plot of differential light sensitivity (DLS) (ordinate) with age 
(abscissa), showing the fitted regression line which produces the normative database DLS 
values, the 5%, 2% and 1% prediction limits are also shown that correspond to the Total 
Deviation probability levels of the normative database. Right: Linear regression of 85th
percentile corrected DLS values with age, showing the 5%, 2% and 1% prediction limits that 
correspond to the Pattern deviation probability levels. 
Total Deviation derivation
The regression 95%, 98% and 99% prediction limits corresponded to the TD 
probability levels at the 5%, 2% and 1% for the normative database (Figure 4.7).  
Pattern Deviation derivation
The 85th percentile of each individual’s TD values were calculated and subtracted from 
the individual’s DLS values to produce 85th percentile corrected DLS values. Linear 
regression of 85th percentile corrected DLS values with age were produced for each 
of the stimulus locations. The prediction levels (95%, 98% and 99%) of these were 
then used to derive the PD probability limits (5%, 2% and 1%) for the normative 
database (Figure 4.7). 
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Database use with clinical data
When using this database to examine new DLS values, pointwise DLS values were 
compared to pointwise normative database values for the individual’s age. The 
difference between the pointwise new DLS values and pointwise normative database 
values provides the pointwise TD values. The pointwise new DLS values were then 
compared to the corresponding pointwise prediction limits to derive the associated 
probability level. The 85th percentile of the individual’s TD values was then subtracted 
from the TD values to derive the PD values. The PD values were then compared to 
the elevator corrected prediction limits to derive the pointwise PD probability level 
(Figure 4.8).  
Figure 4.8 Flow diagram of the use of method 2 database with new individual’s DLS values
4.3.1.3 Statistical analysis 
The data was analysed using Microsoft Excel 2013, SPSS Statistical Package version 
20 (SPSS, Inc., Chicago) and the open source environment R (R Core Team 2015).  
To examine, over three visits, the characteristics of the MVF with age and eccentricity. 
The difference in the magnitude of the MS and pointwise DLS as a function of age, 
eccentricity and visit was analysed for Method 1 and Method 2. 
For MS, a two-way repeated measures Analysis of Variance (ANOVA) with visit as a 
within-subject factor, and age as a between-subject factor was employed. 
115 
For pointwise DLS, eccentricity was defined in terms of four concentric annuli: within 
a radius of 1°, between a radius of 1° and 3°, between a radius of 3° and 5° and 
between 5° and 7° (Figure 4.9).  
For Method 1, the DLS corresponding to the normal values, and at which 5%, 2% and 
1% TD and PD prediction limits occurred were investigated using a separate two-way 
repeated measures ANOVA, with location and visit as separate within-subject factors. 
As Method 2 also included age, a separate three-way repeated measures ANOVA 
with location and visit as separate within-subject factors and age as a between-
subjects factor was used. 
A pointwise comparison of the database DLS normal values, TD and PD prediction 
limits (95%, 98% and 99%) between adjusted age method (Method 1) and the age-
specific method (Method 2) for each of the visits was carried out using a two-tailed 
independent samples t-test. Significance was defined as ≤0.05 in all cases. Individual 
case data were also examined to visualise the difference between normative 
databases on a clinical level. 
Figure 4.9 Eccentric annuli used within this study: within a radius of 1°, between a radius of 1° 
and 3°, between a radius of 3° and 5° and between 5° and 7°. 
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The following results are presented: firstly, characteristics of the healthy individuals 
and the microperimetry results; secondly the analysis performed on each of the 
databases derived in this study (Method 1 and Method 2); finally, the comparison 
between the two databases with a clinical example. 
4.4.1 Characteristics of healthy individuals 
Five of the 80 individuals were excluded due to existing ocular co-morbidities (3 due 
to details from the medical history, and following ocular examination, one due to 
epiretinal membrane formation and one due to early AMD). A further 5 failed to 
complete all three visits and one was excluded due to a lens artefact in the visual field 
recording, resulting in a cohort of 65 individuals (38 female, 27 males).  
The characteristics of the individuals, including the MAIA and HFA visual field 
characteristics, are presented in Table 4.1.  
N=66 Median (IQR)
Age (years) 43.0 (26.0, 65.0)
Mean sphere (DS) 0.0 (1.4 , -2.1)
VA (LogMAR) -0.1 (-0.1, -0.2)
IOP (mmHg) 14 (13, 17)
HFA 30-2 (dB)
MD
PSD
-0.5 (-1.5, 0.4)
1.5 (1.3, 1.8)
MAIA Mean Sensitivity (dB)
Visit 1
Visit 2
Visit 3
29.7 (28.4, 30.5)
29.8 (28.6, 30.5)
29.9 (29.2, 31.0)
Table 4.1 Characteristics of the healthy individuals. Median (IQR) values are presented for: 
age, spectacle prescription, visual acuity (VA), intra ocular pressure (IOP), Humphrey field 
analyser (HFA) and Macular Integrity Assessment (MAIA) microperimetry. 
The measured MS declined with age for each of the three visits (p<0.001) (Figure 
4.10), as did the measured DLS at each of the 40 locations. However, MS was not 
significantly different between visits (p=0.19). The pointwise slope values of DLS 
against age for each of the three visits are presented in Figure 4.11.  
117 
Figure 4.10 Linear regression of Mean Sensitivity (ordinate) against age (abscissa) for Visit 1 
(top), Visit 2 (middle) and Visit 3 (bottom). The linear regression line (solid line), 95% 
confidence limits (inner curved lines) and 95% prediction limits (outer curved lines) are shown, 
as are the R², p and slope values. 
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Figure 4.11 Slope of DLS against age expressed as decibels per decade of age at each 
stimulus location for Visit 1 (top), Visit 2 (middle) and Visit 3 (bottom). The increasingly darker 
colour represents an increasingly steeper slope. 
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4.4.2 Normative database results: Method 1 
The following results describe the analysis performed on the normative database 
derived by Method 1 and therefore include the calculated normal DLS values and the 
magnitude of DLS at which the 95%, 98% and 99% TD and PD probability levels 
occurred. 
The DLS magnitudes at which 95% TD (top) and PD (bottom) lower probability limits 
occurred for each visit, as a function of eccentricity, are given in Figure 4.11. The 
normal DLS values referenced to the mean age of 45.97 are also shown in Figure 
4.12. The two graphs are ordered by eccentric annuli (1° to 7° from fixation). The 
normal values, TD lower limits and PD lower limits decrease from 1° to 7° from 
fixation. The normal values at Visit 1 were generally higher than those at Visit 2, 
however this difference was minimal.  
The normal DLS values across all stimulus locations increased with visit (p<0.001) 
and declined with increase in eccentricity (p<0.001) (Table 4.2; Table 4.4). This was 
also the case for the magnitude of DLS at which the TD and PD 95%, 98% and 99% 
prediction limits occurred (Table 4.2; Table 5).  
The post hoc analyses (Tukey’s test) showed the increase in normal DLS values, and 
95%, 98% and 99% TD and PD probability limits all consistently occurred between 
Visits 1 and 3 (all p<0.01). Similarly, post hoc Tukey’s tests showed significant 
differences between DLS within 1° and 7° for normal DLS values and all the TD and 
PD probability limits (all<0.05).  
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Figure 4.12 Differential light sensitivity (DLS) as a function of retinal eccentricity and 95% 
prediction limits for normal individuals. DLS values are presented along the ordinate and 
eccentricity along the abscissa. DLS values at which the 95% TD probability limit (top) and 
95% PD probability limit (bottom) occurred are shown as a function of eccentricity. Eccentricity 
is presented by annuli (1°to 7°), ordered superior, temporal, inferior and nasal, from left to 
right. Data are shown for Visit 1 (filled black circle), Visit 2 (grey filled triangle) and Visit 3 
(empty black square).  
121 
df SS MS F P
Normal
Visit 2 3.75 1.88 14.61 <0.01**
Eccentricity 3 17.63 5.88 45.86 <0.01**
95% TD
Visit 2 3.04 1.52 4.55 0.01**
Eccentricity 3 23.58 7.86 23.52 <0.01**
95% PD
Visit 2 28.19 14.10 35.05 <0.01**
Eccentricity 3 22.08 7.36 18.30 <0.01**
Table 4.2 ANOVA summary table to show the variation in pointwise normal DLS values and 
95% TD and PD limits with visit, eccentricity and the interaction between them. Only 95% 
prediction limits have been included due to similarity in results to the 98% and 99% limits. 
**p<0.01 and *p<0.05 
4.4.3 Normative database results: Method 2 
The following results describe the analysis performed on the normative database 
derived by Method 2 and therefore include the calculated normal DLS values and the 
DLS magnitudes at which the 95%, 98% and 99% TD and PD probability levels 
occurred. 
The TD and PD values associated with the 95% lower prediction limits at each visit 
as a function of eccentricity are given in Figure 4.13 and Figure 4.14, respectively. 
The normal DLS values are also provided for reference. In each figure, the three 
graphs represent different ages (25, 45 and 65 years). In all graphs both the normal 
values, TD lower limits and PD lower limits decrease from 1° to 7°. 
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The normal DLS values across all stimulus locations increased with visit (p<0.001), 
but decreased with increasing age (p<0.001) and eccentric annuli (p<0.001) (Table 
4.3; Table 4.4). Simiarly, the magnitude of DLS at which the 95%, 98% and 99% TD 
and PD prediction limits occurred, also increased with visit (both p<0.001) and 
declined with increasing age (both p<0.001), and eccentric annuli both (p<0.001) 
(Table 4.3).   
Figure 4.13 Normal DLS values, 95% TD limits (ordinate), by eccentric annuli (abscissa) for 
Visit 1 (black filled circles), 2 (grey filled triangle) and 3 (empty black square), for 25 year old 
(top), 45 year old (middle) and 65 year old (bottom). 
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Figure 4.14 Normal DLS values, 95% PD limits (ordinate), by eccentric annuli (abscissa) for 
Visit 1 (black filled circles), Visit 2 (grey filled triangle) and Visit 3 (empty black square), for 25 
year old (top), 45 year old (middle) and 65 year old (bottom). 
The post hoc analysis (Tukey’s test) for the normal DLS values and the DLS 
magnitude at which the 95% TD and PD probability limits occurred showed that the 
increase occurred between each of the visits (all p<0.01) and the decrease occurred 
between each eccentric annulus (p<0.01) and between each age group (p<0.01).  
As expected, the magnitude of DLS at which the 98% and 99% TD prediction limits 
occurred gave similar results, whereby the magnitudes increased with visit and 
declined with age and eccentric annuli. Post hoc analysis (Tukey’s test) results again 
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mimicked the results for the 95% prediction limits with the exception that no increase 
was present between Visit 1 and 2 for either 98% (p=0.06) or 99% limits (p=0.11).  
df SS MS F P
Normal
Visit 2 31.63 15.82 91.65 <0.01**
Eccentricity 3 121.50 40.50 234.71 <0.01**
Age 6 719.98 120.0 695.41 <0.01**
TD 95%
Visit 2 47.03 23.52 61.76 <0.01**
Eccentricity 3 135.49 45.16 118.60 <0.01**
Age 6 763.03 127.17 333.96 <0.01**
PD 95%
Visit 2 128.4 64.19 145.62 <0.01**
Eccentricity 3 109.6 36.55 82.92 <0.01**
Age 6 560.8 93.46 212.04 <0.01**
Table 4.3 ANOVA summary table of to show pointwise DLS normal values with visit, eccentric 
annuli and age, and the interactions between them. **p<0.01 and *p<0.05 
Similarly, 98% and 99% PD prediction limits also increased with visit (p<0.001) and 
declined with age (p<0.001) and eccentric annuli (p<0.001). The post hoc analysis 
(Tukey’s test) showed comparable results in that there was no increase between Visit 
1 and 2 for either the 98% (p=0.96) or 99% (p=0.85) prediction limits, there was also 
a decline with age present between each age group (all p<0.05). However, the decline 
with eccentricity was not present between the 1° and 3° annuli (p=0.15) for the 98% 
limit and was not present between the 1° and 3° annuli (p=0.37) and the 3° and 5° 
annuli (p=0.09) for the 99% limit.  
4.4.4 Comparison between methods to derive the normative database 
The mean normal DLS values and the mean DLS magnitude at which the TD (95%, 
98% and 99%) and PD (95%, 98% and 99%) limits occurred for each of the databases 
(Method 1 and Method 2) were investigated for Visits 1, 2 and 3 (Table 4.4). DLS and 
prediction limits values at the mean age of the cohort (46 years) were greater for 
Method 1 than Method 2 (all p<0.01) (Table 4.4).  
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Method 1 Method 2
V1 V2 V3 V1 V2 V3
Normal 29.4** 29.5** 29.8** 28.9** 29.1** 29.4**
TD 95% 26.2** 26.4** 26.6** 24.6** 24.8** 25.2**
TD 98% 25.2** 25.3** 25.7** 23.8** 24.0** 24.4**
TD 99% 24.4** 24.5** 25.0** 23.3** 23.4** 23.8**
PD 95% 25.1** 24.4 25.6** 24.3** 24.3 25.1**
PD 98% 24.1** 24.4** 24.8** 23.0** 23.0** 23.9**
PD 99% 23.6** 24.0** 24.3** 22.2** 22.1** 23.1**
Table 4.4 Mean values of normal, TD (95%, 98% and 99%) and PD (95%, 98% and 99%) 
limits for each visit, for Method 1 and Method 2, at 46 years. Significant differences resulting 
from an independent t-test comparing the difference between visits for the values are 
displayed, where ** indicates p<0.01. 
Figure 4.15 shows pointwise normal DLS values and the magnitude of DLS at which 
the TD probability limits (95%, 98% and 99%) and PD probability limits (95%, 98% 
and 99%) occur for database 3 (derived from Visit 3) for both methods, arranged by 
eccentricity. Method 1 derived higher decibel values at the 95% TD probability limit 
for all locations, which indicates that defects would be detected at an earlier stage 
than with Method 2.  
A clinical case study of an individual with AMD (recruited as part of the study 
described in Chapter 6) is presented in Figure 4.16 and in Figure 4.17; comprising the 
MAIA microperimetry output consisting of an infrared fundus image with overlaid DLS 
pointwise measurements, CFP, SD-OCT (Cirrus HD-OCT) horizontal line scan 
through the fovea, and the TD and PD probability plots derived using database 1, 2 
and 3 for both Method 1 (Figure 4.16) and Method 2 (Figure 4.17). 
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Figure 4.15 Normal DLS values and the magnitude of DLS (ordinate) at which the 95% 
(triangle), 98% (square) and 99% (diamond) TD probability levels (top) and 95% (triangle), 
98% (square) and 99% (diamond) PD probability levels (bottom) occur, for Method 1(grey) 
and Method 2 (black), as a function of eccentricity (abscissa), at 46 years.
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Figure 4.16 Clinical case of a 78 year old individual with AMD with the MAIA infra-red image, 
colour fundus photograph and SD-OCT line scan shown (top). The DLS results have been 
analysed with Method 1, with Visit 1 (top), Visit 2 (middle) and Visit 3 (bottom) normative 
databases to produce Total Deviation (TD) (left) and Pattern Deviation (PD) (right) plots with 
95% (yellow), 98% (orange) and 99% (red) probability levels colour coded. 
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Figure 4.17 Clinical case of a 78 year old individual with AMD with the MAIA infra-red image, 
colour fundus photograph and SD-OCT line scan shown (top). The DLS results have been 
analysed with Method 2, with Visit 1 (top), Visit 2 (middle) and Visit 3 (bottom) normative 
databases to produce Total Deviation (TD) (left) and Pattern Deviation (PD) (right) plots with 
95% (yellow), 98% (orange) and 99% (red) probability levels colour coded.
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The primary aim of this study was to derive a pointwise age-corrected normative 
database with a statistical model to perform global and localised probability analyses. 
The secondary aims were twofold: to examine over three visits the characteristics of 
the MVF with age and eccentricity from microperimetry; and to compare two different 
methods of deriving the normative database. 
A linear regression model was found to be the most appropriate method to apply to 
the age-related decline in DLS with the MAIA (Centervue, Padova, Italy) 
microperimeter. This is consistent with the results of previous research on the MP-1 
instrument (Midena, Vujosevic and Cavarzeran 2010; Acton, Bartlett and Greenstein 
2011) and as is also the method used by convention in SAP (Heijl, Lindgren and 
Olsson 1987b; Flanagan et al. 1993). It is likely that including a larger proportion of 
individuals over the age of 70 years would influence the linearity of the model. With a 
larger dataset, a segmented regression model could be considered to reflect a 
potential worsening of the DLS with older age.  
Two methods of deriving a normative database have been utilised herein. Both 
methods have been developed to enable probability analysis of clinical data. Method 
1, the adjusted age method, is utilised by Zeiss for the HFA (Heijl, Lindgren and 
Olsson 1987a). Method 2, the age-specific method, used linear regression (Altman 
1991) of age with DLS. It is apparent that Method 1 derives probability defects at a 
higher DLS value than Method 2 for each level of TD and PD probability defects. Thus, 
Method 2 is a more conservative method and would result in categorising fewer 
individuals with defects than Method 1. This difference between methods is a result 
of the mathematical derivation of the normal values and the associated probability 
limits. The normal values for Method 1 are derived using the mean age adjusted DLS 
values, whereas for Method 2 they are derived using the measured DLS values. The 
probability limits for Method 1 were derived using the distribution of the age-adjusted 
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individuals, and Method 2 were derived from the prediction limits of the linear 
regression model. These different derivation techniques have led to apparent 
differences in the analysis of the microperimetry outcomes. However, due to the lack 
of a ‘gold standard’ method of database derivation it is beyond the scope of this study 
to perform sensitivity and specificity analyses to evaluate the accuracy of defect 
identification between methods.  
For the purpose of this thesis, a conclusion as to the most appropriate method to be 
taken forward for future analyses must be made. Whilst, Method 1 would lead to the 
detection of defects at an earlier stage, this risks the detection of a large number of 
false positives. Conversely, Method 2 may detect a greater number of false negatives. 
To the author’s knowledge, the rationale and statistical reasoning behind the choice 
of the method of derivation used by Zeiss is not in the public domain. Method 2 is 
statistically appropriate for further analyses in this thesis, given the results from the 
tests of the assumptions of linear regression. Additionally, Method 2 accounts for the 
increased variability in the younger and older age groups by increasing the size of the 
prediction limits at these extremes. This is particularly relevant to those with AMD, 
given their older age. For these reasons, Method 1 will be excluded from future 
analysis in this thesis.  
Method 2 normative DLS values and TD probability limits differ with visit, and 
therefore, give differing defects dependent upon the database used. The perimetric 
learning effect is a phenomenon whereby DLS improves with experience (Heijl, 
Lindgren and Olsson 1989; Heijl, Lindgren and Olsson 1987b; Wild et al. 1989). The 
evidence is conflicting as to the number of perimetry examinations required to 
extinguish this effect (Wood et al. 1987; Gardiner, Demirel and Johnson 2008; Heijl, 
Lindgren and Olsson 1989). Currently, in SAP research studies, visual field 
examinations are disregarded until the third visit (Pierre-Filho et al. 2010). Previous 
microperimetry literature has suggested that after Visit 2 the learning effect is no 
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longer present (Wu et al. 2013). However, the results from the present study suggest 
that the perimetric learning effect is still present at Visit 3. Therefore, to minimise the 
effect of learning on the normative database all further analysis in this thesis will be 
based on the normative database derived from the third visit. 
Future research using microperimetry to investigate a larger number of visits at 
different intervals would enable a more thorough characterisation of the perimetric 
learning effect in microperimetry. Future development of normative databases that 
are weighted according to the visit number, could enable initial microperimetry results 
to be used in analysis, rather than discarded. 
Consistent with previous research (Heijl, Lindgren and Olsson 1987a), in this study, 
the normative DLS values and the DLS values at which the TD and PD lower 
probability limits occurred, reduced with both eccentricity and age. The age-
dependant decline of DLS reported in this study is in agreement with that for SAP 
(Bengtsson and Heijl 1999), for microperimetry (Acton, Bartlett and Greenstein 2011; 
Midena, Vujosevic and Cavarzeran 2010) and for short-wavelength automated 
perimetry (Bengtsson and Heijl 2003). 
A strength of the study is that the method of normative data collection meets the 
minimum requirements of the international standards for ophthalmic equipment (ISO 
12866) for the development of a normative database. The normative databases 
developed will allow for localised and globalised visual field loss to be defined (Heijl, 
Lindgren and Olsson 1987a) in AMD and other macular diseases. This will lead to 
more specific quantification of the functional deficit that is present in AMD (Acton, 
Gibson and Cubbidge 2012).  
A limitation of the normative databases derived in this work is that they can only be 
applied to the specific stimulus locations used, in this study, to obtain the normal DLS 
values. Therefore, these normative databases are not appropriate for use with 
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different stimulus patterns or those with non-foveal fixation. Methods of interpolation 
can be used to overcome this limitation (Weber and Geiger 1988; Weleber et al. 
2015). A recently developed normative database that implements this technique, uses 
computational surfaces to interpolate normative data between stimulus locations in 
relation to an individual’s fixation (Denniss and Astle 2016). Despite this benefit, the 
use of computational simulation does not reflect the reality of a perimetric 
examination, as opposed to clinical data. Additionally, the loss of foveal fixation is 
most frequently associated with late AMD and associated areas of atrophic retina, 
which typically present with absolute scotomata i.e. DLS of <0dB and therefore lying 
outside of the 99% probability limits. Thus, the benefit of a normative database that 
accounts for loss of foveal fixation may be limited. The analyses presented in this 
thesis will only include those with foveal fixation in reference to TD, PD and probability 
analyses. 
To conclude, the adjusted age method of deriving the normative database is less 
conservative than the age-specific method. The age-specific method is both 
statistically appropriate and accounts for the increased variability with age, and 
consequently, will be employed throughout all subsequent chapters. Database 3 will 
also be used in subsequent work to reduce the learning effect. The derivation of a 
normative database is essential for the quantification of functional deficits in AMD, 
detected using MAIA microperimetry. This allows for more specific assessment of the 
topographical nature of AMD and the associated functional outcomes with respect to 
vision-related quality of life. 
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Chapter 5: The association between microperimetry 
and SD-OCT outcomes 
Purpose: To examine the association between AMD-related retinal microstructure 
abnormalities and microperimetry outcomes at 5° eccentricity from fixation.  
Methods: The cohort comprised 42 participants with early to late AMD. The median 
age was 80 years (IQR 75, 83 years). All participants were otherwise 
ophthalmologically normal, with the exception of mild lens opacities. Participants 
underwent MAIA microperimetry (40 location 7° stimulus pattern); and volumetric 
imaging with the Cirrus SD-OCT (20° x 20° scan, 512 x 128 A-scans). DLS by 
microperimetry was referenced to a normative database (n=66). CFPs and SD-OCT 
images were used to classify AMD severity and identify AMD associated retinal 
features. Volumetric SD-OCT scans were segmented (9 boundaries, 8 retinal layers) 
using the Iowa Reference Algorithm (Retinal Image Analysis Lab, Iowa). 
Results: The median microperimetry outcomes at 5° were: MS 23.6dB; MTD -4.6dB; 
MPD: -2.6dB. Forty six percent of the variance in MTD and 45% of the variance in MS 
was explained by the presence or absence of photoreceptor atrophy, when the 
AREDS classification was controlled for. 
Conclusion: At a retinal eccentricity of 5° a significant proportion of the 
microperimetry outcomes can be explained by the presence of photoreceptor atrophy. 
However, this relationship is not sufficiently strong for microperimetry and SD-OCT to 
be interchangeable.   
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A combination of morphological and visual function outcomes are commonly used in 
clinical trials in AMD. The success of these trials is often measured by the 
improvement of visual function and change in retinal features associated with AMD. 
This chapter will investigate the association between AMD-related retinal 
microstructure abnormalities and microperimetry outcomes. Prior to describing the 
study, the relevant functional and morphological biomarkers in AMD will be 
summarised. 
A number of functional measures have been identified as potential biomarkers in 
AMD, for example: flicker threshold (Dimitrov et al. 2011; Mayer et al. 1992; Brown 
and Lovie-Kitchin 1987), colour thresholds (Eisner et al. 1992; O’Neill-Biba et al. 2010; 
Downie, Cheng and Vingrys 2014; Dimitrov et al. 2012; Holz et al. 1995) and dark 
adaptation (Dimitrov et al. 2012; Owsley et al. 2016; Owsley et al. 2001; Owsley et al. 
2007; Gaffney, Binns and Margrain 2011; Gaffney, Binns and Margrain 2013). 
Furthermore, decline in visual function is associated with worsening structural AMD 
classification (Dimitrov et al. 2012; Acton, Gibson and Cubbidge 2012; Owsley et al. 
2016; Flamendorf et al. 2015).
Microperimetry has previously been advocated as a useful biomarker in AMD (Acton 
et al. 2012b, Wu et al. 2014c, Fragiotta et al. 2017a). It measures DLS, whilst 
simultaneously imaging the fundus at 25Hz, enabling fixation losses to be monitored. 
Reduced DLS is associated with disruption in the RPE  (Wu et al. 2014c),  EZ band 
(Querques et al. 2012; Wu et al. 2014c) and ELM (Querques et al. 2012; Hartmann 
et al. 2015; Fragiotta et al. 2017a); OS thinning and RPE thickening in early AMD 
(Acton et al. 2012b; Wu et al. 2016); and both a thickening and a thinning of the whole 
retina in nAMD (Hartmann et al. 2015; Sabour-Pickett et al. 2013). These associations 
suggest that microperimetry has the potential to detect changes in visual function that 
are a result of retinal microstructure abnormalities associated with AMD.  
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Morphological biomarkers identified by SD-OCT have also been suggested, however 
these differ with stage and type of AMD. In nAMD, central retinal thickness is a 
common method to quantify retinal changes, but is limited by the lack of information 
relating to the type and depth of retinal fluid present (Schmidt-Erfurth and Waldstein 
2016). Presence of intraretinal fluid (IRF) (Schmidt-Erfurth et al. 2015), subretinal fluid 
(SRF) (Schmidt-Erfurth et al. 2017) and PEDs (Clemens et al. 2012; Dirani et al. 
2015a) are more informative biomarkers than retinal thickness (Schmidt-erfurth 
2016). Recently, further potential biomarkers in nAMD have been identified: 
hyperreflective foci (Nagiel et al. 2015) and ORTs (Dirani et al. 2015b). The main 
biomarker, in research, of disease progression in early AMD is the presence of drusen 
(Schmidt-Erfurth et al. 2017; Dimitrov et al. 2012). Where baseline drusen volume is 
predictive of progression to late AMD (de Sisternes et al. 2014; Abdelfattah et al. 
2016; Folgar et al. 2016). Additionally, RPD (Sivaprasad et al. 2016; Steinberg et al. 
2015b) and disruption and intensity of the EZ band (Gin et al. 2017) should also be 
considered as biomarkers. SD-OCT also allows detailed analysis of GA (Schmitz-
Valckenberg et al. 2009; Holz et al. 2014) and loss of photoreceptors is an important 
predictor of progression to GA (Niu et al. 2016). 
The present study aims to examine the association between AMD-related retinal 
microstructure abnormality and microperimetry outcomes at 5° from fixation. This 
eccentricity was used for three reasons. Firstly, at 5° eccentricity the influence of the 
foveal depression on retinal layer thickness analysis will be avoided (Curcio, Owsley 
and Jackson 2000), as the anatomical shape of the foveal pit only extends to 2.75° 
(Curcio, Owsley and Jackson 2000). Secondly, mesopic microperimetry is mediated 
by a cone response (Simunovic et al. 2016) and, whilst the cone population peaks at 
the fovea, at 5° the cone density remains high at 11,600 cells/mm² (Park et al. 2013). 
Finally, a previous study found that visual field defects in AMD are most common 
within the central 5° of the visual field (Acton, Gibson and Cubbidge 2012). 
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In the evaluation of retinal microstructures, this study will focus on the detailed 
identification of AMD associated retinal features and retinal thickness measurements 
by SD-OCT, which have been previously suggested as potential biomarkers in AMD. 
With the development of automated SD-OCT segmentation software, retinal thickness 
measurements can be produced faster and with more accuracy. OCT Explorer will be 
used in the present study, which is part of the Iowa Reference Algorithm (Section 
1.3.2.2) (Retinal Image Analysis Lab, IOWA Institute for Biomedical Imaging, Iowa 
City, IA) (Abràmoff, Garvin and Sonka 2010; Quellec et al. 2010; Antony et al. 2011; 
Xinjian Chen et al. 2012). This automated segmentation software segments 11 retinal 
layers and two choroidal layers.
A full description of the procedures and techniques used in this study can be found in 
Chapter 3, an overview will be presented here. Briefly, 52 individuals with AMD were 
recruited from Cardiff Eye Unit at the University Hospital of Wales and attended two 
visits at the School of Optometry and Vision Sciences, Cardiff University, in short 
succession. All participants were otherwise ophthalmologically normal, with the 
exception of mild lens opacities. Detailed inclusion and exclusion criteria are listed in 
Section 3.3.1.2. 
At Visit 1 experimental procedures were performed to ensure the individuals met the 
study inclusion criteria (Section 3.3.1.2) and the imaging data (Cirrus HD-OCT and 
CFP using 3D-OCT 1000, Topcon) were acquired. Visit 2 involved the collection of 
the microperimetry data. 
The test eye was chosen as the eye with a diagnosis of AMD. If both eyes had been 
diagnosed with AMD the test eye was chosen at random.  
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5.3.1  Analysis 
5.3.1.1  Imaging techniques 
Fundus photographs and SD-OCT images were acquired using the Topcon 3D-OCT 
1000 and Cirrus HD-OCT, respectively, using the methods described in Chapter 3. In 
summary, a 45° colour fundus photograph, and a horizontal line scan and a 20° x 20° 
(512 x 128) volume scan were obtained. The colour fundus photographs were 
classified using the AREDS grading system (Section 3.3.3.1.8). The 512 x 128 volume 
scans were segmented into 10 retinal layers using OCTSeg, a fully automated 
segmentation algorithm, which is a module of OCT Explorer and part of the Iowa 
Reference Algorithms (Retinal Image Analysis Lab, Iowa Institute for Biomedical 
Imaging, Iowa City, IA). Of the 10 retinal layers segmented, 9 retinal layers were 
selected for analysis (Table 5.1) (Section 3.3.3.1.9). These 9 layers were analysed  
given the relevance to retinal microstructural alterations in inner and outer retinal 
layers (Hood et al. 2009; Acton et al. 2012b; Wu et al. 2016).  
Boundaries Retinal layers
1-2 Retinal nerve fibre
2-3 Ganglion cell 
3-4 Inner plexiform
4-5 Inner nuclear
5-6 Outer nuclear
8-10 Outer segment 
10-11 Retinal pigment epithelium
5-11 Total receptor plus RPE
1-11 Total retina
Table 5.1 Definition of nine retinal layers used for analysis, including single and combined 
layers.
Retinal thickness measurements were undertaken at the equivalent locations to the 
MAIA stimulus positions as described in Chapter (Section 3.3.3.1.9). For RNFL and 
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GCL layer thickness measures, the grid was displaced to account for the anatomical 
displacement of the retinal ganglion cells near the fovea (Hood and Raza 2011). 
Each of the 40 locations was examined for the presence of retinal features associated 
with AMD (Section 3.3.3.2.10). Briefly, drusen, PEDs, ORTs, RPD, atrophy and CNV 
(intra- and/or sub-retinal fluid, and fibrovascular material) were recorded as either 
present or absent, and the EZ band integrity was also graded 0-3 (Wu et al. 2014c).  
Given the anatomical shape of the fovea (Curcio, Owsley and Jackson 2000) and 
known frequency of defects in AMD (Acton, Gibson and Cubbidge 2012) the analysis 
was undertaken within the annulus at 5°, consisting of 16 stimulus locations (Figure 
5.1). Both the retinal thickness and the retinal features within the 5° annulus were 
averaged.  
Figure 5.1 Locations within each eccentric annuli were defined as: within a radius of 1°, 
between a radius of 1° and 3°, between a radius of 3° and 5° and between 5° and 7°. 
5.3.1.2  Microperimetry outcomes 
MAIA DLS values were transformed to right eye format. MAIA DLS results for those 
with foveal fixation were converted into mean MTD and MPD values using the 
normative database developed in Chapter 4.  
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5.3.1.3  Statistical analysis 
The approach for statistical analyses was firstly an assessment for normality (Shapiro-
Wilk test), followed by a Spearman’s rank correlation and lastly multiple linear 
regression. 
A Spearman’s rank correlation matrix was undertaken to demonstrate the association 
between all outcomes: the microperimetry outcomes (MS; MTD; MPD; number of TD 
defects ≥5% probability; and number of PD defects ≥5% probability), retinal features 
(EZ band disruption, drusen, retinal fluid, PED, atrophy and fibrovascular material) 
(Section 3.3.3.2.0), and retinal thicknesses (RNFL, GCL, IPL, INL, ONL, OS, RPE, 
total receptor and total retina) (Section 3.3.3.1.9) (Table 5.1). This process was 
performed to identify the variables that were not associated with microperimetry 
outcomes. Any predicting variables that were highly correlated with each other (r≥0.8) 
were not included into the same multiple regression model.  
Only the strongest associations with microperimetry outcomes were then included into 
the multiple regression models. Each microperimetry outcome was investigated 
separately. Several multiple regression models including different combinations of 
factors were examined to find the most appropriate model to explain the variance in 
microperimetry outcomes from microstructural abnormalities. The multiple regression 
models were limited to one factor (predicting variable) per 10 participants (Altman 
1991), therefore in this study, for a sample of n=47, each model should include a 
maximum of 4 factors. However, reducing the number of factors leads to a stronger 
model (Altman 1991). The assumptions of each linear regression model were 
examined, using the identical method described in Chapter 4 (Section 4.3.1.1). When 
outliers were present, but regarded as clinically significant, robust regression was 
utilised. Robust regression applies less weight to outliers or influential observations 
when estimating the regression slope (Andrews 1974). 
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Statistical analyses were performed using R (Version 3.2.2) and SPSS (version 20.0). 
A p value of ≤0.05 was considered to be statistically significant for all analyses. 
Bonferroni correction was not implemented in this analysis as Type 1 errors, the 
increased likelihood of getting a significant result by chance as a result of multiple 
testing, were more preferable to Type 2 errors where the actual effects may have 
been missed (Armstrong 2014). The descriptive statistics for all measures are 
presented as a median and inter-quartile range (IQR) to allow for comparison.  
The following results are presented: firstly, the assessment of normality results; 
secondly, the characteristics of the individuals with AMD; thirdly the characteristics of 
both the retinal features and the retinal thickness measurements; finally, the 
correlation and multiple regression analyses of the SD-OCT outcomes with the 
microperimetry outcomes. 
5.4.1  Assessment of normality 
Distributions were examined using the Shapiro-Wilk test and the majority of outcomes 
were found to have a non-Gaussian distribution (p<0.05), only RNFL (p=0.06), GCL 
(p=0.6), IPL (p=0.3) and INL (p=0.7) thicknesses were normally distributed.  
5.4.2  Characteristics 
Of the 52 individuals, 1 failed to complete both visits, 5 individuals were excluded due 
to existing co-morbidities (4 due to details from the medical history, and 1 due to high 
myopia), 1 was unable to perform the micrometry examination and 3 had non-foveal 
fixation, resulting in 42 individuals. 
Forty-two individuals (25 females) with AMD met the study inclusion criteria and 
completed both visits. The demographic characteristics of the individuals with AMD, 
including the MAIA visual field characteristics at 5° eccentricity and AREDS 
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classification are presented in Table 5.2. Fifteen right eyes and 27 left eyes were 
examined. 
N=42 Median (IQR)
Age (years) 80 (75, 83)
Rx (BVS) 0.25 (-0.25, 1.25)
MS (dB) 23.6 (20.8, 26.0)
MTD (dB) -4.6 (-8.3, -2.3)
MPD (dB) -2.6 (-3.9, -1.9)
Number of TD defects (≤5%) 7 (2, 12)
Number of PD defects (≤5%) 2 (0, 4)
AREDS classification N (%)
1
2
3
4
3 (7)
2 (5)
1 (2)
36 (86)
Table 5.2 Characteristics of individuals with AMD including: age, refractive correction (Rx), 
Mean Sensitivity (MS), Mean Total Deviation (MTD), Mean Pattern Deviation (MPD), number 
of Total Deviation (TD) values exhibiting a probability level of worse than 5% and number of 
PD values exhibiting a probability level of worse than 5%.
5.4.3  AMD associated retinal microstructure characteristics 
5.4.3.1  Retinal features 
Retinal features were graded at 672 stimulus locations, within the 5° annulus, from 42 
individuals. Of the 672 locations, 638 were successfully graded. Features could not 
be graded for 34 locations from 7 individuals, due to insufficient SD-OCT scan quality. 
These individuals were classed as partially graded, and only the locations that could 
be graded were included in the analysis. 
Two individuals had no AMD associated retinal features present within the 5° annulus, 
of the 40 remaining individuals, the majority had EZ band disruption grades 1-3 (n=40) 
and over half were in combination with other microstructural changes (n=26) (Figure 
5.2). 
AMD-related retinal features were present at 350 locations (55%), at 5° eccentricity. 
Some locations had more than one retinal feature present at one location. Three 
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hundred and eight of the 638 locations had EZ band disruption, graded 1-3 (48%), 
with 152 of the 638 locations having grade 2 disruption (24%). In 44 and 36 of 638 
locations, drusen and PEDs (serious, fibrovascular or drusenoid) were present, 
respectively (Table 5.3). 
Figure 5.2 The frequency of, and the relationship between, the AMD associated retinal 
features within the 5˚ annulus (for n=40). Retinal features include: Ellipsoid Zone (EZ) band 
disruptions (grades 1-3), Choroidal neovascularisation (CNV), Drusen, pigment epithelial 
detachment (PED; Drusenoid, serous and fibrovascular) and retinal pigment epithelium (RPE) 
and photoreceptor (PR) atrophy. 
N= 638 Number of locations (%)
Without retinal features 288 (45)
Retinal features
EZ band grade 1 88 (14)
EZ band grade 2 152 (24)
EZ band grade 3 68 (11)
Drusen 44 (7)
Retinal fluid 4 (1)
PED 37 (6)
Atrophy 86 (14)
Fibrovascular material 9 (1)
Table 5.3 Number and percentage of total locations with and without AMD related retinal 
features within 5° eccentricity. More than one retinal feature was present at some locations 
and the sum of the percentages therefore exceeds 100%. 
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5.4.3.2  Retinal thickness 
Three individuals were excluded from retinal thickness analysis due to the inability of 
the automated segmentation software to segment the volume scans. For individuals 
in which segmentation was successful at some, but not all locations, only thicknesses 
at those locations where it was successful, were included in the analysis (i.e. data 
was excluded from a total of 18 locations from 2 individuals). The median (IQR) of the 
mean retinal thicknesses at 5° eccentricity are presented in Table 5.4. 
N=39 Median (IQR)
Retinal thicknesses 
(μm)
RNFL 36.2 (32.4, 38.7)
GCL 27.1 (24.7, 30.7)
IPL 34.1 (32.6, 36.6)
INL 35.7 (32.3, 37.4)
ONL 24.1 (22.6, 26.7)
OS 30.0 (26.6, 33.6)
RPE 15.4 (14.2, 17.9)
Total receptor 161.0 (152.6, 170.0)
Total retina 294.7 (284.1, 308.6)
Table 5.4 Median (IQR) thicknesses for each retinal layer: retinal nerve fibre (RNFL), ganglion 
cell layer (GCL), inner plexiform layer (IPL), inner nuclear layer (INL), outer nuclear layer 
(ONL), outer segment (OS) and retinal pigment epithelium (RPE), plus total receptor and total 
retina.
5.4.4  Association between microperimetry outcomes and retinal 
abnormalities 
Of the associations between the AMD-related retinal features and microperimetry 
outcomes (Table 5.5), the strongest significant correlation was between MPD and the 
presence of photoreceptor atrophy (r=-0.66, p<0.01).  
Of the associations between the retinal thickness measurements and the 
microperimetry outcomes (Table 5.6), the strongest correlation was between number 
of PD defects and GCL thickness (r=0.39, p=0.01). 
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5.4.5  Multiple linear regression 
RPE atrophy and photoreceptor atrophy are anatomically closely related and were 
highly correlated (r=0.8, p<0.01). Therefore, of these two features only one was 
entered into each multiple regression model. Each multiple regression model included 
the AREDS grade to control for difference in severity of AMD.  
The most appropriate multiple regression models are presented in Table 5.7 and all 
include photoreceptor atrophy as a predicting variable. All other models, which 
included combinations of other predicting variables (retinal features and thicknesses) 
were weaker. All models met the assumptions of linear regression (Section 4.3.1.1), 
except for the model including MPD and photoreceptor atrophy, which was performed 
using robust regression to avoid the influence of outliers (Table 5.7). MTD produced 
the strongest model with photoreceptor atrophy when AREDS grade was controlled 
for (R²=0.46, p<0.01). 
Retinal features
EZ 
band Drusen fPED sPED
RPE 
atrophy
PR 
atrophy CNV
MS -0.21(0.25)
-0.31
(0.10)
-0.38
(0.05)
-0.01
(0.68)
-0.49 
(<0.01)
-0.57 
(<0.01)
-0.27
(0.08)
MTD -0.25(0.25)
-0.35
(0.09)
-0.41 
(0.04)
0.09
(0.50)
-0.54 
(<0.01)
-0.60 
(<0.01)
-0.26
(0.10)
No TD 
defect
0.22
(0.18)
0.26
(0.11)
0.28
(0.08)
-0.07
(0.60)
0.36 
(<0.01)
0.39 
(<0.01)
0.32 
(0.03)
MPD -0.24(0.16)
-0.32 
(0.04)
-0.27 
(0.01)
-0.04
(0.79)
-0.60 
(<0.01)
-0.66 
(<0.01)
-0.07
(0.30)
No PD 
defects
0.25
(0.14)
0.34
(0.14)
0.24
(0.12)
-0.03
(0.12)
0.58 
(<0.01)
0.57 
(<0.01)
0.07
(0.15)
Table 5.5 Spearman’s rho values for correlations between retinal features and the 
microperimetry outcomes. Retinal features include:  Ellipsoid zone band disruption (EZ band), 
Drusen, fibrovascular pigment epithelial detachment (fPED) and serous PED (sPED), RPE 
atrophy, photoreceptor (PR) atrophy and choroidal neovascularisation (CNV). Microperimetry 
outcomes included are Mean Sensitivity (MS), Mean Total Deviation (MTD), number of TD 
defects, Mean Pattern Deviation (MPD) and number of PD defects. P values are given in 
brackets and those with significance ≤0.05 are highlighted in grey.
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Retinal thicknesses
Total 
retina
Total 
receptor RPE OS ONL INL IPL GCL RNFL
MS 0.16(0.41)
0.26
(0.08)
-0.20
(0.52)
0.07
(0.75)
0.30
(0.03)
0.13
(0.24)
0.37 
(0.01)
-0.28 
(0.01)
-0.22 
(0.01)
MTD 0.12(0.50)
0.26
(0.09)
-0.21
(0.48)
0.10
(0.83)
0.33 
(0.02)
0.09
(0.31)
0.30 
(0.03)
-0.34 
(0.01)
-0.23 
(0.01)
No TD 
defect
-0.06
(0.82)
-0.16
(0.51)
0.18
(0.16)
-0.02
(0.36)
-0.20
(0.10)
-0.08
(0.63)
-0.27
(0.06)
0.26
(0.18)
0.17
(0.12)
MPD 0.16(0.85)
0.29
(0.40)
-0.13
(0.61)
0.14
(0.96)
0.37 
(0.02)
-0.02
(0.41)
0.25
(0.13)
-0.32 
(<0.01)
-0.14 
(0.04)
No PD 
defects
0.07
(0.25)
-0.13
(0.77)
0.08
(0.33)
-0.09
(0.24)
-0.30
(0.05)
0.16
(0.69)
-0.20
(0.15)
0.39 
(0.01)
0.28 
(<0.01)
Table 5.6 Spearman’s rho values for correlations between retinal thicknesses and the 
microperimetry outcomes. Retinal thicknesses include: retinal nerve fibre layer (RNFL),  
ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear layer (INL), outer nuclear 
layer (ONL), outer segment layer (OS), retinal pigment epithelium (RPE), total receptor layer 
and total retina. Microperimetry outcomes included are Mean Sensitivity (MS), Mean Total 
Deviation (MTD), number of TD defects, Mean Pattern Deviation (MPD) and number of PD 
defects. P values are given in brackets and those with significance ≤0.05 are highlighted in 
grey. 
Model Adj R² F p
Variables 
in model Coef SE t p
MS 0.45 (2,39) = 17.5 <0.01
AREDS
PR
-0.10
-10.0
0.77
1.69
-0.12
-5.91
0.90
<0.01**
MTD 0.46 (2,38) = 18.3 <0.01
AREDS 
PR
-0.06
-10.2
0.76
1.68
-0.08
-6.03
0.94
<0.01**
No TD 
defect 0.24
(3,37) 
= 5.2 <0.01
AREDS 
PR
CNV
-1.27
4.83
6.15
0.85
1.87
2.50
-1.48
2.59
2.45
0.15
0.01**
0.02*
MPD 0.27 (2, 38) = 42.0 <0.01
AREDS 
PR
-0.44
-5.59
0.28
0.61
-1.57
-9.14
0.12
<0.01**
No PD 
defects 0.32
(2,38) 
= 10.5 <0.01
AREDS
RPE
0.16
3.94
0.45
0.86
0.35
4.57
0.73
<0.01**
Table 5.7 Results of the multiple linear regression analysis to explain the microperimetry 
outcomes (Mean Sensitivity, MS; Mean Total Deviation, MTD; number of TD defects, No TD 
defect; Mean Pattern Deviation, MPD; and number of PD defect, no PD defects). The variables 
in the models are AREDS grade, photoreceptor atrophy (PR), choroidal neovascularisation 
(CNV) and retinal pigment epithelium (RPE) atrophy. For MPD (italicised), the model did not 
meet the assumptions of linear regression, therefore a robust regression model was used.
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This study examined the relationship between microperimetry outcomes and retinal 
microstructure features and thicknesses associated with AMD, at 5° eccentricity. The 
strongest models included the microperimetry outcomes, MTD and MS, and explained 
46% and 45% of the variance, respectively. In both models photoreceptor atrophy 
was the only predicting variable. These findings can be placed in the context of known 
changes in AMD, in which photoreceptor death (Takahashi et al. 2016) and GA (Hariri 
et al. 2016) are characteristically associated with worse visual function measured by 
microperimetry. In another study, ELM loss caused a significant reduction in DLS and 
loss of RPE was able to predict the presence of absolute scotomata, in GA (Sayegh 
et al. 2014).  
EZ band disruption occurred most commonly, at 50% of the locations, both alone and 
in the presence of other features. However, no relationship between EZ band 
disruption and microperimetry outcomes was established and this is in contrast to that 
found in a previous study by Landa et al. (2011). The discrepancy could be explained 
by the following differences in methodology. Firstly, the absence of stimulus 
eccentricity information in the previous study confounds comparison to the results of 
the present study. Secondly, the previous study is limited by the use of a polar or 
radial type of stimulus pattern, which lacks regular sampling in peripheral locations. 
Thirdly, the EZ band in the previous study was graded as either present or absent, 
whereas the current study graded the EZ band based on the level of disruption 
present. Finally, the microperimetry outcome of the previous study was MS i.e. it did 
not implement an age-correct normative database, unlike the probability analyses 
used within the present study. 
Despite more moderate univariate associations between the retinal layer thicknesses 
and microperimetry outcomes, this variable did not reach statistical significance in the 
multiple regression models. Previous studies have linked microperimetry and outer 
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retinal layer changes: abnormal TD values were related to a thinner OS layer in early 
AMD (Acton et al. 2012b); abnormal MS was associated with outer retinal thinning in 
the presence of RPD (Steinberg et al. 2016); and abnormal MS was associated with 
both a thickening and a thinning of the whole retina in nAMD (Hartmann et al. 2015; 
Sabour-Pickett et al. 2013). Conversely, in the present study, inner retinal layer 
thicknesses were associated with MS, MTD, MPD and number of PD defects. 
Reduced inner retinal thickness is more commonly associated with glaucoma, 
however a number of studies have found thinning of the inner retina and of the 
ganglion cell complex in intermediate AMD (Rimayanti et al. 2014; Toto et al. 2017; 
Borrelli et al. 2017).  
The relative measures used in the analyses of DLS and retinal thickness measures 
did not require consideration of axial length-dependant image scaling. Axial length 
influences the superimposition of the projected stimulus position to the fundus image. 
The scaling estimation for the MAIA is based solely upon spherical refractive error, as 
is that of the Cirrus HD-OCT, therefore magnitude of such error is negligible. Whilst 
correction for axial length is essential when making comparisons between retinal 
thickness measurements from different instruments (Terry et al. 2016), it is not 
considered to improve strength of structural and functional relationships in healthy 
individuals or in those with glaucoma (Nowroozizadeh et al. 2014).  
Many of the individuals included in this study had late AMD and therefore the results 
do not represent the full range of AMD severities. Therefore, the incorporation of the 
AREDS grade is of limited value, given the marked bias (36 of 42 eyes) to grade 4. 
Individuals with late AMD are more likely to present with photoreceptor atrophy 
compared to those with early disease. The association of decreased MS in the 
presence of photoreceptor atrophy has been reported previously (Takahashi et al. 
2016).  
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The identification of pointwise retinal features is a time consuming process. The 
development of automated segmentation software that enables retinal boundaries to 
be identified in the presence of lesions associated with AMD, might enable robust 
automated feature identification (Hussain et al. 2016). In the present study, only a 
small proportion of SD-OCT scans failed to be segmented, despite the presence of 
severe retinal layer disruptions that have been previously reported to cause 
segmentation error (Lee et al. 2015b; Lee et al. 2015a; de Sisternes et al. 2015). The 
continued improvement of automated retinal segmentation in the context of the 
current development of machine learning software to detect disease associated 
features in fundus photographs and SD-OCT images is expected to lead to automated 
identification of AMD associated lesions (www.moorfields.nhs.uk, 2017). Further 
technological advances in combined microperimetry and SD-OCT instrumentation will 
enable a multimodal evaluation for comprehensive diagnosis and monitoring of the 
disease process. 
In conclusion, at 5° eccentricity, microperimetry outcomes (MS and MTD) can be 
explained, to a large extent, by the presence of photoreceptor atrophy. However, this 
relationship is not sufficiently strong for microperimetry and SD-OCT to be 
interchangeable.  
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Chapter 6: Vision-related QoL in individuals with 
age-related macular degeneration 
Purpose: To establish the relationship between vision-related QoL and clinical, 
psychosocial- and health-related measures in individuals with AMD. 
Methods: Forty-five individuals with AMD (27 female, 18 males) attended for two 
visits. Measures of visual function comprised: ETDRS distance VA; Mars Letter CS; 
reading speed (IReST) and microperimetry (MAIA). Vision-related QoL was assessed 
using the IVI; health- and psychosocial-related measures were assessed by EQ-5D-
3L, PHQ-9 and WEMWBS questionnaires. Rasch analysed scoring tables were 
produced for the IVI and WEMWBS. Univariate regression was performed to establish 
the relationships between the IVI and the dependant outcomes, prior to inclusion into 
a multiple regression model.
Results: The median (IQR) total IVI score was 2.37 (1.70 - 3.21). The optimum 
multiple regression model accounted for 41% of the variance in vision-related QoL 
(IVI score) and comprised MTD or MS (by MAIA microperimetry) and PHQ-9 score 
(depressive symptoms).
Discussion:  A combination of a microperimetry outcome and depressive symptom 
scores explained a significant proportion of variance in vision-related QoL.  
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Age-related macular degeneration has detrimental effects on QoL (Williams et al. 
1998), which is arguably the most important aspect to consider for these individuals. 
It is, therefore, beneficial to establish the clinical outcomes that can predict those at 
risk of a reduction in QoL due to AMD in order to enable appropriate and timely 
management strategies. This chapter will investigate factors that determine vision-
related QoL, assessed by the IVI, in individuals with AMD. However, before describing 
the study in detail it is important for the reader to have a good understanding of the 
relevant background related to QoL and AMD, and the factors that may influence QoL 
such as psychosocial-related factors, visual function and health-related factors. 
Additionally, the questionnaires and techniques used to assess QoL and the 
influencing factors will be summarised. 
Quality-of-life is a multidimensional concept and is influenced by many factors 
including physical and mental health, education, and social and economic status 
(WHOQOL 1995). The reduction in QoL in individuals with AMD is well-established 
(Cruess et al. 2007) and may be a consequence of difficulty with tasks of daily living. 
These include difficulties with self-care such as meal preparation and grooming 
(Ivanoff et al. 2000); limitations when going outside including travelling and shopping 
(Hochberg et al. 2012); and inability to perform leisure activities such as sewing, 
reading or watching the television (Scilley et al. 2002). Further consequences of AMD 
are an increased risk of falls (Knudtson, Klein and Klein 2009), reduction in mobility 
(Sengupta et al. 2015), and a decline in independence with a subsequent decrease 
in social interaction (Wong et al. 2004) leading to psychological and emotional distress 
(Bennion, Shaw and Gibson 2012; Berman and Brodaty 2006; Williams et al. 1998).  
The distress associated with AMD is not, however, related to the severity of vision 
loss (Moore and Miller 2003). Newly diagnosed individuals will likely be distressed, 
whereas those who have had time to adapt to the diagnosis may be more accepting 
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of their situation (Bennion, Shaw and Gibson 2012). Visually impaired individuals are 
twice as likely to suffer from depression (Evans, Fletcher and Wormald 2007; Brody 
et al. 2001) and the distress caused by AMD is comparable to that caused by other 
severe chronic health conditions such as cancer (McDaniel et al. 1995). A cycle 
therefore ensues in which depression may reduce functional ability which in turn  
leads to problematic daily life activities and a worsening of depressive symptoms 
(Rovner, Casten and Tasman 2002; Cimarolli et al. 2015). The PHQ-9 is a well-
established questionnaire that is recommended for use in clinical practise by NICE to 
measure depressive symptoms (Smarr and Keefer 2011). It has been previously 
implemented in low vision (Acton et al. 2016) and in AMD (Rovner et al. 2014). 
Although the prevalence of depression in AMD is well known, a less investigated area 
is well-being. Mental well-being differs from mental health as it refers to the positive 
aspects of an individual’s everyday functioning (Ryan and Deci 2001). There are few 
publications that assess well-being in a population with AMD. In one study of 
individuals with low vision that comprised 60% of cases with AMD, no differences in 
mental well-being were found between those who had received vision rehabilitation 
and a control group (Acton et al. 2016). However, the relationship between well-being 
and vision-related QoL was not assessed. Rasch analysis is undertaken by 
convention when examining questionnaires within medical research, as it provides a 
robust assessment of the psychometric properties of a questionnaire, and converts 
ordinal Likert scale values into a linear logit scale suitable for parametric testing (See 
Section 1.5). Whilst Rasch analysis has been used to validate the WEMWBS (Bass 
et al. 2016; Clarke et al. 2011), and Rasch scoring of the WEMWBS has been used 
in a cohort with low vision (Acton et al. 2016); it has not been validated in individuals 
with AMD. Therefore, the present study will implement Rasch analysis before 
exploring the relationship between well-being, as measured by the WEMWBS, and 
vision-related QoL. 
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The IVI measures vision-related QoL and is appropriate for individuals with AMD. It is 
based upon participation in daily activities and the emotions associated with vision 
impairment (Hassell, Weih and Keeffe 2000). It can be either scored as a whole 
questionnaire or as three subscales: mobility and independence; reading and 
assessing information; and emotional well-being. The psychometric properties of the 
IVI have been extensively examined with Rasch analysis (Lamoureux et al. 2008; 
Lamoureux et al. 2007c; Lamoureux et al. 2006). Previous Rasch analysis of the IVI 
led to a reduction in the number of items from 32 to 28 (Lamoureux et al. 2006) and 
to a merger of the response categories (Lamoureux et al. 2007c). The 28 item IVI has 
since been validated in individuals with AMD and is deemed as a suitable measure 
that satisfied the Rasch model (Lamoureux et al. 2008).  
An unbiased assessment of an individual’s visual impairment can be calculated using 
the TTO. The TTO was originally established to assess health status (Redelmeier and 
Detsky 1995) but can be adapted to measure utility values related to visual loss 
(Brown 1999; Brown 2000). This involves the adjustment of the questioning, so the 
trade-off years are replaced for ‘perfect vision’, rather than ‘perfect health’ (Brown 
1999; Brown 2000). 
Visual function can be measured by questionnaires and by clinical techniques. The 
VF-14 questionnaire measures visual function and was originally designed for use in 
those with cataract (Valderas et al. 2004). It has been validated in individuals with 
AMD (Mackenzie et al. 2002; Riusala, Sarna and Immonen 2003) and has also been 
subject to Rasch analysis in AMD (Hewitt et al. 2006). The VF-14 is different from the 
IVI in that it only measures visual function, based upon the difficulty experienced with 
certain daily tasks and does not include questions on emotional state.  
VA, CS and reading tests are clinical measures of visual function and represent 
measures of foveal function. In some studies, impaired vision-related QoL was 
associated with reduced distance VA (Seland et al. 2011), near VA, reading speed 
153 
(Cahill et al. 2005), and CS (Hernandez Trillo and Dickinson 2012). A large 
impairment in vision-related QoL has been found in the presence of only a mild loss 
of VA (better than 6/12) (Hassell, Lamoureux and Keeffe 2006).  
It is, however, important to consider that AMD can affect a wider retinal area than 
solely the fovea. Hence, a topographical assessment of visual function may be more 
useful, such as that provided by microperimetry. Two studies have examined the 
association between vision-related QoL and microperimetry in individuals with AMD 
(Meleth et al. 2011; Parravano et al. 2013). However, these two studies are limited by 
the lack of probability analyses of the microperimetry outcomes. The present study 
will evaluate microperimetry outcomes, derived by robust probability analyses, in the 
form of TD and PD. 
When considering QoL outcomes it is also important to consider health status, as 
AMD commonly exists in the presence of comorbidity. In individuals with low vision, 
both physical and mental health were found to be associated with vision-related QoL 
score, and to activities of daily living (Hernandez Trillo and Dickinson 2012).  
In summary, when evaluating QoL in those with AMD, it is important to consider 
clinical measures of visual function (VA, CS, reading tests and microperimetry), health 
status, depressive symptoms and well-being. Consequently, the current study aims 
to establish, in individuals with AMD, the relationship between vision-related QoL, as 
measured by the Rasch analysed IVI questionnaire, and the following variables: AMD 
severity, VA, CS, reading speed and microperimetric outcomes; additional vision-
related self-reported outcomes, assessed by the Rasch analysed VF-14 and by the 
modified TTO (modified to measure vision-related utility value); depression (PHQ-9); 
health status (EQ-5D-3L); and well-being (Rasch analysed WEMWBS).  
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A detailed description of the procedures and techniques used in this chapter can be 
found in Chapter 3. Briefly, 52 individuals with a median (IQR) age of 79.5 years (75.0, 
83.0) were recruited from the Cardiff Eye Unit at the University Hospital of Wales. 
They attended the School of Optometry and Vision Sciences, Cardiff University, on 
two occasions each separated by a median (IQR) of 14 days (9, 24). 
At Visit 1, the individuals underwent examinations to ensure they met the study 
inclusion criteria (Section 3.3.1.2). Following this, SD-OCT scans and fundus 
photographs were acquired (Figure 6.1). Visit 2 involved the collection of the clinical 
measures of visual function (CS, VA, reading speed and microperimetry outcomes), 
vision-related QoL (IVI), additional vision-related questionnaires (VF-14 and modified 
TTO), and the health-related and psychosocial-related measures (health status, EQ-
5D; depression, PHQ-9; and well-being, WEMWBS) (Figure 6.1). 
Figure 6.1 Procedures at Visit 1 and Visit 2, listed in the order performed. 
Individuals with AMD who also had IOLs (n=11) were included in the analysis. The 
potential impact of including these individuals could be an artificial improvement in 
visual function in those with IOLs. However, preliminary analysis demonstrated that 
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there was no significant difference in the visual function measures between those with 
IOLs and those with a crystalline lens (independent t-test all p>0.05). 
6.3.1 Analysis 
Binocular measurements of VA, CS and reading speed outcomes were included in 
the analysis as they were deemed most appropriate for QoL.  
6.3.1.1 Questionnaires  
A detailed description of the questionnaires employed in this study, and the 
associated scoring procedures are provided in Chapter 3. To summarise: 
6.3.1.1.1 EQ-5D 
 The EQ-5D-3L index calculator was used to estimate the index score (Rabin 
and de Charro 2001), where a maximum value of 1 is given for perfect health 
and a value of 0 represents death (Dixon, Dakin and Wordsworth 2016). 
 The EQ-5D also includes a visual analogue scale in which the individual is 
asked to rate their overall health state on the day of testing, using a scale of 
0-100, with 0 being the worst imaginable health state and 100, being the best.  
6.3.1.1.2 PHQ-9 
 The PHQ-9 item scores were summed to produce a total score, which 
determines the level of depressive symptoms exhibited by the individual. A 
total score of 0 indicates an absence of depressive symptoms, 1-4 as minimal 
depressive symptoms, 5-14 as mild to moderate depressive symptoms, 15-19 
as moderately severe symptoms and 19-27 as severe depressive symptoms.  
6.3.1.1.3 Modified TTO 
 The TTO was modified to provide a vision-related outcome (Chapter 3). The 
answers to the two questions were converted into a single utility value by 
subtracting the number of trade-off years from the number of years expected 
to live and then dividing by the number of years expected to live. This results 
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in a value between 0 and 1, where 1 represents a trade-off of all of the 
individual’s remaining years, and 0 represents no time traded.
6.3.1.1.4 WEMWBS, IVI and the VF-14 
 Rasch analysed scoring tables were produced to convert the Likert responses, 
for each of these questionnaires, into logit scores. The lower the logit score 
the worse the well-being, the vision-related QoL and the visual function, 
respectively. 
 The overall score for each questionnaire was calculated as the sum of logit 
scores for all items divided by the number of questions answered. 
6.3.1.2 Imaging techniques 
Colour fundus photographs were graded using the AREDS classification system 
(AREDS 2001). SD-OCT foveal line scans were also utilised to confirm or identify 
PEDs, intraretinal fluid and other retinal features associated with AMD, as described 
in Chapter 3.  
6.3.1.3 AMD severity 
Participants were classified on the basis of an established binocular classification 
system (Aspinall et al. 2007) that included mild, moderate and severe categories. Mild 
is indicated by the presence of early or intermediate AMD in one or both eyes; 
moderate as the presence of late AMD (nAMD or GA) in one eye; and severe as the 
presence of late AMD in both eyes. Due to the limited numbers in the study the three 
classifications were combined into a binary scale to allocate individuals by mild or 
moderate classification (Grade 1) and by severe classification (Grade 2). 
6.3.1.4 Microperimetry outcomes 
The left eye DLS results were transformed into right eye format. The DLS values for 
those with foveal fixation were then converted into TD and PD values with 
corresponding probability defects using the MAIA normative database derived in the 
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previous study (Chapter 4). Unweighted mean TD (MTD) and mean PD (MPD) were 
utilised for analysis.  
The best MTD approach was implemented, whereby the eye with the best MTD was 
used to provide a binocular estimate for microperimetry (Arora et al. 2013). Two 
individuals did not have foveal fixation and therefore binocular estimates were based 
on the eye with the best MS for these individuals. This was to avoid the interpretation 
of the microperimetry results based on misaligned normative values due to eccentric 
fixation. Further data for these individuals were excluded from all analyses that use 
MTD or MPD. 
6.3.1.5 Statistical analyses 
The approach for statistical analyses was firstly an assessment for normality (Shapiro-
Wilk test), followed by a Spearman’s rank correlation matrix of all outcomes variables, 
and lastly univariate linear regression and multiple linear regression with IVI as the 
dependant variable. 
Correlation analysis was utilised, initially, to reduce the number of potential 
associations and subsequently only the significant associations were used in the 
univariate linear regression analysis (Armstrong, Eperjesi and Gilmartin 2005).  
A Spearman’s rank correlation matrix was undertaken to determine the strength of 
the association between all outcomes, including clinical measures of visual function, 
vision-related QoL, the health-related and psychosocial-related measures, age and 
AMD severity. This process was performed to identify the variables that were 
associated with vision-related QoL. When independent variables were highly 
correlated (r≥0.8) only one was included into each multiple regression model.  
The strongest correlates of vision-related QoL were then examined by univariate 
regression analyses to establish the most appropriate variables to include into the 
final multiple regression models.  
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Lastly, several multiple regression models including different combinations of factors 
were then examined to find the most appropriate model to explain the variance in IVI 
score. The multiple regression models were limited to one factor per 10 participants 
as described in Section 5.3.1.3. The assumptions of each linear regression model 
were examined, as detailed in Chapter 4. 
Statistical analyses were performed using the open source environment R (Version 
3.2.2) and SPSS (version 20.0). A p value of ≤0.05 was considered to be statistically 
significant for all analyses. A Bonferroni correction was not implemented in this 
analysis to avoid Type 2 errors (Armstrong 2014). The descriptive statistics for all 
measures are presented as a median and inter-quartile range (IQR).  
The following results are presented: firstly, the assessment of normality and the 
demographic characteristics of the individuals with AMD; secondly, a summary of the 
Rasch analyses performed on the IVI, WEMWBS and VF-14; thirdly, the 
characteristics of the individuals in terms of vision-related QoL, clinical measures of 
visual function and health-related and psychosocial-related outcomes; and finally, the 
correlation, univariate regression and multiple regression analyses to explain the 
variance in vision-related QoL. 
6.4.1 Assessment of normality 
The majority of outcomes were found to have a non-Gaussian distribution (age, EQ-
5D, PHQ-9, modified TTO, MS, VA, MTD, MPD and IVI, all p<0.05). Three outcomes 
had a Gaussian distribution: WEMWBS (p=0.29), CS (p=0.26) and reading speed 
(p=0.42). 
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6.4.2 Characteristics 
Five of the 52 individuals were excluded due to existing co-morbidities (4 due to 
details from the medical history, and one following refraction due to high myopia), 
resulting in 47 individuals included in the study. 
 Of the 47 individuals, 2 failed to attend both visits resulting in a cohort of 45 individuals 
(27 female, 18 males). The characteristics of the individuals with AMD are presented 
in Table 6.1.  
Variables N=45
Age (years)
Median age
IQR
80
75 – 83
Binocular AMD severity, n (%)
Grade 1
Grade 2
19 (42.2)
26 (57.8)
Duration of AMD, n (%)
<2 years
>2 years
23 (51.1)
22 (48.9)
Living, n (%)
Alone
Spouse/family
22 (48.9)
23 (51.1)
Table 6.1 The characteristics of the 45 individuals with AMD.
6.4.3 Rasch analysis 
6.4.3.1 Warwick-Edinburgh Mental Well-being Scale 
The psychometric properties of the WEMWBS have not been previously examined in 
individuals with AMD. Firstly, the performance of the response categories were 
evaluated (Figure 6.2). Category 2 (“Rarely”) was identified as not having a range 
over which it was likely to be chosen, as it overlapped with both category 1 and 3 
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(Figure 6.2, left). Therefore, response options 1 and 2 were merged. Having merged 
these, the categories functioned well (Figure 6.2, Panel B). 
Figure 6.2 Probability curve to show the operation of the original response categories for the 
Warwick-Edinburgh Well-being scale (A, left) (Cat 1= “None of the time”, Cat 2= “Rarely”, Cat 
3= “Some of the time”, Cat 4= “Often”, Cat 5 =”All of the time”) and the improved response 
categories (B, right)( Cat 1=”None of the time”, Cat 2 = “Rarely” or “some of the time”, Cat 3=” 
Often”, Cat 4= “All of the time”).
Secondly, the person fit statistics were assessed. One individual was found to have a 
value outside the accepted range (>1.4) (Linacre 2006) and was therefore removed 
from the analysis.  
Figure 6.3 shows the item range from -1.8 logits to 2.0 logits. Where items at the 
bottom of the map (e.g. item 12 “I have been feeling loved”) discriminate between 
those with low levels of well-being, and those at the top of the map (e.g. item 5 “I have 
had energy to spare”) discriminate between those with high levels of well-being. On 
the left of the map the person ability is shown and although the items are slightly 
biased towards the lower levels of well-being, there is a large range of items spanning 
the person abilities. 
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Figure 6.3 Person and item map showing the spread of item difficulty (right) with person ability 
(X = an individual), measured in logits (left). 
Person and item reliability were both close to 1 (0.88 and 0.93 of the modelled data 
respectively) suggesting the estimates were accurate (Court, Greenland and Margrain 
2010). Both the person and item separation were greater than 2.0 (2.75 and 3.77 
respectively) and therefore reliably positioned on the Rasch scale (Court, Greenland 
and Margrain 2010).  
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The infit and outfit values from the WEMWBS were all less than 2.0 (Table 6.2). 
However, three items had infit values greater than 1.5, and two outfit values were over 
1.5 suggesting only a modest fit with the ‘well-being’ concept being assessed by the 
questionnaire overall. Although not ideal, such fit statistics did not degrade the 
performance of the questionnaire and therefore it was decided to retain these items, 
preserving the integrity of the original questionnaire (Linacre 2006). 
Table 6.2 Fit statistics (Mean-square [MNSQ] infit and outfit values) and item difficulty (in 
logits) for the Warwick-Edinburgh Mental Well-being scale provided by Rasch analysis. 
The scoring table to covert the WEMWBS Likert scale into logit values was then 
calculated (Table 6.3). 
Item Item difficulty (SE) Infit (MNSQ) Outfit (MNSQ)
1 Optimistic 0.95 (0.22) 1.37 1.71
2 Useful 0.58 (0.21) 1.26 1.18
3 Relaxed 0.22 (0.22) 0.59 0.56
4 Interested in other people -0.31 (0.22) 1.46 1.76
5 Energy to spare 2.05 (0.23) 1.15 1.09
6 Dealing with problems well -0.06 (0.22) 0.58 0.56
7 Thinking clearly -0.93 (0.24) 0.79 0.74
8 Good about myself 0.58 (0.21) 0.69 0.67
9 Close to other people -0.71 (0.23) 1.12 1.02
10 Confident 0.03 (0.22) 0.62 0.59
11 Make up my own mind -0.93 (0.24) 0.99 1.01
12 Loved -1.62 (0.27) 1.63 1.45
13 Interested in new things 0.26 (0.22) 1.52 1.56
14 Cheerful -0.11 (0.22) 0.47 0.46
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Response category
Item 1 2 3 4
1 Optimistic -2.01 0.03 1.89 3.87
2 Useful -1.43 0.61 2.47 4.45
3 Relaxed -1.21 0.83 2.69 4.67
4 Interested in other people -1.52 0.52 2.38 4.36
5 Energy to spare 0.53 2.57 4.43 6.41
6 Dealing with problems well 0.47 2.51 4.37 6.35
7 Thinking clearly -0.46 1.58 3.44 5.42
8 Good about myself 0.12 2.16 4.02 6.00
9 Close to other people -0.59 1.45 3.31 5.29
10 Confident -0.56 1.48 3.34 5.32
11 Make up my own mind -1.49 0.55 2.41 4.39
12 Loved -3.11 -1.07 0.79 2.77
13 Interested in new things -2.85 -0.81 1.05 3.03
14 Cheerful -2.96 -0.92 0.94 2.92
Table 6.3 Rasch analysed scoring table (logits) for each item of the Warwick-Edinburgh Mental 
Well-being scale.
6.4.3.2 Impact of Vision Impairment 
Rasch analysis metrics indicated that the total IVI questionnaire had good 
psychometric properties. The category responses were ordered well, both the item 
and person reliability coefficients were high (0.94 and 0.93, respectively), as were the 
item and person separation ratios (4.0 and 3.6, respectively). The infit and outfit mean 
square values were all less than 1.5. These findings are in agreement with earlier 
reports on the IVI (Lamoureux et al. 2006; Lamoureux et al. 2007c). The scoring table 
is presented in Table 6.4. 
164 
Response category
Item 0 1 2 3
1 TV -5.05 -1.46 1.96 4.06
2 Recreational activities -5.12 -1.53 1.89 3.99
3 Shopping -4.72 -1.13 2.29 4.39
4 Reading -1.49 2.10 5.52 7.62
5 Visiting friends/family -6.67 -3.08 0.34 2.44
6 Recognising/meeting -4.85 -1.26 2.16 4.26
7 Getting information -2.39 1.20 4.62 6.72
8 Looking after appearance -5.71 -2.12 1.30 3.40
9 Opening packaging -6.15 -2.56 0.86 2.96
10 Reading labels on medicines -3.62 -0.03 3.39 5.49
11 Household appliances -5.45 -1.86 1.56 3.66
12 Getting about outdoors -5.09 -1.50 1.92 4.02
13 Careful to avoid falling -4.08 -0.49 2.93 5.03
14 Travelling/transport -5.19 -1.60 1.82 3.92
15 Steps/stairs/curbs -4.14 -0.55 2.87 4.97
16 Safety at home -5.77 -2.18 1.24 3.34
17 Spilling/breaking things -5.53 -1.94 1.48 3.58
18 Safety out of home -4.92 -1.33 2.09 4.19
19 Stopped doing things -5.17 -1.58 1.84 3.94
20 Need help from others -5.75 -2.16 1.26 3.36
21 Embarrassed -6.56 -2.97 0.45 2.55
22 Frustrated -4.66 -1.07 2.35 4.45
23 Lonely/isolated -7.41 -3.82 -0.40 1.70
24 Sad/low -5.55 -1.96 1.46 3.56
25 Worried about getting worse -3.95 -0.36 3.06 5.16
26 Concerned about coping -4.98 -1.39 2.03 4.13
27 Nuisance or burden -6.10 -2.51 0.91 3.01
28 Interfered with life in general -5.05 -1.46 1.96 4.06
Table 6.4 Rasch analysed scoring table (in logits) for each item of the Impact of Vision 
Impairment questionnaire.
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6.4.3.3 VF-14 
The assessment of the psychometric properties of the VF-14 highlighted an 
unsatisfactory overlap between the response categories and a poor fit for question 13 
(outfit value= 4). It was concluded that the VF-14 was unsatisfactory for use in 
individuals with AMD, without significant modification. As the results from the VF-14 
were not the primary outcome measure in this study, it was excluded from further 
analysis. 
6.4.4 Characteristics of visual function and questionnaire outcomes 
Descriptive statistics for the IVI, the clinical measures (VA, CS, reading speed and 
microperimetry) and each of the health- and psychosocial-related measures are 
presented in Table 6.5. Despite the proportion of individuals being classified as severe 
AMD (n=26), binocular VA was maintained at a high level (Table 6.5). In those with 
foveal fixation (n=43), the median (IQR) of the MTD was -4.5 (-1.7, -7.6) and for MPD 
was -2.7 (-2.1, -3.9).  
The individuals had a median (IQR) of 3 (2, 4) comorbidities and were taking a median 
of 3 (1, 4) medications. The most common comorbidities were hearing impairments 
(n=29) and musculoskeletal disorders (n=26). 
The EQ-5D VAS median (IQR) score was 80 (70, 87), for the EQ-5D index was 0.70 
(0.66, 0.77) (Table 6.5). Self-care was the area with the least number of problems 
(n=4). Over half of the individuals experienced problems with pain or discomfort 
(n=25) (Table 6.5).  
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N=45
IVI score (logits), median (IQR)
Range
2.4 (1.7, 3.2)
-1.5 – 3.9
Clinical measures, median (IQR)
Mean sensitivity (dB)
Visual acuity (logMAR)
Reading speed (wpm)
Contrast sensitivity (log units)
23.7 (20.4, 26.9)
0.1 (0.0, 0.2)
158.8 (126.4, 192.6)
1.4 (1.2, 1.6)
EQ-5D VAS, median (IQR)
Range
80 (70,87)
9 - 100
EQ-5D index, median (IQR)
Range
0.7 (0.7, 0.8)
0.3 – 1.0
EQ-5D dimensions, n (%)
Mobility
Problems
No problems
Self-care
Problems
No problems
Usual activities
Problems 
No problems
Pain/discomfort
Problems 
No problems
Anxiety/ depression
Problems 
No problems
24 (53.3)
21 (46.7)
4 (8.9)
41 (91.1)
20 (44.4)
25 (55.6)
25 (55.6)
20 (44.4)
11 (24.4)
34 (75.6)
PHQ-9 total score, median (IQR)
Range
3 (2, 5)
0 - 24
PHQ-9 depression severity, n (%)
No depression
Minimal depression
Mild depression
Moderate depression
Severe depression
6 (13.3)
23 (51.1)
14 (31.1)
1 (2.2)
1 (2.2)
WEMWBS (logits), median (IQR)
Range
2.3 (1.6, 3.0)
-0.9 – 4.7
Modified TTO, median (IQR)
Range
1.0 (0.8, 1.0)
0.0 – 1.0
Table 6.5 Descriptive statistics for vision-related QoL (Impact of Vision Impairment, IVI) and 
the clinical measures of visual function and each of the health-related and psychosocial-
related outcomes. For the IVI, Warwick-Edinburgh Mental Well-being Scale (WEMWBS), 
modified TTO and EQ-5D the higher the score the better the QoL, well-being, utility value and 
health status, respectively. For the PHQ-9 a higher scored indicates worse depressive 
symptoms.
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The median (IQR) PHQ-9 total score was 3 (2, 5). Over half of the individuals had 
minimal or no depressive symptoms (n=29) and a third of individuals displayed only 
mild depressive symptoms (n=14) (Table 6.5). Three individuals were receiving 
treatment for depression prior to the start of the study. One individual was identified 
on the PHQ-9 as displaying moderate depressive symptoms and one individual as 
exhibiting severe depressive symptoms. Both of these individuals agreed to be 
referred to their GP, according to the study protocol (Section 3.3.3.2.3).  
6.4.5 Correlation analysis 
The correlation matrix is presented in Figure 6.4. The Spearman’s rho values 
representing the associations between each of the clinical measures were assessed 
to ascertain any commonality between them. A value over or equal to 0.8 was 
considered as highly correlated. There was moderate correlation between all clinical 
measures as may be expected. The associations between MS, MTD and MPD were, 
unsurprisingly, high (all r≥0.8), because all were derived from the same 
microperimetric DLS values (Figure 6.4).  
The correlations between the study outcomes and the IVI score are presented in 
Table 6.6. Each clinical measure, health-related and psychosocial-related measures 
declined with IVI score. The PHQ-9 score and the IVI score showed the strongest 
association (r=-0.46). All the clinical measures were moderately associated with IVI 
score, and MPD demonstrated the strongest association (r=0.38). Age, AMD severity 
and modified TTO score were not significantly correlated with the IVI score (Table 
6.6).  
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Figure 6.4.Correlation matrix for each of the clinical outcomes: visual acuity (VA), contrast sensitivity 
(CS), reading speed (RS), Mean Sensitivity (MS), Mean Total Deviation (MTD and Mean Pattern 
Deviation (MPD). The Spearman’s rho values ≥0.8 are highlighted in orange.
Rho 
values p value
Age -0.02 0.44
Visual acuity -0.31* 0.04
Contrast sensitivity 0.36* 0.02
Reading speed 0.30** 0.01
Mean Sensitivity 0.36** <0.01
Mean Total Deviation 0.36** <0.01
Mean Pattern 
Deviation 0.38** <0.01
AMD severity -0.08 0.35
EQ-5D 0.35** 0.01
PHQ-9 -0.46** <0.01
WEMWBS 0.34* 0.04
Time trade-off 0.03 0.71
Table 6.6 Spearman's rank correlation for the association between IVI total score and clinical 
measures, health-related measures, age and AMD severity. * p≤0.05 and **p≤0.01
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6.4.6 Univariate linear regression  
The outcomes from the univariate linear regression analysis are presented in Figure 
6.5. As age, AMD severity and the modified TTO exhibited no association with IVI 
score, these outcomes were excluded from further analysis.  
Each of the microperimetry outcomes produced identical relationships with IVI score 
(all R²=0.20, p<0.01), confirming that only one of these should be used within the 
subsequent multiple regression model. From all the measures investigated, the PHQ-
9 was the strongest univariate predictor of IVI score (R²=0.21, p<0.01). Of the clinical 
measures of visual function, the microperimetry outcomes and CS produced the 
strongest univariate relationships with IVI score (all R²=0.20).  
Health status and well-being produced significant but weaker relationships with IVI 
score compared to the PHQ-9 (EQ-5D, R²=0.14, p=0.01; and WEMWBS, R²=0.10, 
p=0.04). 
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Figure 6.5 Univariate linear regression of IVI total score (ordinate) as a function of Mean Sensitivity (A), 
Mean Total Deviation (B), reading speed (C), Mean Pattern Deviation (D), Visual acuity (E), Contrast 
sensitivity (F), EQ-5D (G) and PHQ-9 (H) (abscissa). The grey shaded area represents the 95% 
confidence limits for linear regression. 
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6.4.7 Multiple linear regression  
The clinical measures identified as having the strongest univariate relationships with 
vision-related QoL (PHQ-9, CS and the microperimetry outcomes) were examined 
further in combination with each other and with the other clinical, health- and 
psychosocial-related measures, as part of the multiple regression analysis.  
Several multiple regression models, limited to a maximum of 4 predicting variables for 
n=45 (Section 5.3.1.3), were compared, to find the strongest model to predict total IVI 
score. Only one of the microperimetry outcomes was utilised within the same model 
due to the high correlation between them. 
MTD or MS in combination with the PHQ-9 produced identical models accounting for 
41% of the variance in IVI score (Table 6.7, Model A and B respectively). The model 
including CS and PHQ-9 accounted for 37% of the variance in IVI score (Table 6.7, 
Model C). None of the other clinical measures were significant within the multiple 
regression models.  
Model Adj R² F p
Variables 
in model Coef SE t p
A 0.41 (2,42) = 16.0 <0.01
MTD
PHQ-9 
0.12
-0.15
0.03
0.04
4.11
-4.15
0.01**
0.00**
B 0.41 (2,42) = 16.0 <0.01
MS
PHQ-9
0.12
-0.15
0.03
0.04
4.11
-4.15
0.01**
0.00**
C 0.37 (2,42) = 13.6 <0.01
CS
PHQ-9 
0.58
0.04
0.58
0.04
3.61
-4.34
0.01**
0.00**
Table 6.7 Two multiple regression models to predict the IVI total score. Model A includes Mean 
Total Deviation (MTD)or Mean Sensitivity (MS) and the patient health questionnaire-9 (PHQ-
9) and model C includes contrast sensitivity (CS) and the PHQ-9.
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The present study investigated the relationship between vision-related QoL and 
clinical measures of visual function, psychosocial-related measures and health-
related measures. The strongest univariate predictor of vision-related QoL was the 
PHQ-9, accounting for 21% of the variance. However, MS, MTD and CS all explained 
a similar variance of 20%.  
Vision-related QoL was predicted by MS or MTD in combination with the PHQ-9. 
These key predictors were effective in explaining 41% of the variance in IVI score, 
which is twice that accounted for by the same measures univariately. This finding 
supports the clinical utility of microperimetry, and is consistent with the well-
established links between vision-related QoL and depression in AMD (van der Aa et 
al. 2015; Rovner, Casten and Tasman 2002; Slakter and Stur 2005). The results 
reinforce our knowledge that a relationship exists between reduced visual field loss 
and worsened QoL (Medeiros et al. 2015). A similar variance of 42% has been 
previously reported in a study that predicted the activities of daily living (Activities of 
Daily Vision Scale) from clinical measures including VA, but did not include 
microperimetry outcomes (Mangione et al. 1999). By determining the clinical 
measures that predict vision-related QoL, these findings could have clinical 
implications for monitoring functional loss in individuals with AMD in the context of 
QoL. The combination of microperimetry outcomes and level of depressive symptoms 
could help identify those with a reduced vision-related QoL and, subsequently allow 
effective management of those most at risk. 
Microperimetry outcomes were key predictors of vision-related QoL in individuals with 
AMD and this supports previous literature. Two previous studies examined the 
change in microperimetric outcomes and vision-related QoL after treatment of AMD 
by macular translocation surgery (Mettu et al. 2011) and photodynamic therapy 
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combined with Ranibizumab (Parravano et al. 2013). Only one of these assessed the 
association between microperimetry and vision-related QoL, whereby microperimetry 
was moderately correlated (r=0.35) with NEI-VFQ-25 score following macular 
translocation surgery, which was not the case pre-operatively (Mettu et al. 2011). 
However, the microperimetric outcome was limited to the median DLS and 
percentage non responsive locations (percentage of locations with no response to the 
brightest stimulus) (Mettu et al. 2011). Another study examined the comparison of 
vision-related QoL, between open angle glaucoma and AMD, and included SAP 
performed with the HFA as an outcome (Ugurlu, Karagoz and Ekin 2017). In a 
correlation analysis between MD values of the 10-2 visual field and total NEI-VFQ-25 
score, the correlation coefficient was r=0.36. This is identical to the correlation 
between MTD and IVI score established in the present study (see results in Table 
6.6). However, stronger associations between vision-related QoL and both VA 
(r=0.96), and CS (average r=0.73) were found than those in the present study.  
It is also of interest that the microperimetry outcomes, MS and MTD, demonstrated 
stronger relationships with vision-related QoL, than VA and reading speed. This might 
suggest that microperimetry could replace VA and reading speed in the determination 
of vision-related QoL in individuals with AMD. 
A further novel aspect of the current study was the application of Rasch analyses to 
the WEMWBS in individuals with AMD. The results of this analysis show that, after 
combining the response categories, the WEMWBS is a valid measurement tool, with 
which to quantify mental well-being in individuals with AMD. The items of the 
questionnaire form a valid unidimensional linear scale to measure well-being. As the 
WEMWBS is now validated in this cohort, further studies should establish if well-being 
is affected in a separate cohort of individuals with AMD. Future studies should include 
the assessment of well-being in a large sample of individuals with a range of AMD 
severities, but also in comparison with age-matched controls. 
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Although a large proportion of the variance in vision-related QoL was explained by 
the multivariate model, the unexplained variance is a consequence of the 
multidimensional nature of QoL, whereby other factors such as socio-economic status 
(e.g. household income and level of education) affect the individual’s QoL. Another 
explanation for the moderate strength of the model is that the clinical measures 
utilised in this study do not reflect ‘real world’ scenarios and therefore the association 
with vision-related QoL is limited. Previous studies have measured ‘real world’ ability 
by assessing performance on tasks within a controlled environment, for example 
timed activities such as walking up the stairs (West et al. 2002b). Other tasks have 
been developed to mimic real world situations such as viewing faces, for both 
recognition and expression perception (Alexander et al. 1988; Vuilleumier et al. 2003) 
and everyday scene searching tasks (Taylor et al. 2017). These more realistic 
measures of visual function may lead to stronger relationships with vision-related 
QoL; however, due to their time consuming nature and the additional research 
instrumentation required, they are unlikely to be adopted in clinical practice. It is, 
therefore, important to make conclusions based upon instrumentation and techniques 
translational to AMD clinics, to enable widely applicable findings, for appropriate 
advice to professionals.  
A limitation of the current study was the lack of age-matched controls, which limits the 
ability to isolate the effects of AMD on vision-related QoL. A further study including 
such a comparison would verify the findings from this study. Another potential 
limitation, was the proportion of participants with late AMD included in this study, 
which could have introduced bias towards a more severe vision-related QoL. Despite 
this, there was a range of vision-related QoL results within this study, but no 
relationship was found between AMD severity and vision-related QoL.  
It can be argued that the aim of any AMD treatment is to improve an individual’s QoL. 
It is not common for lengthy questionnaires to be used in clinical practice due to time 
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constraints. In the present study, we have identified that MTD or MS and level of 
depressive symptoms can explain a significant proportion of the variance in vision-
related QoL. Further investigation as to whether the same clinical measures can also 
be used to explain the change in vision-related QoL over 1 year will be examined in 
the following chapter.  
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Chapter 7: The relationship between change in vision-
related QoL and clinical outcomes: Follow-up at 1 
year 
Purpose: The aim of this study was twofold. Firstly, to determine if change was 
present in vision-related QoL, clinical measures of visual function, health status, 
depression and well-being outcomes at 1 year from the baseline assessment. 
Secondly, to evaluate the factors that determine any change in vision-related QoL at 
1 year. 
Methods: Twenty-nine individuals with AMD (18 female) attended a follow-up visit at 
1 year. Measures of visual function comprised: ETDRS distance VA; Mars letter CS; 
reading speed by the IReST and MAIA microperimetry. Vision-related QoL was 
assessed by the IVI questionnaire, health status by the EQ-5D and depression and 
well-being by the PHQ-9 and WEMWBS, respectively. Univariate linear regression 
analysis was performed to establish the strongest predictors of any change. The 
predictors were then incorporated into a multiple regression model.
Results: There was no significant change over 1 year in the IVI score, EQ-5D, PHQ-
9, WEMWBS, CS, reading speed or VA. Each of the microperimetry outcomes 
worsened over the 1 year follow-up. Baseline CS (R²=0.36, p<0.01) was the strongest 
univariate predictors of change in IVI score, The optimum multiple regression model 
accounted for 43% of the change in IVI score and included baseline CS, change in 
reading speed and change in EQ-5D score.
Conclusion: Change in vision-related QoL over 1 year can, to a significant extent, be 
explained by baseline CS, changes in health status and changes in reading speed. 
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The prevalence of AMD is expected to increase due to the ageing population (Owen 
et al. 2012) and this is likely to have significant personal, social and economic 
consequences (Prenner et al. 2015; Cruess et al. 2007). Current research largely 
concentrates on treatment and early detection of AMD, yet QoL is equally as important 
in terms of patient management (Yuzawa et al. 2013). The previous chapter (Chapter 
6) showed that a combination of clinical outcomes and health- and psychosocial-
related measures could predict, to some extent, an individual’s vision-related QoL in 
a cross-sectional cohort with AMD. Therefore, it may be possible to predict those most 
at risk of vision-related QoL deterioration i.e. clinical measures of visual function and 
health- and psychosocial-related measures may be biomarkers for future loss of 
vision-related QoL.  
Many have studied the factors that affect vision-related QoL in those with AMD 
(Coleman et al. 2010; Scilley et al. 2002; Ugurlu, Karagoz and Ekin 2017), yet fewer 
studies have evaluated the change in vision-related QoL over time in AMD (Markun 
et al. 2015; Finger et al. 2014; Yuzawa et al. 2015; van Nispen et al. 2010). Change 
in QoL has been adopted as an outcome measure in clinical trials in the evaluation of 
therapeutic and rehabilitation interventions in AMD (Markun et al. 2015; Finger et al. 
2014; Yuzawa et al. 2015; van Nispen et al. 2010).  
Progression from mild to severe visual impairment adversely impacts on vision-
related QoL (Coleman et al. 2010). In early stages of AMD, where good VA is 
maintained, difficulty with everyday activities such as driving and near vision tasks are 
experienced, which subsequently lead to reductions in vision-related QoL (Scilley et 
al. 2002; Ugurlu, Karagoz and Ekin 2017).  
Current AMD treatment is monitored by clinical assessment, which may include 
imaging and measures of visual function, but measures of vision-related QoL are 
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seldom considered. The identification of those with a change in vision-related QoL, 
could help practitioners to allocate resources more appropriately.  
Microperimetric outcomes have not been previously investigated with respect to 
change in vision-related QoL. In glaucoma, a worsening in the binocular HFA visual 
field (binocular summation of the 24-2 pattern) was associated with a change in vision-
related QoL (Medeiros et al. 2015). This is consistent with the results from the 
preceding study (Chapter 6), despite the difference between disease processes 
between glaucoma and AMD. In Chapter 6, it was found that microperimetric results 
(MS and MD) at baseline can predict, to some extent, baseline vision-related QoL 
and, therefore, may also be associated with change in vision-related QoL. 
Additionally, there is no literature examining the combination of factors that determine 
the change in vision-related QoL that is not a consequence of intervention. 
The aim of this study was twofold. Firstly, to quantify the change (both improvement 
and deterioration) in vision-related QoL, clinical measures of visual function, health 
status, depression and well-being after a follow-up period of 1 year. Secondly, to 
evaluate the factors that determine change in vision-related QoL after 1 year. The 
clinical measures of visual function included VA, CS, reading speed and 
microperimetry outcomes (Chapter 3). Depressive symptoms (PHQ-9), well-being 
(WEMWBS), general health status (EQ-5D) and the TTO (modified to measure vision-
related utility values) were also assessed (Chapter 3). Vision-related QoL was 
quantified using the total score of the Impact of Visual impairment (IVI) questionnaire 
(Chapter 3).  
Each of the measures undertaken in this chapter are described in detail in Chapter 3. 
In brief, 52 individuals with AMD took part in a baseline assessment. Each individual 
attended two visits to the School of Optometry and Vision Sciences, Cardiff University, 
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within 14 days (9, 24). At these two visits, the vision-related QoL, clinical measures of 
visual function, depression, well-being and health status were collected (Figure 7.1).  
Thirty-two of the 52 individuals had completed a one year cycle and, therefore, were 
invited to return for a follow-up visit, on a consecutive basis (see sample size 
calculation Section 3.3.1.1). The follow-up visit took place 1 year after the baseline 
visit, median (IQR) of 13.6 months (12.5, 14.6).  
The follow-up visit included all of the assessments performed at the baseline visits 
and also consisted of an updated medical, lifestyle and living situation history (Figure 
7.1) (Chapter 3).  
Figure 7.1  Assessments undertaken at baseline Visits 1 and 2 and the 1 year follow-up visit. 
Questionnaire interview part 1 consisted of IVI, EQ-5D and WEMWBS, and questionnaire 
interview part 2 consisted of VF-14, PHQ-9 and the modified TTO. 
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7.3.1 Analysis 
Binocular measures of VA, CS and reading speed were used for the analysis. 
7.3.1.1 Questionnaires 
The WEMWBS and the IVI were assessed using the Rasch scoring tables produced 
in Chapter 6 (Section 6.4.3). The PHQ-9, EQ-5D and the modified TTO were scored 
as previously described (Section 3.3.3.2.3). 
7.3.1.2 Imaging techniques 
The colour fundus photographs were graded using the AREDS classification system 
(AREDS 2001). The SD-OCT volume scans were used to confirm and identify the 
presence of PEDs, intraretinal fluid and other retinal features associated with AMD 
(Section 3.3.3.1.8).  
7.3.1.3 AMD severity 
The severity of AMD was classified as mild, moderate or severe, using an established 
binocular classification system (Aspinall et al. 2007) (Section 6.3.1.3). Due to the 
limited number of individuals in the study, the three classifications were combined into 
a binary scale of Grade 1 mild or moderate classification, and Grade 2 severe 
classification. 
7.3.1.4 Microperimetry 
DLS results were transformed into right eye format. MAIA DLS results for those with 
foveal fixation were then converted into TD and PD values using the normative 
database developed in Chapter 4. The best MTD approach was implemented, 
whereby the eye with the best MTD was used to provide a binocular estimate for 
microperimetry (Arora et al. 2013). The microperimetry outcomes used in this analysis 
were MS, MTD and MPD. 
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7.3.1.5 Statistical analysis 
The approach for statistical analyses was, firstly, an assessment for normality 
(Shapiro-Wilk test) of each of the variables, followed by a paired t-test between 
baseline and 1 year outcomes for each of the variables. A Spearman’s rank 
correlation matrix of all variables was constructed, and lastly univariate linear 
regression and multiple linear regression, both with IVI as the dependent variable, 
were performed. 
Distributions of the change in each variable were examined using the Shapiro-Wilk 
test for normality. Differences in measures between baseline and the 1 year follow-
up were evaluated with a paired t-test for Gaussian data and the Wilcoxon test for 
non-Gaussian data. 
A Spearman’s rank correlation matrix was produced between the change in vision-
related QoL and each of the baseline clinical, psychosocial-related and health-related 
measures, and between the change in each of the measures over the 1 year period. 
This process was performed to identify the significant correlations, which were further 
investigated with univariate linear regression, to find the strongest predictors of 
change in IVI score.  
Any significant univariate predictors were then incorporated into a multiple linear 
regression. Several multiple linear regression models were developed in order to 
determine the strongest significant model of the change in IVI. The multiple regression 
models were limited to one factor per 10 participants as described in Section 5.3.1.3. 
The assumptions of each linear regression model were examined, as detailed in 
Section 4.3.1.1.  
Statistical analyses were performed using R (Version 3.2.2) and SPSS (version 20.0). 
A p value of ≤0.05 was considered to be statistically significant. Bonferroni correction 
was not implemented in this analysis to avoid Type 2 errors and the loss of any real 
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affects within the analysis (Armstrong 2014), as detailed in Chapter 5. Descriptive 
data were reported using median (IQR) values.  
The following results are presented: firstly, the assessment of normality and the 
demographic characteristics of the individuals with AMD that attended the 1 year 
follow-up visit; secondly, the change in the clinical measures of visual function, vision-
related QoL, depression, well-being and health status, between baseline and 1 year; 
and finally, the correlation, univariate regression and multiple regression analyses to 
explain the change in vision-related QoL. 
7.4.1 Assessment of normality 
The majority of outcomes were found to have a non-Gaussian distribution (change in: 
EQ-5D, PHQ-9, modified TTO, MS, VA, MTD and MPD, all p<0.05). Change in IVI 
was found to have a Gaussian distribution (p=0.45), as were change in CS (p=0.12), 
reading speed (p=0.78) and WEMWBS (p=0.12).  
7.4.2 Characteristics 
Of the 32 individuals, who were invited to return for the 1 year follow-up visit, 3 were 
unable to attend within the designated time scale of 1 year.  
Twenty-nine individuals (18 females, 11 males) attended the 1 year follow-up visit. 
The characteristics of the 29 individuals are presented in Table 7.1. The majority of 
individuals had Grade 1 AMD (n = 18), and 41% were receiving treatment (n=12). 
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Variables N=29
Age (years)
Median age
IQR
78
74 – 84
Binocular AMD severity, n (%)
Grade 1 (mild/mod)
Grade 2 (severe)
18 (62.1)
11 (37.9)
Duration of AMD, n (%)
<2 years
>2 years
14 (48.3)
15 (51.7)
Current treatment, n (%)
Yes
No
12 (41.4)
17 (58.6)
Living, n (%)
Alone
Spouse/family
12 (48.9)
17 (58.6)
Number of comorbidities
Median
IQR
3
2 – 4
Number of medications
Median
IQR
4
1 – 6
Table 7.1 Characteristics of the 29 individuals with AMD, who attended the 1 year follow-up 
visit.
7.4.3 Change between baseline and the 1 year follow-up 
The IVI score was not statistically different between baseline and the 1 year follow-up 
(paired t-test, p=0.52) (Figure 7.2). However, overall 15 people had a deterioration, 
11 had an improvement and 3 had no change in IVI score between baseline and 1 
year (Figure 7.3). Of those that deteriorated (below the line, Figure 7.3) 34% were not 
receiving treatment, and of those that had an improvement (above the line, Figure 
7.3) 21% were receiving treatment. 
The EQ-5D, PHQ-9, WEMWBS and modified TTO outcomes at the baseline and 
follow-up examination are shown in Table 7.2.  
Examination of VA, CS and reading speed showed minimal change from baseline to 
follow up (Figure 7.4), which was not statistically significant (VA, p=0.39; CS, p=0.58; 
reading speed, p=0.73). Microperimetry outcomes worsened between baseline and 
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follow up visit, and MS and MTD worsened by a greater amount than MPD. The 
changes in all microperimetric outcomes were significant (all p<0.05) (Figure 7.5). 
Figure 7.2 Baseline and follow up total scores for the Impact of Visual Impairment 
questionnaire (logits).Boxplot limits indicate the minimum, 1st quartile, median, 3rd quartile and 
maximum. Outliers are represented by a black circle. 
185 
Figure 7.3 Scatter plot of change in IVI score (ordinate) as a function of baseline IVI score 
(abscissa), with those receiving treatment (black circle) and those not receiving treatment 
(grey circle) highlighted. 
N=29 Baseline Follow up Change p 
value
EQ-5D VAS, 
median (IQR)
Range
80 (70, 94)
9 - 100
75 (60, 90)
45 - 100
-1.0 (-10.0, 7.8)
-20.0 – 56.0
0.83
EQ-5D index, 
median (IQR)
Range
0.7 (0.7, 0.9)
0.6 – 1.0
0.7 (0.6, 0.8)
0.5 – 1.0
0.0 (-0.1,0.0)
-0.2 – 0.3
0.06
PHQ-9 total score, 
median (IQR)
Range
3 (0, 7)
0 - 24
3 (0, 6)
0 – 14
0 (-2, 0)
-10 – 7
0.39
WEMWBS, 
median (IQR)
Range
2.6 (1.6, 3.1)
-0.9 – 4.7
2.0 (1.1, 3.2)
0.2 – 3.9
-0.3 (-0.9, 0.1)
-1.6 – 1.6
0.27
Modified TTO, 
median (IQR)
Range
1.0 (0.8, 1.0)
0.0 – 1.0
1.0 (0.5,1.0)
0.0 – 1.0
0.0 (-0.1, 0.0)
-0.6 – 0.2
0.06
Table 7.2 Median, interquartile range (IQR) and range for the baseline and follow up scores, 
and the median (IQR) of individual change in score for the EQ-5D, Patient Health 
Questionnaire (PHQ-9), Warwick-Edinburgh mental well-being scale (WEMWBS) and the 
modified time trade-off (TTO).
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Figure 7.4 Baseline and follow up total scores for contrast sensitivity (left), reading speed 
(middle) and VA (right). Boxplot limits indicate the minimum, 1st quartile, median, 3rd quartile 
and maximum. An outlier is represented by a black circle. 
7.4.4 Correlation and univariate linear regression 
The Spearman’s rho values for the association between change in IVI score, and 
baseline, and change in, clinical outcomes, health status, depressive symptoms and 
well-being are presented in Table 7.3. Baseline reading speed (p=0.03), CS (p<0.01), 
MS (p=0.02) and MTD (p=0.05) were all associated with change in total IVI score. 
The change in total IVI score was also significantly associated with change in VA 
(p=0.02), reading speed (p=0.05), MPD (p=0.03) and EQ-5D health index (p=0.03) 
(Table 7.3). 
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 Figure 7.5 Baseline and follow up total scores for MS (left), MTD (middle) and MPD (right). 
Boxplot limits indicate the minimum, 1st quartile, median, 3rd quartile and maximum, an outlier 
is represented by a black circle and Wilcoxon test p values * p<0.05, **p<0.01. 
Baseline Change
Age -0.01
VA -0.36 0.45*
Reading 0.39* -0.42*
CS 0.54** 0.05
MS 0.35* -0.21
MTD 0.32* -0.11
MPD 0.05 -0.47*
EQ-5D index -0.32 0.31*
EQ-5D VAS 0.06 0.32
PHQ-9 0.12 -0.01
WEMWBS -0.03 0.04
Table 7.3 Spearman’s rank correlation (rho values) of the associations between change in 
total IVI score, and baseline clinical and health-related outcomes: age, VA, reading speed, 
CS, MS, MTD, MPD, EQ-5D index value, EQ-5D visual analogue scale score (EQ-5D VAS), 
PHQ-9 and WEMWBS; as well as the association between the change in IVI score and change 
in the same outcome measures. *p<0.05 and **p<0.01
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The baseline and the change in depression and well-being measures were not 
significantly correlated with change in IVI score (both p>0.05). Age, AMD severity, 
EQ-5D visual analogue scale, and depression and well-being were not significantly 
correlated with change in IVI score and, therefore, were each eliminated from further 
analysis.  
The significant associations were investigated further with univariate linear 
regression. Baseline CS was the strongest univariate predictor of change in IVI score 
(R²=0.36). Baseline reading speed (R²=0.17), baseline MS (R²=0.19), change in 
reading speed (R²=0.14) and change in EQ-5D score (R²=0.16) were also significant 
univariate predictors of change in IVI score (Figure 7.6).  
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Figure 7.6 Univariate regression analysis to predict the change in total IVI score (ordinate) on 
the basis of baseline contrast sensitivity (top left), baseline reading speed (top right), baseline 
Mean Sensitivity (middle left), change in reading speed (middle right) and change in EQ-5D 
index value (bottom left) (abscissa). The grey shaded area represents the 95% confidence 
limits for linear regression. 
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7.4.5 Multiple linear regression analysis 
 Baseline CS was included in all multiple regression models, in combination with the 
other significant predictors of change in total IVI score. Each model was limited to a 
maximum of three predictors per model for n=29 (Section 5.3.1.3) (Altman 1991).  
Baseline CS, change in reading speed and change in EQ-5D score were the strongest 
predictors of change in IVI score accounting for 43% of the variance (Table 7.4).  
Table 7.4 Multiple regression analysis to determine the predictors of the IVI total score. The 
following variables were included: change in reading speed (RS), change in EQ-5D and 
baseline contrast sensitivity (CS). 
The first aim of this study was to examine the change in vision-related QoL and the 
outcome measures over 1 year. Despite 52% of the individuals experiencing a 
deterioration in vision-related QoL, when examining the overall change in vision-
related QoL there was no significant change at the 1 year follow-up. The 
microperimetry outcomes worsened significantly over the follow-up period, but all 
other outcome measures showed no significant change.  
The second aim was to identify the factors that determine change in vision-related 
QoL over 1 year. CS at baseline, and change in reading speed and in EQ-5D index 
score can be used to identify change in vision-related QoL, in individuals with AMD. 
These key predictors explain a significant proportion (43%) of the variance in vision-
related QoL. Interestingly, baseline CS was the strongest single predictor of change 
in IVI score, predicting 36% of the variance, whereby a lower CS score at baseline 
resulted in a worse IVI score at 1 year. This result is consistent with the concept that 
CS is more representative of daily visual function than VA (Owsley and Sloane 1987). 
Model Adj R² F p
Variables in 
model Coef SE t p
IVI 0.43 (3,25) = 8.16 <0.01
RS change
EQ-5D change
CS baseline
-0.01
-1.32
1.37
<0.01
0.76
0.38
-1.70
-1.72
3.61
0.10
0.10
<0.01
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Reduced CS leads to difficulty with everyday vision-related tasks such as identifying 
faces, road signs and other objects (Owsley and Sloane 1987). Specifically, in those 
with macular disease CS is associated with vision-related QoL (Hazel et al. 2000) and 
the ability to perform tasks of daily living (McClure et al. 2000). However, these studies 
differed from the current study as they examined the association at a single time point 
rather than the change over 1 year.  
In the present study, change in EQ-5D index score and change in reading speed both 
explained a proportion of the change in IVI score. The outcome for the EQ-5D is in  
agreement with previous findings that a change in an individual’s health status affects 
vision-related QoL (Hernandez Trillo and Dickinson 2012). Additionally, reading ability 
is reduced in a high proportion of those with AMD (Crossland et al. 2007) and is also 
acknowledged to be of importance to those with visual impairment (Elliott et al. 1997). 
Reading ability has previously been associated with self-reported visual ability 
(McClure et al. 2000) and vision-related QoL in individuals with macular disease 
(Hazel et al. 2000). 
To the author’s knowledge, this was the first investigation to examine the association 
between microperimetry outcomes and longitudinal changes in vision-related QoL in 
individuals with AMD. The univariate model of baseline MS and change in IVI score 
was significant, whereby the lower the MS at baseline the larger the reduction in logit 
score for the IVI at 1 year. In glaucoma, more severe baseline defects were 
associated with greater change in vision-related QoL (Medeiros et al. 2015). However, 
in contrast to the current study, the change in MS predicted a change in the vision-
related QoL (Medeiros et al. 2015). However, the omission of CS from the analysis of 
the previous study (Medeiros et al. 2015) was potentially a significant omission. 
There was no relationship between baseline VA and the change in VA with vision-
related QoL. This could be attributed to the large proportion of individuals receiving 
anti-VEGF treatment, and therefore, the increased likelihood of the maintenance of 
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vision over the follow-up period. Additionally, the well documented limitations of VA 
measurement and its lack of real world applicability may also be a further issue 
(Krezel, Hogg and Azuara-Blanco 2015). Moderate associations exist between 
change in VA and change in vision-related QoL, but these were determined over 24 
months (Reeves et al. 2009), and between 10 and 15 years (Coleman et al. 2010), 
respectively.  
It is anticipated that a long term follow-up study would confirm that individuals with the 
most profound change in AMD severity would be at risk of a larger reduction in IVI 
score (Coleman et al. 2010). The current study was limited by the size of the case 
series, and by the low proportion of individuals in the mild and moderate AMD severity 
group. The recruitment of individuals at earlier stages of the disease would provide a 
more even distribution of AMD severity within the case series. This would also enable 
more comprehensive analysis of the association between both baseline and change 
in AMD severity, and the change in IVI score. Additionally, the identification of those 
at risk of a reduction in QoL is limited given the lack of significant change in the IVI 
score over the one year follow up. Continuing the follow-up period for a longer period 
would likely yield greater change in the IVI scores and clinical measures of visual 
function. Such results would enable a more robust prediction of vision-related QoL 
change from clinical measures and more definitive clinical advice for practitioners.  
This study provides evidence that change in vision-related QoL over 1 year can, to a 
significant extent, be explained by baseline CS. Changes in health status and reading 
speed over the same period of time also impact on the change in vision-related QoL. 
Whilst vision-related QoL is well-established as an important factor to the individual, 
its measurement is restricted to the use of questionnaires, which are rarely used in 
clinical practice. If a change in vision-related QoL can be predicted from less time-
consuming clinical measures, then clinicians could use this information to identify 
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those who require additional or targeted assistance, such as additional support from 
rehabilitation services.  
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Chapter 8: Discussion and future work 
Vision-related QoL is arguably one of the most important factors in the management 
of those with AMD. Consequently, there is a clear need for an understanding of the 
clinical outcomes that influence vision-related QoL in order to inform management 
strategies. The importance of this research is further justified by the increasing 
prevalence of AMD, given the ageing population, and the associated economic and 
social burdens (Saxena et al. 2016; Day et al. 2011). The principle aim of this research 
was to determine the factors that predict QoL in those with AMD, both at baseline and 
after 12 months.  
Summarised below are the major findings from each chapter, ideas for future work 
and the potential clinical implications. 
The critical review of current literature on the use of microperimetry in assessing visual 
function in AMD provided promising evidence for its continued use in this disease, 
with the further development of implemented methodologies. AMD-related 
morphological changes such as disruptions of the EZ band and RPE, outer segment 
thinning and RPE thickening in early AMD, and retinal thickness changes in CNV are 
clearly associated with reduced DLS. However, there are limitations in this literature. 
Firstly, the lack of robust age-corrected probability analysis software in microperimetry 
is currently a major omission of the technique. Secondly, the quality of reporting in 
many studies lacks significant methodological detail, and although this has improved 
over time, it is a weakness of the current evidence. 
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The development of a pointwise age-corrected normative database for the MAIA 
microperimeter was a prerequisite to evaluating abnormality in AMD. The normative 
database enabled localised probability analysis and the consequent separation of 
focal from generalised functional loss, to determine abnormality by MAIA 
microperimetry in AMD and, subsequently, in other visual pathway diseases.  
Two methods of developing a normative database were explored: the adjusted age 
method and the age-specific method. These methods resulted in differing outcomes 
from the same individuals with AMD. The adjusted age method detected defects at 
an earlier stage than the age-specific method. Further assessment of the sensitivity 
and specificity was beyond the scope of this study, but should be considered for future 
work. For the purpose of this thesis, the age-specific method was chosen for use in 
the chapters subsequent to Chapter 4, due to its appropriate statistical methodology.
A secondary aim of the thesis was to examine the association between 
microperimetry outcomes and SD-OCT outcomes. Such an association was 
investigated at 5° eccentricity with respect to AMD-related microstructural changes.  
Detailed topographical comparisons between microstructural changes and visual 
function measured by microperimetry were examined. The microperimetry outcomes 
(MS and MTD) were explained, to a large extent, by the presence of photoreceptor 
atrophy. However, this relationship was not sufficiently strong for microperimetry and 
SD-OCT to be interchangeable. 
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A primary aim was to investigate the factors that determine vision-related QoL in 
individuals with AMD. The microperimetry outcome, MTD, and level of depressive 
symptoms predicted, to a significant extent, vision-related QoL. It is already well 
established that depression affects QoL in AMD; however, the influence of a 
microperimetry outcome on QoL was a novel finding.  
The investigation of the changes in clinical outcomes after 1 year and the factors that 
determine change in vision-related QoL over the same time period were examined. 
Baseline CS was the strongest univariate predictor of change in vision-related QoL. 
Multivariate analyses indicated change in vision-related QoL was explained by 
baseline CS and change in both health status and reading speed over the same 
period. These findings highlight the importance of CS in the consideration of vision-
related QoL in those with AMD. Additionally, health status should be recognised as 
important in the assessment of change in vision-related QoL. 
The strengths and areas in which the current research could be improved upon are 
summarised briefly and the potential for future work is discussed herein. 
Key strengths of this thesis include: the acquisition of high quality clinical data both 
from healthy individuals and individuals with AMD; the implementation of a normative 
database in the analysis of microperimetry data; the consideration of appropriate 
regression techniques for each study; the use of Rasch analysis, where appropriate, 
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to enable robust statistical analysis of questionnaire data; the longitudinal evaluation 
of vision-related QoL and clinical outcomes over 1 year; and the successful 
recruitment, to target, of individuals with AMD. 
Recruitment targets were met with respect to the sample size calculations within each 
of the studies of this thesis. However, the spread of individuals in the case series was 
limited in terms of the proportion with mild to moderate AMD. Targeted recruitment of 
individuals at earlier stages of the disease would provide a more evenly distributed 
case series. Such an extension would enable improved understanding of the 
relationship between clinical measures and QoL outcomes with respect to AMD 
severity. 
Another improvement to the present research would be the extended duration of the 
follow-up period from a medium-term period of 1 year to a long-term period. This 
would be expected to yield more profound changes in vision-related QoL and clinical 
outcome measures, in order to examine patterns of long-term change in vision-related 
QoL. Such findings have the potential to validate the current results with greater 
statistical confidence. 
8.7.1 Normative databases 
Normative databases for clinical instruments are essential in the definition of 
abnormality. However, they are usually a costly and time consuming process to derive 
as a consequence of the requirement for a large number of normal individuals, usually 
over a number of research centres. The HFA normative database, for example, was 
collected over 4 sites and included over 400 visual field examinations (Heijl, Lindgren 
and Olsson 1987a). The study presented in Chapter 4 was a single centre study with 
minimal resources and, therefore, the sample size reflected this. Future normative 
databases could be compiled from a number of independent small scale studies to 
increase the sample size, which would avoid the large financial disadvantage of 
multicentre studies. 
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It is standard within the visual field literature to discard data collected from the initial 
visits, in an attempt to reduce the learning effect. However, an alternative approach 
would be to collect and derive a normative database for each visit, which takes into 
account the difference in variability at each visit. This would require a large number of 
individuals to complete examinations on a number of consecutive examinations and 
also at set time periods, and therefore, would be a timely and costly process. 
Nevertheless, with a number of independent small scale studies, the time and cost 
could be shared and collaborations encouraged. 
8.7.2 Scotopic microperimetry 
The development of scotopic microperimetry has enabled detailed research relating 
specifically to the rod photoreceptors (Steinberg et al. 2016; Steinberg et al. 2015a; 
Pfau et al. 2017). A combination of mesopic and scotopic microperimetry would 
enable examination of both rod and cone function with respect to retinal 
microstructure changes. Rods are known to be affected before cones in early AMD 
(Curcio, Owsley and Jackson 2000), and rod function, as measured by scotopic 
microperimetry, is affected in the presence of RPD (Steinberg et al. 2015a) and hard 
drusen (Nebbioso, Barbato and Pescosolido 2014). It would be of interest to 
investigate rod and cone function, by microperimetry, in a full range of AMD severities 
across the entire macular area, to enable the localisation of the deterioration of rod 
and cone function. 
8.7.3 Personality types 
The multidimensionality of QoL creates difficulties in determining predictors of an 
individual’s QoL. Economic situation and years of education are commonly 
considered in relation to QoL (Coleman et al. 2010; Brody et al. 2001; Hernandez 
Trillo and Dickinson 2012). These factors, combined with the individual’s overall 
outlook on life, could influence how the questionnaires were answered. Previous 
research in glaucoma suggests that personality types are associated with vision-
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related QoL (Warrian et al. 2009). Personality dimensions are also determinates of 
QoL in systemic diseases (Weber et al. 2015; Harper et al. 2014; Boyette et al. 2014). 
This would be an interesting concept to investigate in those with AMD, and may 
account for a larger proportion of the variance in vision-related QoL. 
8.7.4 Minimal important differences for quality-of-life 
Measures of QoL are currently not widely used in a clinical setting due to their time 
consuming nature. An additional limitation is the lack of information regarding the 
smallest change in self-reported QoL that an individual distinguishes as important, 
either positively or negatively. Minimal important difference (MID) is an index that 
represents such a quantification (Johnston et al. 2015). 
MID is based upon normal values for the questionnaire of interest (Johnston et al. 
2015). The MID is compared to the disease group mean difference to give a 
magnitude of difference, which can be used to make clinical decisions (Johnston et 
al. 2016). To the author’s knowledge, MIDs have not previously been studied in 
individuals with AMD. Such studies could inform the selection of outcomes for clinical 
trials in which the quantification of the effect of an intervention is required. 
Furthermore, in everyday clinical practice, in which management decisions are 
required, quantification of vision-related QoL in terms of cut-off values of “good” or 
“bad”, would allow for more informed decisions. The availability of such information 
could aid the clinician in making well-informed management decisions. 
This research has showed promising results when investigating the predictors of 
vision-related QoL in individuals with AMD. Baseline vision-related QoL was predicted 
by a microperimetry outcome and the presence of depressive symptoms. This finding 
is strengthened by the inclusion of robust methods of analysing microperimetry data 
using an age-corrected normative database. Further clinical implications are firstly, 
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the questionable utility of the widely used clinical measure of visual function, VA, when 
assessing vision-related QoL. Secondly, the results emphasise the clinical application 
of microperimetry and support its adoption into clinical practice. Thirdly, the findings 
further reinforce the emerging clinical opinion that depressive symptoms should be 
considered in those with AMD.  
When examining change in vision-related QoL after 1 year, baseline CS was a 
significant predictor of change in IVI score as was, to a lesser extent, the changes in 
health status and in reading speed. These outcomes support previous research that 
highlights the importance of CS when assessing ‘real world’ functionality and vision-
related QoL. However, CS is still not a commonly used measure within clinical 
environments and the results further strengthen the evidence for the increased clinical 
use of CS. 
Overall, the findings provide an evidence base for the most clinically useful measures 
of visual function in identifying those with a reduced QoL or those at risk of a reduced 
QoL. This implies that greater importance should be placed upon CS in the clinical 
setting. An increased use of microperimetry would provide a clinical measure of visual 
function that is relevant to vision-related QoL. It is also clear that both depressive 
symptoms and health status are important outcome measures and both should be 
measured within a clinical setting.  
In conclusion, this thesis has provided sufficient evidence to encourage a modification 
of the clinical outcome measures most relevant to vision-related QoL and most 
appropriate for clinical practice. Vision-related QoL can, to a significant extent, be 
predicted from less time-consuming clinical measures, and therefore, clinicians 
should use this information to aid management decisions, such as referral to 
rehabilitation services.  
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Appendix B: Quality of evidence table.
AMD: age-related macular degeneration; AREDS: Age-related Eye Disease; DLS: differential light sensitivity; ETDRS: Early Treatment Diabetic 
Retinopathy Study; FA: fluorescein angiography; GA: geographic atrophy; MD: Mean Deviation; MS: Mean Sensitivity; nAMD: neovascular AMD; 
OCT: Optical coherence tomography; PSD: Pattern Standard Deviation; TD: Total Deviation Study. 
Reference Study design AMD identification and classification DLS measures used Quality of evidence
(Acton et al. 
2012b)
Observational: 
case-controlled
Early AMD: International 
Classification and 
Grading System
MS (68 locations within 10°), number of TD 
defects, MD and PSD (derived from previous 
normative data)
High
(Broadhead et 
al. 2017)
Observational: 
case-control
Early to intermediate 
AMD: AREDS 
classification (grades 2 
and 3)
DLS (13 locations: fixation and nasal, 
temporal, superior and inferior locations at 
1˚,3˚ and 5˚)
High
(Chandramohan 
et al. 2016)
Observational: 
case-controlled
Early and intermediate 
AMD: AREDS 
classification (grades 2 
and 3)
MS (37 locations within 5°), central MS (foveal 
locus and 12 locations at 1 °) and percentage 
reduced threshold (under 25dB)
High
(Denniss et al. 
2017)
Observational: 
case-series
AMD: any manifest stage MD and PSD (37 locations within 10˚) and
Mean TD and mean PD with associated 
normal limits 
High
(Ergun et al. 
2003)
Observational: 
case series
nAMD: identified by FA Size of absolute and relative scotoma High
(Forte et al. 
2013)
Observational: 
case series
GA: identified with colour 
fundus photography
MS (49 locations within 3.5°), Dense scotoma 
(0dB) and relatively dense scotoma (<5dB)
High
(Hariri et al. 
2016)
Observational: 
cross-sectional
Early to late AMD (GA): 
identified and classified 
by OCT (presence of 
drusen = intermediate, 
GA larger than 0.1 = GA)
MS (in different zones associated with GA) High
265 
(Iwama et al. 
2010)
Observational: 
case series
Soft confluent drusen: 
International 
Classification and 
Grading System
MS (57 locations over 10°, in central 2° and at 
specific locations with pathomorphology)
High
(Munk et al. 
2013)
Experimental: 
Quasi-experiment 
(interrupted time-
series)
nAMD: naïve to 
treatment, identified with 
FA
MS (ETDRS grid areas), Number of absolute 
scotoma (0dB), severe relative scotoma (1-
6dB), mild relative scotoma (7-12dB) and 
normal (>13dB) were counted.
High
(Ozdemir et al. 
2012)
Experimental: 
Quasi-experiment 
(interrupted time-
series)
nAMD: identified with FA 
and OCT
MS (12 locations within 4˚) and number of 
absolute scotoma (0dB) from all 76 stimulus 
locations within 20˚
High
(Parisi et al. 
2007)
Observational: 
case-controlled
Early AMD: classified by 
Wisconsin Age-related 
Maculopathy Grading 
System
Central MS (4 locations within 2.5˚) and 
paracentral MS(28 locations in annuli between 
2.5 and 5˚)
High
(Querques et al. 
2012)
Observational: 
cross-sectional
Early to late AMD (GA): 
presence of soft indistinct 
drusen with RPE 
changes, and/or GA, 
identified with colour 
fundus photography
MS (49 locations within 4.5°), pointwise DLS 
(at specific locations with pathomorphology)
High
(Sato et al. 
2015)
Observational: 
cross-sectional
nAMD: identified by OCT 
and FA
MS and Median DLS (29 locations within 10°) High
(Sayegh et al. 
2014)
Observational: 
case series
GA: identified by fundus 
examination
Pointwise DLS (at specific locations with 
pathomorphology)
High
(Sulzbacher et 
al. 2015)
Experimental, 
Quasi-experiment 
(interrupted time-
series)
nAMD: naïve to 
treatment, identified with 
FA
MS (33 locations within 6°), pointwise DLS (at 
specific locations with pathomorphology)
High
(Vujosevic et al. 
2011)
Observational: 
case-controlled
Early to intermediate 
AMD: AREDS 
classification (stage 2 to 
3)
MS (61 locations within 5°), K value: total 
number of locations <24dB, pointwise DLS
High
266 
(Weigert et al. 
2013)
Experimental, 
RCT
Early to late AMD (GA): 
AREDS classification 
(stage 2, 3, and 4)
MS (41 locations within 6°) High
(Wu et al. 2013) Observational: 
case-controlled
Intermediate AMD: 
Beckman classification
MS (37 locations within 6°), pointwise DLS High
(Wu et al. 
2014a)
Observational: 
case-controlled
Intermediate AMD: 
Beckman classification
MS (corresponding to mfERG hexagons) High
(Wu et al. 
2014b)
Observational: 
cross-sectional
Intermediate AMD: 
Beckman classification
MS (5 locations within central 1˚) High
(Wu et al. 
2014c)
Observational: 
cross-sectional
Intermediate AMD: 
Beckman classification
Pointwise DLS (at specific locations with 
pathomorphology) and Z score (average of 2 
examinations in relation to normative data)
High
(Wu et al. 
2015a)
Observational: 
longitudinal case-
controlled
Intermediate AMD: 
Beckman classification
MS (37 locations within 6°) and pointwise DLS High
(Wu et al. 
2015b)
Observational: 
cross-sectional
Intermediate AMD: 
Beckman classification
MS (associated with groups of AMD pathology 
severity) and pointwise DLS (at specific 
locations with pathomorphology)
High
(Wu et al. 
2015c)
Observational: 
cross-sectional
Intermediate AMD: 
Beckman classification
MS (25 locations within 4°) High
(Wu et al. 2016) Observational: 
longitudinal case 
series
Intermediate AMD: 
Beckman classification
MS (37 locations within 6°), MS within EDTRS 
grid sections
High
(Wu, Guymer 
and Finger 
2016)
Observational: 
cross-sectional
Intermediate AMD: 
Beckman classification
MS (37 locations within 6°) and central MS (5 
locations within 1°)
High
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(Amore et al. 
2013)
Observational: 
case series
AMD: with absolute 
scotoma and central 
fixation identified by 
microperimetry
Global MS and central MS. Size (in degrees) 
of central spared area (ring scotoma patients).
Medium
‘central vision area’ DLS definition 
not reported
AMD: not stated method AMD is 
classified 
(Bolz et al. 
2010)
Experimental: 
Quasi-experiment 
(interrupted time-
series)
nAMD: naïve to 
treatment
MS (foveal locus and circle of locations at 3.5˚) Medium
OCT: boundaries used to define 
central retinal thickness not 
reported
AMD: method nAMD is identified 
not stated
(Chieh, Stinnett 
and Toth 2008)
Experimental: 
Quasi-experiment 
nAMD Median DLS within surgery areas and number 
of areas with absolute scotoma (<0dB)
Medium
AMD: method nAMD is identified 
not stated
(Cho et al. 
2013)
Experimental: 
Quasi-experiment 
(interrupted time-
series)
nAMD: naïve to 
treatment, identified by 
FA and/or OCT
MS (28 locations within 6˚) Medium
OCT: boundaries used to define 
central retinal thickness not 
reported
(Dunavoelgyi et 
al. 2011)
Experimental: 
RCT
nAMD: naïve to 
treatment 
MS (41 locations within 6˚), number of 
locations and size of absolute scotoma (0dB) 
and relative scotoma (<10dB)
Medium
AMD: method nAMD is identified 
not stated
(Fujii et al. 
2003)
Observational: 
cross-sectional
nAMD: identified by FA Percentage presence of dense central 
scotoma (defined as having >3 locations of 
<0dB within 1.5°)
Medium
Microperimetry: stimulus location 
pattern and stimulus details not 
reported
(Grenga et al. 
2013)
Experimental: 
Quasi-experiment 
(interrupted time-
series)
nAMD: naïve to 
treatment
MS (45 locations over 10˚), number of absolute 
scotoma locations
Medium
Microperimetry: Absolute scotoma 
definition not reported
AMD: method nAMD is identified 
not stated
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(Hartmann et al. 
2015)
Experimental: 
Quasi-experiment 
(interrupted time-
series)
nAMD: presence of 
˃250μm retinal 
thickness, subretinal fluid 
or PED.
MS (24 locations within 10˚) Medium
OCT: boundaries used to define 
retinal thickness not reported
(Huang et al. 
2015)
Experimental: 
RCT
Early AMD: AREDS 
classification (grade 2)
MS (average DLS at 1, 3 and 5° from fixation) Medium
Microperimetry: stimulus pattern 
not reported
(Kiss et al. 
2009)
Experimental: 
Quasi-experiment 
(interrupted time-
series)
nAMD: identified with FA MS (25 stimulus locations within 7.9˚), central 
0˚, paracentral 3.5˚ and eccentric 7.9˚ MS and 
absolute scotoma size.
Medium
Microperimetry: absolute scotoma 
definition and mode of analysis not 
reported
(Landa et al. 
2011)
Observational: 
cross-sectional
Early to late AMD (GA): 
drusen or atrophic 
changes, and nAMD: 
CNV, intra/subretinal 
fluid and haemorrhages
MS (28 locations), pointwise DLS Medium
Microperimetry: Stimulus degrees 
not reported
AMD: method AMD is identified or 
classified not stated
(Mettu et al. 
2011)
Experimental: 
Quasi-experiment 
(interrupted time-
series)
nAMD: identified with FA Median DLS (30 locations) and percentage 
non response (<0dB).
Medium
Microperimetry: stimulus degrees 
not reported
(Ooto et al. 
2015)
Observational: 
cross-sectional
Early to late AMD (GA): 
AREDS classification 
(2,3, or 4)
MS (29 locations within 20˚ and parafovea: 
central 9 locations)
Medium
Microperimetry: how stimulus 
pattern not reported
(Pilotto et al. 
2011)
Observational: 
case series
GA: identified from 
fundus examination
MS and number of locations with relatively 
dense scotoma (≤5dB)
Medium
Microperimetry: stimulus pattern 
and degrees not reported
(Pilotto et al. 
2016)
Observational: 
cross-sectional
GA: identified from 
fundus examination
MS (customised grid within 8˚ including all 
areas of GA), divided into 3 groups based on 
MS, relative and dense scotoma rate
Medium
Microperimetry: relative scotoma 
definition not reported
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(Sabour-Pickett 
et al. 2013)
Experimental: 
Quasi-experiment 
(interrupted time-
series)
nAMD: identified with FA MS (fixation, central 5° and all 21 locations 
within 16˚)
Medium
OCT: retinal boundaries used 
were ‘thickness between outer 
most boundaries of scan’ however, 
these are not specified.
(Steinberg et al. 
2016)
Observational: 
case-controlled
Early or intermediate 
AMD with reticular 
pseudodrusen: Beckman 
classification and IR 
images
MS (56 locations) of areas with RPD compared 
to areas without (scotopic and mesopic)
Medium
Microperimetry: stimulus degrees 
not reported
(Sulzbacher et 
al. 2012)
Observational: 
case series
nAMD: identified with 
colour fundus 
photography, OCT and 
FA
MS (33 locations within 6°), pointwise DLS (at 
specific locations with pathomorphology)
Medium
Microperimetry: ‘central retinal 
sensitivity’ definition not reported
(Sulzbacher et 
al. 2013)
Experimental, 
Quasi-experiment 
(interrupted time-
series)
nAMD: naïve to 
treatment, identified with 
colour fundus 
photography, OCT and 
FA
MS (33 locations within 6°), pointwise DLS (at 
specific locations with pathomorphology)
Medium
OCT: pathomorphology used 
within analysis not defined and 
method of identification not 
reported
(Takahashi et 
al. 2016)
Observational:
cross-sectional
GA: identified by fundus 
examination
MS (57 locations within 10° and over specific 
areas of retinal damage)
Medium
Microperimetry: stimulus pattern 
not reported
(Giacomelli et 
al. 2013)
Observational: 
cross-sectional
Advanced AMD MS (19 locations over 10°) Medium:
AMD: method AMD is identified or 
classified not stated
(Hartmann et al. 
2011)
Observational: 
case-controlled
Early to late AMD (GA): 
presence of drusen on 
fundus examination
Ranked DLS threshold values and MS (28 
locations within 10°), pointwise DLS overlying 
drusen
Medium:
AMD: method AMD is classified 
not stated
(Hautamäki et 
al. 2014)
Observational: 
cross-sectional
nAMD: naïve to 
treatment
MS and ranking order of DLS (28 locations 
within 7.5°)
Medium:
AMD: method AMD is identified not 
stated
(Fragiotta et al. 
2017a)
Observational 
case-series
Intermediate AMD: 
Beckman classification
DLS (68 locations within 20˚) Moderate
Microperimetry: Stimulus pattern 
not reported
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(Vujosevic et al. 
2017)
Observational: 
longitudinal 
cross-sectional 
Early to intermediate 
AMD: AREDS 
classification (grades 2 
and 3)
MS (61 locations within 10˚), DLS within 2˚ and 
number of dense scotomas
Moderate
OCT: ELM and IS/OS band 
integrity parameters not defined.
(Alexander et al. 
2012)
Experimental: 
Quasi-experiment 
(interrupted time-
series)
nAMD: enrolled from 
anti-VEGF clinic
MS, macular integrity index (MAIA software) Poor
Confusing terminology (stable and 
unstable used to refer to both 
fixation and AMD status)
Microperimetry: stimulus pattern, 
number of locations, algorithm and 
stimulus details not reported
OCT: scan details not included and 
boundaries used to define retinal 
thickness not reported
AMD: how nAMD is identified not 
stated
(Anastassiou et 
al. 2013)
Experimental: 
RCT
Early to late AMD (GA): 
AREDS classification 
(grades 2,3 and 4)
MS (37 locations within 10°) Poor
Microperimetry: stimulus pattern, 
algorithm and stimulus details not 
defined
OCT: scan details not included and 
method of measuring retinal and 
choroidal thickness not reported
(Dinc et al. 
2008)
Observational: 
case-controlled
Intermediate AMD: 
AREDS classification 
(grade 3)
MS (76 locations within 10˚) and mean defect. Poor
Microperimetry: Mean defect 
derivation not reported, assumed it 
is from MP-1 software, stimulus 
pattern not reported
OCT: scan details not included and 
boundaries used to define central 
retinal thickness not reported  
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(Iaculli et al. 
2015)
Experimental: 
Quasi-experiment 
(interrupted time-
series)
nAMD: identified by OCT 
and FA
MS (8°) Poor
Microperimetry: stimulus pattern 
and details not defined
OCT: scan details not included and 
boundaries used to define central 
retinal thickness not reported  
(Lazzeri et al. 
2015)
Experimental: 
Quasi-experiment 
(interrupted time-
series)
nAMD: identified with FA MS (33 locations within 6˚) Poor
Confusing terminology: both 
‘mean central retinal sensitivity’ 
and ‘mean retinal sensitivity’ used; 
and ‘Central retinal thickness’ and 
‘central macular thickness’ both 
used. Difference in terms not 
reported.
Microperimetry: stimulus pattern 
and details not reported 
OCT: scan details not included and 
boundaries used to define central 
retinal thickness not reported  
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Appendix E: Record sheet
ID INFO. SHEET Y N
CONSENT 
FORM
Y N
DATE OF 
BIRTH GENDER M F
M
GH
MMSE  Score
Pass/ Fail
Medication
COPD/Asthma Musculoskelet
al
Diabetes Heart
Hearing 
Impairment Hypertension
OH
Early/Moderate/Lat
e
Dry Wet
Injections (number, 
last one?)
Last appointment?
Extra 
(living 
situati
on, 
magnif
iers, 
hobbie
s and 
SS 
input)
Falls in the past 
year?
Other:  
Alone Spouse Friend/relative
Residential 
home/sheltere
d accom.
Visual 
hallucinations?
Focimetry VA (ETDRS) Reading 
speed 
(wpm)
CS
OD
OS
Refract
ion and 
BCVA
279 
Anterio
r Eye
OD
Posterior Eye
OD
OS OS
Van 
Herick 
angle
OD
IOP
(mm
Hg)
OD
OCT ()
OD
OS OS
LOCS 
III 
gradin
g
OD OS Fundus 
Photograph 
()
OD
OS OS
MAIA 1 () MAIA2 () Dilation?
OD OS OD OS
Scatter (logs)
OD OS Time:
Notes
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Appendix F: The shortened version of the Mini mental state 
examination (Schultz-Larsen, Lomholt and Kreiner 2007). 
I would like you to repeat the following three words:  APPLE, PENNY, TABLE 
(Repeat until the patient registers all three words) 
A1 What is the day? Correct Yes No
A2 What is the month? Correct Yes No
A3 What is the year? Correct Yes No
A4 Spell WORLD 
backwards
D L R O W Number 
correct
(Final cognitive screening question A5 follows the questions on visual function)
What were the 3 words that I asked you at the 
beginning?
(apple, penny, table)
Number correct 
1) ___________________
2) ___________________
3) ___________________
_______________________
Did the patient pass the cognitive screen? 
Yes  (1)     (day, year, month correct; 3/5 WORLD; remember at least 2 words) 
No  (0)  Patient is ineligible 
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Appendix G: Coding to obtain retinal layer thickness values at 
stimulus locations corresponding to the MAIA grid pattern in OCT 
explorer (.xml file).
<?xml version="1.0" encoding="UTF-8"?> 
<grid> 
 <version>3.0</version> 
 <type>square</type> 
 <unit>mm</unit> 
 <region_num>40</region_num> 
 <region> 
  <label>1</label> 
<!-- from the center of the grid --> 
  <left>-0.43</left> 
  <top>-2.23</top> 
  <right>-0.3</right> 
  <bottom>-2.1</bottom> 
 </region> 
 <region> 
  <label>2</label> 
  <left>0.3</left> 
  <top>-2.23</top> 
  <right>0.43</right> 
  <bottom>-2.1</bottom> 
 </region> 
 <region> 
  <label>3</label> 
  <left>-1.03</left> 
  <top>-1.63</top> 
  <right>-0.9</right> 
  <bottom>-1.5</bottom> 
 </region> 
 <region> 
  <label>4</label> 
  <left>-0.43</left> 
  <top>-1.63</top> 
  <right>-0.3</right> 
  <bottom>-1.5</bottom> 
 </region> 
 <region> 
  <label>5</label> 
  <left>0.3</left> 
  <top>-1.63</top> 
  <right>0.43</right> 
  <bottom>-1.5</bottom> 
 </region> 
 <region> 
  <label>6</label> 
  <left>0.9</left> 
  <top>-1.63</top> 
  <right>1.03</right> 
  <bottom>-1.5</bottom> 
 </region> 
 <region> 
  <label>7</label> 
  <left>-1.63</left> 
  <top>-1.03</top> 
  <right>-1.5</right> 
  <bottom>-0.9</bottom> 
 </region> 
 <region> 
  <label>8</label> 
  <left>-1.03</left> 
  <top>-1.03</top> 
  <right>-0.9</right> 
  <bottom>-0.9</bottom> 
 </region> 
 <region> 
  <label>9</label> 
  <left>-0.43</left> 
  <top>-1.03</top> 
  <right>-0.3</right> 
  <bottom>-0.9</bottom> 
 </region> 
 <region> 
  <label>10</label> 
  <left>0.3</left> 
  <top>-1.03</top> 
  <right>0.43</right> 
  <bottom>-0.9</bottom> 
 </region> 
 <region> 
  <label>11</label> 
  <left>0.9</left> 
  <top>-1.03</top> 
  <right>1.03</right> 
  <bottom>-0.9</bottom> 
 </region> 
 <region> 
  <label>12</label> 
  <left>1.5</left> 
  <top>-1.03</top> 
  <right>1.63</right> 
  <bottom>-0.9</bottom> 
 </region> 
 <region> 
  <label>13</label> 
  <left>-2.23</left> 
  <top>-0.43</top> 
  <right>-2.1</right> 
  <bottom>-0.3</bottom> 
 </region> 
 <region> 
  <label>14</label> 
  <left>-1.63</left> 
  <top>-0.43</top> 
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  <right>-1.5</right> 
  <bottom>-0.3</bottom> 
 </region> 
 <region> 
  <label>15</label> 
  <left>-1.03</left> 
  <top>-0.43</top> 
  <right>-0.9</right> 
  <bottom>-0.3</bottom> 
 </region> 
 <region> 
  <label>16</label> 
  <left>-0.43</left> 
  <top>-0.43</top> 
  <right>-0.3</right> 
  <bottom>-0.3</bottom> 
 </region> 
 <region> 
  <label>17</label> 
  <left>0.3</left> 
  <top>-0.43</top> 
  <right>0.43</right> 
  <bottom>-0.3</bottom> 
 </region> 
 <region> 
  <label>18</label> 
  <left>0.9</left> 
  <top>-0.43</top> 
  <right>1.03</right> 
  <bottom>-0.3</bottom> 
 </region> 
 <region> 
  <label>19</label> 
  <left>1.5</left> 
  <top>-0.43</top> 
  <right>1.63</right> 
  <bottom>-0.3</bottom> 
 </region> 
 <region> 
  <label>20</label> 
  <left>2.1</left> 
  <top>-0.43</top> 
  <right>2.23</right> 
  <bottom>-0.3</bottom> 
 </region> 
 <region> 
  <label>21</label> 
  <left>-2.23</left> 
  <top>0.3</top> 
  <right>-2.1</right> 
  <bottom>0.43</bottom> 
 </region> 
 <region> 
  <label>22</label> 
  <left>-1.63</left> 
  <top>0.3</top> 
  <right>-1.5</right> 
  <bottom>0.43</bottom> 
 </region> 
 <region> 
  <label>23</label> 
  <left>-1.03</left> 
  <top>0.3</top> 
  <right>-0.9</right> 
  <bottom>0.43</bottom> 
 </region> 
 <region> 
  <label>24</label> 
  <left>-0.43</left> 
  <top>0.3</top> 
  <right>-0.3</right> 
  <bottom>0.43</bottom> 
 </region> 
 <region> 
  <label>25</label> 
  <left>0.3</left> 
  <top>0.3</top> 
  <right>0.43</right> 
  <bottom>0.43</bottom> 
 </region> 
 <region> 
  <label>26</label> 
  <left>0.9</left> 
  <top>0.3</top> 
  <right>1.03</right> 
  <bottom>0.43</bottom> 
 </region> 
 <region> 
  <label>27</label> 
  <left>1.5</left> 
  <top>0.3</top> 
  <right>1.63</right> 
  <bottom>0.43</bottom> 
 </region> 
 <region> 
  <label>28</label> 
  <left>2.1</left> 
  <top>0.3</top> 
  <right>2.23</right> 
  <bottom>0.43</bottom> 
 </region> 
 <region> 
  <label>29</label> 
  <left>-1.63</left> 
  <top>0.9</top> 
  <right>-1.5</right> 
  <bottom>1.03</bottom> 
 </region> 
 <region> 
  <label>30</label> 
  <left>-1.03</left> 
  <top>0.9</top> 
  <right>-0.9</right> 
  <bottom>1.03</bottom> 
 </region> 
 <region> 
  <label>31</label> 
  <left>-0.43</left> 
  <top>0.9</top> 
  <right>-0.3</right> 
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  <bottom>1.03</bottom> 
 </region> 
 <region> 
  <label>32</label> 
  <left>0.3</left> 
  <top>0.9</top> 
  <right>0.43</right> 
  <bottom>1.03</bottom> 
 </region> 
 <region> 
  <label>33</label> 
  <left>0.9</left> 
  <top>0.9</top> 
  <right>1.03</right> 
  <bottom>1.03</bottom> 
 </region> 
 <region> 
  <label>34</label> 
  <left>1.5</left> 
  <top>0.9</top> 
  <right>1.63</right> 
  <bottom>1.03</bottom> 
 </region> 
 <region> 
  <label>35</label> 
  <left>-1.03</left> 
  <top>1.5</top> 
  <right>-0.9</right> 
  <bottom>1.63</bottom> 
 </region> 
 <region> 
  <label>36</label> 
  <left>-0.43</left> 
  <top>1.5</top> 
  <right>-0.3</right> 
  <bottom>1.63</bottom> 
 </region> 
 <region> 
  <label>37</label> 
  <left>0.3</left> 
  <top>1.5</top> 
  <right>0.43</right> 
  <bottom>1.63</bottom> 
 </region> 
 <region> 
  <label>38</label> 
  <left>0.9</left> 
  <top>1.5</top> 
  <right>1.03</right> 
  <bottom>1.63</bottom> 
 </region> 
 <region> 
  <label>39</label> 
  <left>-0.43</left> 
  <top>2.1</top> 
  <right>-0.3</right> 
  <bottom>2.23</bottom> 
 </region> 
 <region> 
  <label>40</label> 
  <left>0.3</left> 
  <top>2.1</top> 
  <right>0.43</right> 
  <bottom>2.23</bottom> 
 </region> 
</grid> 
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Appendix H: Questionnaire prompt sheet 
IVI 
VF-14 
WEMWBS 
PHQ-9 
NOT 
AT 
ALL
0
HARDLY 
AT ALL
1
A 
LITTLE
2
A FAIR 
AMOUNT
3
A LOT
4
CAN’T DO 
BECAUSE 
OF 
EYESIGHT
5
DON’T DO 
FOR 
OTHER 
REASONS
8
NOT 
POSSIBLE
0
A LOT OF 
DIFFICULTY
1
SOME 
DIFFICULTY
2
A LITTLE 
DIFFICULTY
3
NO 
DIFFICULTY 
AT ALL
4
NOT AT ALL
0
SEVERAL DAYS
1
MORE THAN 
HALF THE 
DAYS
2
NEARLY EVERY 
DAY
3
NONE OF 
THE TIME
1
RARELY
2
SOME OF 
THE TIME
3
OFTEN
4
ALL OF THE 
TIME
5
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Appendix I: Rasch analysis method. 
 Open Winsteps 
 Import files from SPSS 
 Drag and drop ID (person identification) into person and the questions into item 
response. 
 Construct Winsteps file and save (txt file) 
 Press enter, find txt file and open (enter twice) = Rasch analysis 
 Gives initial summary table: check person and item reliability (close to 1) and 
separation (not below 2). (http://www.winsteps.com/winman/reliability.htm) 
 Along top bar: 
o Diagnosis – Category function (table 3.2) (graphs - category probability curves 
= prettier) 
o Output tables – summary stats (table 3.1) gives same as initial table in main 
window broken down, gives model and real numbers. 
o  Output tables – Variable map (table1) = person-item figure (ruler) 
o Output table – Item fit (tables 10-30, ordered differently) gives infit and outfit 
stats for items 
o Output table – Person Fit (tables 6-41) gives person infit and outfit, and 
measure for each person (logits).  
o Check person fit stats for ‘rogue responders (output tables- person measure): 
misfits = model S.E >1.4. People can be removed at this point but Rasch will 
need to be rerun. 
Interpretation of parameter-level mean-square fit statistics:
>2.0 Distorts or degrades the measurement 
system
1.5 - 2.0 Unproductive for construction of 
measurement, but not degrading.
Top end of acceptable
0.5 - 1.5 Productive for measurement.
<0.5 Less productive for measurement, but 
not degrading. May produce misleadingly 
good reliabilities and separations.
o Output table – Scoring table (table 20) this does not allow for missing data, 
can only be used if all data is present. 
 Scoring table (for each question and each category) = Item calibration/Item measure 
(table 13) + Category Measure/score at cat. (table 3.2). 
o To enter scoring table in SPSS: 
 Transform – Recode with different variable 
 Turn each category into a logit value (add extra columns) 
 Can use as a scoring table in future. 
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Appendix J: GP referral consent form 
Study Title:  Quality of Life and Clinical Outcomes in 
Macular Disease
Names of Researchers: Dr Jennifer Acton 
    Miss Nicola Cassels 
From the questions you have answered today it has been identified that 
you display some depressive symptoms. We would like to offer you a 
referral to your GP due to these findings. Please indicate below if you 
consent to this referral. 
I understand the statement above and consent to a referral to my GP. 
Name of Patient Date Signature
Name of person taking consent Date Signature
Please initial
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Appendix K: R code for the use of Method 1 and Method 2 
normative databases. 
Method 1: TD and PD  
newdb <- function(subject.age, sens, slope){ 
 agediff <- (45.97- subject.age)  
 agediff2<- agediff * slope 
 agediff3<- round(agediff2 + sens,2) 
 } 
##read in slope and AMD data 
read.csv(file.choose(), header=TRUE)->amd 
read.csv(file.choose(), header=TRUE)->slope 
##gives new sens values  
results <- as.data.frame(setNames(replicate(41,numeric(0), simplify = F), c("id", 
seq(1:40)))) 
 for (j in 1:nrow(amd)){ 
  results[j,1] = as.vector(amd[j,1]) 
                   for(i in 1:40){             
  results[j,i+1] <- as.matrix(cbind(newdb(amd[j,2], amd[j,i+2], 
slope[1,i+1]))) 
       }  
        names(results) <- c("id", seq(1:40)) 
} 
##save new values 
 write.csv(results, "newsens.csv") 
###TD reports (load in new AMD)   
read.csv(file.choose(), header=TRUE)->newamd 
read.csv(file.choose(), header=TRUE)->slope 
results <- as.data.frame(setNames(replicate(41,numeric(0), simplify = F), c("id", 
seq(1:40)))) 
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for (j in 1:nrow(newamd)){ 
 results[j,1] = as.vector(newamd[j,1]) 
  for(i in 1:40){ 
  results[j,i+1] <- as.data.frame(newamd[j,i+1] - slope[2,i+1]) 
       }  
        names(results) <- c("id", seq(1:40)) 
   } 
##save 
write.csv(results, "TD.csv") 
##TD probability limits     
probf<- function(td,limit)  { 
  if (td < limit){report <- "Sensitivity below " 
   } 
if (td ==  limit){ report <- "Sensitivity below " 
   } 
if (td > limit){report <- "Sensitivity within " 
   }  
    as.data.frame(cbind(td , report)) 
     } 
###read AMDtd values and get report      
read.csv(file.choose(), header=TRUE)->amdtd 
read.csv(file.choose(), header=TRUE)->slope 
 resultstd <- as.data.frame(setNames(replicate(3,numeric(0), simplify = F), c("id", "td", 
"report"))) 
names(resultstd) <- c("id", "td", "report1") 
for (j in 1:nrow(amdtd)){ 
 for(i in 1:40){ 
  data <- cbind(as.data.frame(cbind(amdtd[j,1], probf(amdtd[j,i+1], 
slope[3,i+1]))))  ###for 95% insert slope[3,i+1] ### for 98% insert  slope[4,i+1]  for 
99% insert  
  names(data) <- c("id", "td", "report") 
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  resultstd <- rbind(resultstd, data) 
 } 
} 
write.csv(resultstd, "IOL3HFA3tdprob0.95.csv") 
 ####PD numbers     
 read.csv(file.choose(), header=TRUE)->amdtd 
resultsPD <- as.data.frame(setNames(replicate(41,numeric(0), simplify = F), c("id", 
seq(1:40)))) 
for(j in 1:nrow(amdtd)){ 
 resultsPD[j,1] =  as.vector(amdtd[j,1]) 
  for(i in 1:40){ 
  elevator <- quantile(as.numeric(amdtd[j,2:41]), .85,na.rm=TRUE) 
  resultsPD[j,i+1]<- as.data.frame(round(as.numeric(amdtd[j,i+1])- 
(elevator),2)) 
  names(resultsPD) <- c("id", seq(1:40)) 
   } 
} 
##save 
write.csv(resultsPD, "PD.csv") 
####PD probability limits   
probf<- function(pd,limit)  { 
if (pd < limit){report <- "Sensitivity below " 
   } 
if (pd ==  limit){report <- "Sensitivity below " 
   } 
if (pd > limit){report <- "Sensitivity within " 
   }  
as.data.frame(cbind(pd , report)) 
     } 
###read AMDpd values and get report            
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read.csv(file.choose(), header=TRUE)->amdpd 
read.csv(file.choose(), header=TRUE)->slope 
 resultspd <- as.data.frame(setNames(replicate(3,numeric(0), simplify = F), c("id", 
"pd", "report"))) 
names(resultspd) <- c("id", "pd", "report1") 
for (j in 1:nrow(amdpd)){ 
 for(i in 1:40){ 
  data<-cbind(as.data.frame(cbind(amdpd[j,1],probf(amdpd[j,i+1], 
slope[6,i+1]))))  ####for 95% insert slope[6,i+1]   ###for 98% insert slope[7,i+1] ### 
for 99% insert  slope[8,i+1]   
  names(data) <- c("id", "pd", "report") 
  resultspd <- rbind(resultspd, data) 
 } 
} 
 write.csv(resultspd, "IOL3HFA3pdprob0.95.csv") 
Method 2: TD for new data          
# Read in data 
read.csv(file.choose(), header=TRUE)->Agesens 
names(Agesens) <- tolower(names(Agesens)) 
sens.pred <- function(location, subject.age, sens, conf.level=0.98){ 
 #Get prediction intervals 
  location.data <- lm(location ~ age) 
  newdata <- data.frame(age=subject.age) 
  predint <- predict(location.data, newdata, level=conf.level, 
interval="predict") 
  td <- round(sens-predint[1],2) 
  dev.neg<-round(predint[2]-predint[1],2) 
  dev.pos<-round(predint[3]-predint[1],2)  
   # TD probability limits 
  if (td < dev.neg){report <- "Sensitivity below normal limits" 
   } 
   if (td ==  dev.neg){report <- "Sensitivity below normal limits" 
   } 
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  if (td > dev.pos){report <- "Sensitivity above normal limits" 
   }  
    if (td  == dev.pos){report <- "Sensitivity above normal limits" 
   }  
  if (td < dev.pos && td > dev.neg){report <- "Sensitivity within normal 
limits" 
   } 
  as.data.frame(cbind(round(td, 2), report)) 
} 
read.csv(file.choose(), header=TRUE)->amd 
attach(Agesens) 
#95% 
results <- as.data.frame(setNames(replicate(4,numeric(0), simplify = F), c("id", "age", 
"td", "report"))) 
names(results) <- c("id", "age", "td", "report") 
for (j in 1:nrow(amd)){ 
 for(i in 1:40){ 
  data <- cbind(as.data.frame(cbind(amd[j,1], amd[j,2], 
sens.pred(Agesens[,(i+2)], amd[j,2], amd[j,i+2],0.95)))) 
  names(data) <- c("id", "age", "td", "report") 
  results <- rbind(results, data) 
  } 
} 
write.csv(results, "0.95.csv") 
#98% 
results <- as.data.frame(setNames(replicate(4,numeric(0), simplify = F), c("id", "age", 
"td", "report"))) 
names(results) <- c("id", "age", "td", "report") 
for (j in 1:nrow(amd)){ 
 for(i in 1:40){ 
  data <- cbind(as.data.frame(cbind(amd[j,1], amd[j,2], 
sens.pred(Agesens[,(i+2)], amd[j,2], amd[j,i+2],0.98)))) 
  names(data) <- c("id", "age", "td", "report") 
  results <- rbind(results, data) 
 } 
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} 
write.csv(results, "0.98.csv") 
#99% 
results <- as.data.frame(setNames(replicate(4,numeric(0), simplify = F), c("id", "age", 
"td", "report"))) 
names(results) <- c("id", "age", "td", "report") 
for (j in 1:nrow(amd)){ 
 for(i in 1:40){ 
  data <- cbind(as.data.frame(cbind(amd[j,1], amd[j,2], 
sens.pred(Agesens[,(i+2)], amd[j,2], amd[j,i+2],0.99)))) 
  names(data) <- c("id", "age", "td", "report") 
  results <- rbind(results, data) 
 } 
} 
write.csv(results, "0.99.csv") 
Method 2: PD for new data 
# Read in data 
read.csv(file.choose(), header=TRUE)->Agesens 
names(Agesens) <- tolower(names(Agesens)) 
sens.pred <- function(location, subject.age, sens, conf.level=0.98){ 
  location.data <- lm(location ~ age) 
  newdata <- data.frame(age=subject.age) 
  predint <- predict(location.data, newdata, level=conf.level, 
interval="predict") 
  td <- round(sens-predint[1],2) 
  dev.neg <-round(predint[2]-predint[1],2) 
  dev.pos <-round(predint[3]-predint[1],2) 
  as.data.frame(round(td, 2)) 
} 
##save TD numbers 
read.csv(file.choose(), header=TRUE)->amd 
attach(Agesens) 
results <- as.data.frame(setNames(replicate(42,numeric(0), simplify = F), c("id", 
"age", seq(1:40)))) 
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for (j in 1:nrow(amd)){ 
 results[j,1] = as.vector(amd[j,1]) 
  results[j, 2] = amd[j,2] 
               for(i in 1:40){ 
  results[j,i+2] <- as.data.frame(sens.pred(Agesens[,(i+2)], amd[j,2], 
amd[j,i+2])) 
       }  
        names(results) <- c("id", "age", seq(1:40)) 
       } 
##save TD numbers 
write.csv(results, "AMDTD") 
###PD numbers        
rm(list=ls()) 
read.csv(file.choose(), header=TRUE)->results  
resultsPD <- as.data.frame(setNames(replicate(42,numeric(0), simplify = F), c("id", 
"age", seq(1:40)))) 
for(j in 1:nrow(results)){ 
 resultsPD[j,1] =  as.vector(results[j,1]) 
  resultsPD[j,2] =  results[j,2] 
   for(i in 1:40){ 
  elevator <- quantile(as.numeric(results[j,3:42]), .85,na.rm=TRUE) 
  resultsPD[j,i+2]<- as.data.frame(round(as.numeric(results[j,i+2])- 
elevator),2)) 
  names(resultsPD) <- c("id", "age", seq(1:40)) 
   } 
} 
##save PD numbers 
write.csv(resultsPD, "AMDPD") 
###PD probability limits 
read.csv(file.choose(), header=TRUE)->Agesens2 
names(Agesens2) <- tolower(names(Agesens2)) 
sens.pd <- function(location, subject.age, pd, conf.level=0.98){ 
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  location.data <- lm(location ~ age) 
  newdata <- data.frame(age=subject.age) 
  predint <- predict(location.data, newdata, level=conf.level, 
interval="predict", na.action = na.exclude) 
  dev.neg <-round(predint[2]-predint[1],2) 
  dev.pos <-round(predint[3]-predint[1],2) 
   if (pd < dev.neg){report <- "Sensitivity below normal limits" 
   } 
  if (pd ==  dev.neg){report <- "Sensitivity below normal limits" 
   } 
  if (pd > dev.pos){report <- "Sensitivity above normal limits" 
   }  
    if (pd  == dev.pos){report <- "Sensitivity above normal limits" 
   }  
  if (pd < dev.pos && pd > dev.neg){report <- "Sensitivity within normal 
limits" 
   } 
    as.data.frame(cbind(pd, report)) 
   } 
##read in saved PD data from above  
read.csv(file.choose(), header=TRUE)->pd2 
attach(Agesens2) 
results <- as.data.frame(setNames(replicate(4, numeric(0),simplify = F), c("id", "age", 
"pd", "report"))) 
names(results) <- c("id", "age", "pd", "report") 
#95% 
for (j in 1:nrow(pd2)){ 
 for(i in 1:40){ 
       data <- cbind(as.data.frame(cbind(pd2[j,1], pd2[j,2], 
sens.pd(Agesens2[,(i+2)], pd2[j,2], pd2[j,i+2],0.95)))) 
      names(data) <- c("id", "age", "pd", "report") 
  results <- rbind(results, data) 
 } 
} 
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write.csv(results, "pd95.csv") 
results <- as.data.frame(setNames(replicate(4, numeric(0),simplify = F), c("id", "age", 
"pd", "report"))) 
names(results) <- c("id", "age", "pd", "report") 
#98% 
for (j in 1:nrow(pd2)){ 
 for(i in 1:40){ 
       data <- cbind(as.data.frame(cbind(pd2[j,1], pd2[j,2], 
sens.pd(Agesens2[,(i+2)], pd2[j,2], pd2[j,i+2],0.98)))) 
      names(data) <- c("id", "age", "pd", "report") 
  results <- rbind(results, data) 
 } 
} 
write.csv(results, "pd98.csv") 
 results <- as.data.frame(setNames(replicate(4, numeric(0),simplify = F), c("id", "age", 
"pd", "report"))) 
names(results) <- c("id", "age", "pd", "report") 
#99% 
for (j in 1:nrow(pd2)){ 
 for(i in 1:40){ 
       data <- cbind(as.data.frame(cbind(pd2[j,1], pd2[j,2], 
sens.pd(Agesens2[,(i+2)], pd2[j,2], pd2[j,i+2],0.99)))) 
      names(data) <- c("id", "age", "pd", "report") 
  results <- rbind(results, data) 
 } 
} 
write.csv(results, "pd99.csv") 
